

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_mpl1r\_wp250

**Request ID:** cder\_mpl1r\_wp250\_nsdv\_v01

**Request Description:** In this report we characterized dispensing and administration patterns of 26 New Molecular Entities (NMEs) approved from January 1, 2018 to July 31, 2018, stratified by age and sex in the Sentinel Distributed Database (SDD).

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis module, version 12.1.2

**Data Source:** We distributed this request to 14 Sentinel Data Partners on September 8, 2023. Because of the potential overlap in patient populations between two data partners for one year in the query period, we excluded results from one data partner and aggregated the results of the remaining 13 data partners in this report. The study period included data from January 1, 2018 to most recent data available. Please see Appendix A for a list of dates of available data for each Data Partner.

**Study Design:** We identified individuals initiating any of the 26 NMEs drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall, and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

**Exposures of Interest:** Our exposures of interest were NMEs approved between January 1, 2018 and July 31, 2018, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

**Cohort Eligibility Criteria:** We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

**Baseline Characteristics:** We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse<sup>1</sup> (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

**Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.**

**Limitations:** Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

**Table of Contents**

**Glossary** List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report  
**(CIDA)**

**Table 1a** Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1b** Aggregated Characteristics of Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1c** Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1d** Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1e** Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1f** Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1g** Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1h** Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1i** Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1j** Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1k** Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1l** Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1m** Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1n** Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1o** Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1p** Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1q** Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1r** Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1s** Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1t** Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1u** Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1v** Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1w** Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1x** Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 1y** Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

## Table of Contents

<b><u>Table 1z</u></b>	Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 2a</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 2b</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 2c</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 2d</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 2e</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 2f</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 3a</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 3b</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 3c</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 3d</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 3e</u></b>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 3f</u></b>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 4a</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 4b</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 4c</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 4d</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex
<b><u>Table 4e</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 4f</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group
<b><u>Table 5a</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023
<b><u>Table 5b</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table of Contents**

**Table 5c** Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 5d** Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 5e** Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 5f** Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 6a** Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 6b** Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 6c** Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 6d** Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 6e** Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 6f** Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 7a** Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 7b** Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 7c** Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 8a** Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 8b** Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

**Table 8c** Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

**Table 9** Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table 10** Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1a** Patient Entry into Study by Month for Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1b** Patient Entry into Study by Month for Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1c** Patient Entry into Study by Month for Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1d** Patient Entry into Study by Month for Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Table of Contents**

**Figure 1e** Patient Entry into Study by Month for Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1f** Patient Entry into Study by Month for Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1g** Patient Entry into Study by Month for Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1h** Patient Entry into Study by Month for Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1i** Patient Entry into Study by Month for Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1j** Patient Entry into Study by Month for Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1k** Patient Entry into Study by Month for Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1l** Patient Entry into Study by Month for Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1m** Patient Entry into Study by Month for Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1n** Patient Entry into Study by Month for Pegvaliase-pqz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1o** Patient Entry into Study by Month for Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1p** Patient Entry into Study by Month for Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1q** Patient Entry into Study by Month for Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1r** Patient Entry into Study by Month for Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1s** Patient Entry into Study by Month for Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1t** Patient Entry into Study by Month for Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1u** Patient Entry into Study by Month for Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1v** Patient Entry into Study by Month for Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1w** Patient Entry into Study by Month for Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1x** Patient Entry into Study by Month for Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1y** Patient Entry into Study by Month for Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Figure 1z** Patient Entry into Study by Month for Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023

**Appendix A** Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 8, 2023)

**Appendix B** List of Nonproprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

**Appendix C** List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposures in this Request

### Table of Contents

**Appendix D** List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this request

**Appendix E** List of Nonproprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

**Appendix F** Specifications Defining Parameters for this Request

**Appendix G** Specifications Defining Parameters for Baseline Characteristics in this Request

**Appendix H** Design Diagram Used in this Request

**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.



**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report

**Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	4,522	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.2	9.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	94	2.1%
41-64 years	1,121	24.8%
≥ 65 years	3,294	72.8%
Sex		
Female	2,218	49.0%
Male	2,304	51.0%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	50	1.1%
Black or African American	346	7.7%
Multi-racial	11	0.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	905	20.0%
White	3,194	70.6%
Hispanic origin		
Yes	67	1.5%
No	3,437	76.0%
Unknown	1,018	22.5%
Year		
2018	536	11.9%
2019	1,079	23.9%
<b>2020</b>		
2021	899	19.9%
2022	899	19.9%
2023	39	0.9%
Health Characteristics		
Acute Myocardial Infarction	25	0.6%
Alzheimer's Disease and related conditions	81	1.8%
Atrial Fibrillation	348	7.7%
Diabetes Mellitus	1,306	28.9%
Heart Failure	413	9.1%
Hyperlipidemia	1,480	32.7%

**Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Hypertension	2,404	53.2%
Depression	806	17.8%
Ischemic Heart Disease	852	18.8%
Rheumatoid Arthritis/Osteoarthritis	529	11.7%
Stroke/TIA <sup>4</sup>	73	1.6%
Breast Cancer	191	4.2%
Colorectal Cancer	253	5.6%
Prostate Cancer	231	5.1%
Lung Cancer	176	3.9%
Endometrial Cancer	15	0.3%
Acquired Hypothyroidism	604	13.4%
Anemia	1,546	34.2%
Asthma	160	3.5%
Benign Prostatic Hyperplasia	285	6.3%
Chronic Kidney Disease	858	19.0%
COPD <sup>5</sup> and Bronchiectasis	266	5.9%
Glaucoma	381	8.4%
Osteoporosis	216	4.8%
Obesity: diagnosed or identified by weight management procedures	634	14.0%
Obesity: identified by weight management-related prescriptions	14	0.3%
Overweight	433	9.6%
Smoking: diagnosed or identified by smoking cessation procedures	1,266	28.0%
Smoking: identified by smoking-related prescriptions	17	0.4%

**Table 1a. Aggregated Characteristics of Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Alcohol Abuse or Dependence</b>		
Drug Abuse or Dependence	145	3.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	239	5.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.9	10.9
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.3	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters		
Mean number of filled prescriptions		
Mean number of generics dispensed	8.2	5.2
Mean number of unique drug classes dispensed	7.7	4.6

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1b. Aggregated Characteristics of Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	175,440	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	47.3	12.6
Age		
0-17 years	966	0.6%
18-24 years	8,703	5.0%
25-40 years	52,127	29.7%
41-64 years	94,953	54.1%
≥ 65 years	18,691	10.7%
Sex		
Female	45,683	26.0%
Male	129,757	74.0%
Race <sup>3</sup>		
American Indian or Alaska Native	1,406	0.8%
Asian	2,114	1.2%
Black or African American	61,711	35.2%
Multi-racial	827	0.5%
Native Hawaiian or Other Pacific Islander	283	0.2%
Unknown	64,846	37.0%
White	44,253	25.2%
Hispanic origin		
Yes	18,031	10.3%
No	103,887	59.2%
Unknown	53,522	30.5%
Year		
2018	35,808	20.4%
2019	58,182	33.2%
2020	46,465	26.5%
2021	16,992	9.7%
2022	16,347	9.3%
2023	1,646	0.9%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	961	0.5%
Alzheimer's Disease and related conditions	2,554	1.5%
Atrial Fibrillation	2,231	1.3%
Diabetes Mellitus	16,790	9.6%
Heart Failure	6,740	3.8%
Hyperlipidemia	24,209	13.8%
Hypertension	35,646	20.3%

**Table 1b. Aggregated Characteristics of Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Depression	40,140	22.9%
Ischemic Heart Disease	11,297	6.4%
Rheumatoid Arthritis/Osteoarthritis	9,097	5.2%
Stroke/TIA <sup>4</sup>	2,726	1.6%
Breast Cancer	545	0.3%
Colorectal Cancer	936	0.5%
Prostate Cancer	1,233	0.7%
Lung Cancer	533	0.3%
Endometrial Cancer	52	0.0%
Acquired Hypothyroidism	3,762	2.1%
Anemia	19,652	11.2%
Asthma	7,844	4.5%
Benign Prostatic Hyperplasia	3,577	2.0%
Chronic Kidney Disease	13,412	7.6%
COPD <sup>5</sup> and Bronchiectasis	9,513	5.4%
Glaucoma	5,296	3.0%
Osteoporosis	1,343	0.8%
Obesity: diagnosed or identified by weight management procedures	16,853	9.6%
Obesity: identified by weight management-related prescriptions	672	0.4%
Overweight	8,576	4.9%
Smoking: diagnosed or identified by smoking cessation procedures	36,769	21.0%
Smoking: identified by smoking-related prescriptions	6,118	3.5%
Alcohol Abuse or Dependence	9,890	5.6%
Drug Abuse or Dependence	23,962	13.7%
History of Cardiac Arrest	130	0.1%
History of Coronary Angioplasty or Bypass	2,712	1.5%

**Table 1b. Aggregated Characteristics of Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	9.1	15.1
Mean number of emergency room encounters	0.6	1.8
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	17.9
Mean number of filled prescriptions	20.5	21.1
Mean number of generics dispensed	6.9	5.6
Mean number of unique drug classes dispensed	6.2	5.0

**Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	3,794	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	24.8	11.2
Age		
0-17 years	1,360	35.8%
18-24 years	787	20.7%
25-40 years	1,229	32.4%
41-64 years	365	9.6%
≥ 65 years	53	1.4%
Sex		
Female	1,889	49.8%
Male	1,905	50.2%
Race <sup>3</sup>		
American Indian or Alaska Native	25	0.7%
Asian	*****	*****
Black or African American	55	1.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,533	40.4%
White	2,160	56.9%
Hispanic origin		
Yes	180	4.7%
No	2,161	57.0%
Unknown	1,453	38.3%
Year		
2018	2,123	56.0%
2019	1,299	34.2%
2020	322	8.5%
2021	32	0.8%
2022	*****	*****
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	15	0.4%
Diabetes Mellitus	921	24.3%
Heart Failure	99	2.6%
Hyperlipidemia	49	1.3%



**Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Hypertension	197	5.2%
Depression	779	20.5%
Ischemic Heart Disease	35	0.9%
Rheumatoid Arthritis/Osteoarthritis	75	2.0%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	75	2.0%
Anemia	305	8.0%
Asthma	670	17.7%
Benign Prostatic Hyperplasia	15	0.4%
Chronic Kidney Disease	236	6.2%
COPD <sup>5</sup> and Bronchiectasis	1,046	27.6%
Glaucoma	43	1.1%
Osteoporosis	92	2.4%
Obesity: diagnosed or identified by weight management procedures	75	2.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	80	2.1%
Smoking: diagnosed or identified by smoking cessation procedures	147	3.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	48	1.3%
Drug Abuse or Dependence	137	3.6%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

**Table 1c. Aggregated Characteristics of Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	9.1	10.0
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	14.1	25.4
Mean number of filled prescriptions	32.9	24.3
Mean number of generics dispensed	11.0	6.0
Mean number of unique drug classes dispensed	10.5	5.5

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	11,580	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	75.4	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	10.1%
≥ 65 years	10,415	89.9%
Sex		
Female	*****	*****
Male	*****	100.0%
Race <sup>3</sup>		
American Indian or Alaska Native	40	0.3%
Asian	168	1.5%
Black or African American	1,525	13.2%
Multi-racial	16	0.1%
Native Hawaiian or Other Pacific Islander	35	0.3%
Unknown	2,265	19.6%
White	7,531	65.0%
Hispanic origin		
Yes	228	2.0%
No	8,800	76.0%
Unknown	2,552	22.0%
Year		
2018	1,283	11.1%
2019	1,656	14.3%
2020	2,582	22.3%
2021	3,248	28.0%
2022	2,599	22.4%
2023	212	1.8%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	94	0.8%
Alzheimer's Disease and related conditions	529	4.6%
Atrial Fibrillation	1,349	11.6%
Diabetes Mellitus	3,039	26.2%
Heart Failure	1,420	12.3%
Hyperlipidemia	4,863	42.0%
Hypertension	6,543	56.5%
Depression	1,337	11.5%

**Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	3,370	29.1%
Rheumatoid Arthritis/Osteoarthritis	1,780	15.4%
Stroke/TIA <sup>4</sup>	328	2.8%
Breast Cancer	670	5.8%
Colorectal Cancer	230	2.0%
Prostate Cancer	11,442	98.8%
Lung Cancer	146	1.3%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	758	6.5%
Anemia	3,485	30.1%
Asthma	255	2.2%
Benign Prostatic Hyperplasia	2,390	20.6%
Chronic Kidney Disease	2,591	22.4%
COPD <sup>5</sup> and Bronchiectasis	992	8.6%
Glaucoma	1,332	11.5%
Osteoporosis	455	3.9%
Obesity: diagnosed or identified by weight management procedures	2,102	18.2%
Obesity: identified by weight management-related prescriptions	66	0.6%
Overweight	1,345	11.6%
Smoking: diagnosed or identified by smoking cessation procedures	3,137	27.1%
Smoking: identified by smoking-related prescriptions	46	0.4%
Alcohol Abuse or Dependence	294	2.5%
Drug Abuse or Dependence	247	2.1%
History of Cardiac Arrest	18	0.2%
History of Coronary Angioplasty or Bypass	1,113	9.6%

**Table 1d. Aggregated Characteristics of Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	18.2	12.9
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	5.0	8.5
Mean number of filled prescriptions	18.0	14.9
Mean number of generics dispensed	8.0	4.8
Mean number of unique drug classes dispensed	7.5	4.3

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	307	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	52.5	12.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	47	15.3%
41-64 years	214	69.7%
≥ 65 years	*****	*****
Sex		
Female	72	23.5%
Male	235	76.5%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	134	43.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	98	31.9%
Hispanic origin		
Yes	21	6.8%
No	219	71.3%
Unknown	67	21.8%
Year		
2018	84	27.4%
2019	99	32.2%
2020	70	22.8%
2021	30	9.8%
2022	*****	*****
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	53	17.3%
Heart Failure	27	8.8%
Hyperlipidemia	77	25.1%
Hypertension	119	38.8%

**Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	91	29.6%
Ischemic Heart Disease	34	11.1%
Rheumatoid Arthritis/Osteoarthritis	24	7.8%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	11	3.6%
Anemia	98	31.9%
Asthma	25	8.1%
Benign Prostatic Hyperplasia	11	3.6%
Chronic Kidney Disease	74	24.1%
COPD <sup>5</sup> and Bronchiectasis	22	7.2%
Glaucoma	22	7.2%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	26	8.5%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	14	4.6%
Smoking: diagnosed or identified by smoking cessation procedures	84	27.4%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	12	3.9%
Drug Abuse or Dependence	34	11.1%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

**Table 1e. Aggregated Characteristics of Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	18.7	22.8
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.5	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	12.4	25.0
Mean number of filled prescriptions	42.8	28.3
Mean number of generics dispensed	13.0	6.4
Mean number of unique drug classes dispensed	10.0	5.3

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



**Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	7,837	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.1	9.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	343	4.4%
41-64 years	1,038	13.2%
≥ 65 years	6,395	81.6%
Sex		
Female	4,152	53.0%
Male	3,685	47.0%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	99	1.3%
Black or African American	183	2.3%
Multi-racial	12	0.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,343	17.1%
White	6,183	78.9%
Hispanic origin		
Yes	73	0.9%
No	6,302	80.4%
Unknown	1,462	18.7%
Year		
2018	40	0.5%
2019	941	12.0%
2020	1,548	19.8%
2021	2,306	29.4%
2022	2,936	37.5%
2023	66	0.8%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	23	0.3%
Alzheimer's Disease and related conditions	154	2.0%
Atrial Fibrillation	589	7.5%
Diabetes Mellitus	1,842	23.5%
Heart Failure	562	7.2%
Hyperlipidemia	2,782	35.5%
Hypertension	3,323	42.4%
Depression	1,316	16.8%

**Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	1,436	18.3%
Rheumatoid Arthritis/Osteoarthritis	1,965	25.1%
Stroke/TIA <sup>4</sup>	107	1.4%
Breast Cancer	148	1.9%
Colorectal Cancer	30	0.4%
Prostate Cancer	150	1.9%
Lung Cancer	42	0.5%
Endometrial Cancer	20	0.3%
Acquired Hypothyroidism	850	10.8%
Anemia	1,083	13.8%
Asthma	252	3.2%
Benign Prostatic Hyperplasia	341	4.4%
Chronic Kidney Disease	795	10.1%
COPD <sup>5</sup> and Bronchiectasis	516	6.6%
Glaucoma	730	9.3%
Osteoporosis	290	3.7%
Obesity: diagnosed or identified by weight management procedures	1,802	23.0%
Obesity: identified by weight management-related prescriptions	59	0.8%
Overweight	675	8.6%
Smoking: diagnosed or identified by smoking cessation procedures	1,421	18.1%
Smoking: identified by smoking-related prescriptions	37	0.5%
Alcohol Abuse or Dependence	171	2.2%
Drug Abuse or Dependence	169	2.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	364	4.6%

**Table 1f. Aggregated Characteristics of Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	13.6	13.0
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.3	6.6
Mean number of filled prescriptions	17.5	16.8
Mean number of generics dispensed	7.9	5.2
Mean number of unique drug classes dispensed	7.3	4.7

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	1,038	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	24.9	15.7
Age		
0-17 years	582	56.1%
18-24 years	75	7.2%
25-40 years	137	13.2%
41-64 years	161	15.5%
≥ 65 years	83	8.0%
Sex		
Female	673	64.8%
Male	365	35.2%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	11	1.1%
Black or African American	111	10.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	511	49.2%
White	393	37.9%
Hispanic origin		
Yes	95	9.2%
No	495	47.7%
Unknown	448	43.2%
Year		
2018	147	14.2%
2019	426	41.0%
2020	261	25.1%
2021	*****	*****
2022	110	10.6%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	26	2.5%
Heart Failure	18	1.7%
Hyperlipidemia	55	5.3%
Hypertension	114	11.0%

**Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	110	10.6%
Ischemic Heart Disease	17	1.6%
Rheumatoid Arthritis/Osteoarthritis	92	8.9%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	47	4.5%
Anemia	56	5.4%
Asthma	24	2.3%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	42	4.0%
COPD <sup>5</sup> and Bronchiectasis	18	1.7%
Glaucoma	16	1.5%
Osteoporosis	32	3.1%
Obesity: diagnosed or identified by weight management procedures	105	10.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	39	3.8%
Smoking: diagnosed or identified by smoking cessation procedures	53	5.1%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	19	1.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

**Table 1g. Aggregated Characteristics of Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	9.7	11.6
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.3	15.7
Mean number of filled prescriptions	9.6	11.9
Mean number of generics dispensed	4.0	3.8
Mean number of unique drug classes dispensed	3.8	3.5

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	1,120	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	62.2	14.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	129	11.5%
41-64 years	374	33.4%
≥ 65 years	579	51.7%
Sex		
Female	621	55.4%
Male	499	44.6%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	105	9.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	374	33.4%
White	584	52.1%
Hispanic origin		
Yes	75	6.7%
No	697	62.2%
Unknown	348	31.1%
Year		
2018	205	18.3%
2019	317	28.3%
2020	225	20.1%
2021	182	16.3%
2022	175	15.6%
2023	16	1.4%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	18	1.6%
Alzheimer's Disease and related conditions	57	5.1%
Atrial Fibrillation	124	11.1%
Diabetes Mellitus	330	29.5%
Heart Failure	181	16.2%
Hyperlipidemia	374	33.4%
Hypertension	597	53.3%
Depression	215	19.2%

**Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	243	21.7%
Rheumatoid Arthritis/Osteoarthritis	188	16.8%
Stroke/TIA <sup>4</sup>	65	5.8%
Breast Cancer	47	4.2%
Colorectal Cancer	18	1.6%
Prostate Cancer	24	2.1%
Lung Cancer	21	1.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	187	16.7%
Anemia	685	61.2%
Asthma	77	6.9%
Benign Prostatic Hyperplasia	75	6.7%
Chronic Kidney Disease	241	21.5%
COPD <sup>5</sup> and Bronchiectasis	123	11.0%
Glaucoma	101	9.0%
Osteoporosis	68	6.1%
Obesity: diagnosed or identified by weight management procedures	280	25.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	111	9.9%
Smoking: diagnosed or identified by smoking cessation procedures	328	29.3%
Smoking: identified by smoking-related prescriptions	11	1.0%
Alcohol Abuse or Dependence	36	3.2%
Drug Abuse or Dependence	47	4.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	80	7.1%



**Table 1h. Aggregated Characteristics of Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	28.4	18.1
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	13.2	18.3
Mean number of filled prescriptions	24.0	20.2
Mean number of generics dispensed	9.6	6.0
Mean number of unique drug classes dispensed	8.9	5.3

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	24,863	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.8	9.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	659	2.7%
41-64 years	5,418	21.8%
≥ 65 years	18,709	75.2%
Sex		
Female	14,012	56.4%
Male	10,851	43.6%
Race <sup>3</sup>		
American Indian or Alaska Native	110	0.4%
Asian	230	0.9%
Black or African American	1,646	6.6%
Multi-racial	51	0.2%
Native Hawaiian or Other Pacific Islander	23	0.1%
Unknown	5,780	23.2%
White	17,023	68.5%
Hispanic origin		
Yes	511	2.1%
No	17,966	72.3%
Unknown	6,386	25.7%
Year		
2018	60	0.2%
2019	5,252	21.1%
2020	7,049	28.4%
2021	6,135	24.7%
2022	6,065	24.4%
2023	302	1.2%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	216	0.9%
Alzheimer's Disease and related conditions	696	2.8%
Atrial Fibrillation	2,690	10.8%
Diabetes Mellitus	6,213	25.0%
Heart Failure	2,953	11.9%
Hyperlipidemia	12,035	48.4%
Hypertension	15,744	63.3%

**Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	5,362	21.6%
Ischemic Heart Disease	6,722	27.0%
Rheumatoid Arthritis/Osteoarthritis	4,873	19.6%
Stroke/TIA <sup>4</sup>	849	3.4%
Breast Cancer	4,947	19.9%
Colorectal Cancer	3,635	14.6%
Prostate Cancer	1,323	5.3%
Lung Cancer	5,990	24.1%
Endometrial Cancer	1,076	4.3%
Acquired Hypothyroidism	4,011	16.1%
Anemia	10,847	43.6%
Asthma	1,486	6.0%
Benign Prostatic Hyperplasia	2,140	8.6%
Chronic Kidney Disease	5,322	21.4%
COPD <sup>5</sup> and Bronchiectasis	5,572	22.4%
Glaucoma	1,903	7.7%
Osteoporosis	1,224	4.9%
Obesity: diagnosed or identified by weight management procedures	6,630	26.7%
Obesity: identified by weight management-related prescriptions	117	0.5%
Overweight	3,906	15.7%
Smoking: diagnosed or identified by smoking cessation procedures	12,297	49.5%
Smoking: identified by smoking-related prescriptions	382	1.5%
Alcohol Abuse or Dependence	853	3.4%
Drug Abuse or Dependence	787	3.2%
History of Cardiac Arrest	43	0.2%
History of Coronary Angioplasty or Bypass	2,291	9.2%

**Table 1i. Aggregated Characteristics of Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	24.2	13.0
Mean number of emergency room encounters	0.6	1.1
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.6	10.3
Mean number of filled prescriptions	19.9	14.7
Mean number of generics dispensed	10.5	5.7
Mean number of unique drug classes dispensed	9.7	5.0

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	5,773	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	46.5	12.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	2,011	34.8%
41-64 years	2,821	48.9%
≥ 65 years	637	11.0%
Sex		
Female	2,998	51.9%
Male	2,775	48.1%
Race <sup>3</sup>		
American Indian or Alaska Native	38	0.7%
Asian	22	0.4%
Black or African American	470	8.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	2,228	38.6%
White	3,000	52.0%
Hispanic origin		
Yes	243	4.2%
No	3,361	58.2%
Unknown	2,169	37.6%
Year		
2018	598	10.4%
2019	2,408	41.7%
2020	1,606	27.8%
2021	536	9.3%
2022	576	10.0%
2023	49	0.8%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	26	0.5%
Alzheimer's Disease and related conditions	77	1.3%
Atrial Fibrillation	104	1.8%
Diabetes Mellitus	668	11.6%
Heart Failure	258	4.5%
Hyperlipidemia	820	14.2%
Hypertension	1,512	26.2%

**Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	2,441	42.3%
Ischemic Heart Disease	438	7.6%
Rheumatoid Arthritis/Osteoarthritis	1,583	27.4%
Stroke/TIA <sup>4</sup>	60	1.0%
Breast Cancer	53	0.9%
Colorectal Cancer	22	0.4%
Prostate Cancer	16	0.3%
Lung Cancer	24	0.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	363	6.3%
Anemia	743	12.9%
Asthma	323	5.6%
Benign Prostatic Hyperplasia	93	1.6%
Chronic Kidney Disease	345	6.0%
COPD <sup>5</sup> and Bronchiectasis	513	8.9%
Glaucoma	127	2.2%
Osteoporosis	88	1.5%
Obesity: diagnosed or identified by weight management procedures	935	16.2%
Obesity: identified by weight management-related prescriptions	45	0.8%
Overweight	376	6.5%
Smoking: diagnosed or identified by smoking cessation procedures	2,062	35.7%
Smoking: identified by smoking-related prescriptions	389	6.7%
Alcohol Abuse or Dependence	659	11.4%
Drug Abuse or Dependence	3,598	62.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	100	1.7%

**Table 1j. Aggregated Characteristics of Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	17.0	20.3
Mean number of emergency room encounters	0.9	2.0
Mean number of inpatient hospital encounters	0.4	1.0
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.7	20.3
Mean number of filled prescriptions	32.0	24.2
Mean number of generics dispensed	10.8	6.8
Mean number of unique drug classes dispensed	9.8	6.0

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	158,717	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	48.8	13.0
Age		
0-17 years	900	0.6%
18-24 years	8,287	5.2%
25-40 years	40,874	25.8%
41-64 years	81,933	51.6%
≥ 65 years	26,723	16.8%
Sex		
Female	135,234	85.2%
Male	23,483	14.8%
Race <sup>3</sup>		
American Indian or Alaska Native	667	0.4%
Asian	875	0.6%
Black or African American	7,784	4.9%
Multi-racial	754	0.5%
Native Hawaiian or Other Pacific Islander	110	0.1%
Unknown	74,116	46.7%
White	74,411	46.9%
Hispanic origin		
Yes	4,001	2.5%
No	75,736	47.7%
Unknown	78,980	49.8%
Year		
2018	20,273	12.8%
2019	46,069	29.0%
2020	43,892	27.7%
2021	27,363	17.2%
2022	19,140	12.1%
2023	1,980	1.2%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	211	0.1%
Alzheimer's Disease and related conditions	2,390	1.5%
Atrial Fibrillation	2,846	1.8%
Diabetes Mellitus	18,103	11.4%
Heart Failure	4,959	3.1%
Hyperlipidemia	29,091	18.3%
Hypertension	37,658	23.7%
Depression	62,258	39.2%



**Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	10,801	6.8%
Rheumatoid Arthritis/Osteoarthritis	31,488	19.8%
Stroke/TIA <sup>4</sup>	3,987	2.5%
Breast Cancer	2,136	1.3%
Colorectal Cancer	270	0.2%
Prostate Cancer	426	0.3%
Lung Cancer	305	0.2%
Endometrial Cancer	170	0.1%
Acquired Hypothyroidism	17,005	10.7%
Anemia	20,095	12.7%
Asthma	12,391	7.8%
Benign Prostatic Hyperplasia	1,423	0.9%
Chronic Kidney Disease	8,350	5.3%
COPD <sup>5</sup> and Bronchiectasis	8,729	5.5%
Glaucoma	7,239	4.6%
Osteoporosis	4,365	2.8%
Obesity: diagnosed or identified by weight management procedures	36,297	22.9%
Obesity: identified by weight management-related prescriptions	2,250	1.4%
Overweight	12,220	7.7%
Smoking: diagnosed or identified by smoking cessation procedures	25,761	16.2%
Smoking: identified by smoking-related prescriptions	2,737	1.7%
Alcohol Abuse or Dependence	2,497	1.6%
Drug Abuse or Dependence	9,584	6.0%
History of Cardiac Arrest	121	0.1%
History of Coronary Angioplasty or Bypass	2,117	1.3%

**Table 1k. Aggregated Characteristics of Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	15.0	12.9
Mean number of emergency room encounters	0.6	1.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.0	11.5
Mean number of filled prescriptions	32.1	25.3
Mean number of generics dispensed	11.5	6.9
Mean number of unique drug classes dispensed	10.7	6.1

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

**Table 11. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	78,091	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.1	14.0
Age		
0-17 years	25	0.0%
18-24 years	284	0.4%
25-40 years	3,800	4.9%
41-64 years	23,205	29.7%
≥ 65 years	50,777	65.0%
Sex		
Female	33,612	43.0%
Male	44,479	57.0%
Race <sup>3</sup>		
American Indian or Alaska Native	603	0.8%
Asian	3,329	4.3%
Black or African American	15,650	20.0%
Multi-racial	148	0.2%
Native Hawaiian or Other Pacific Islander	245	0.3%
Unknown	16,364	21.0%
White	41,752	53.5%
Hispanic origin		
Yes	5,992	7.7%
No	58,404	74.8%
Unknown	13,695	17.5%
Year		
2018	*****	*****
2019	4,155	5.3%
2020	17,192	22.0%
2021	23,804	30.5%
2022	31,527	40.4%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	3,196	4.1%
Alzheimer's Disease and related conditions	8,450	10.8%
Atrial Fibrillation	13,407	17.2%
Diabetes Mellitus	50,998	65.3%
Heart Failure	31,274	40.0%
Hyperlipidemia	46,813	59.9%

**Table 11. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Hypertension	69,131	88.5%
Depression	20,063	25.7%
Ischemic Heart Disease	33,705	43.2%
Rheumatoid Arthritis/Osteoarthritis	15,086	19.3%
Stroke/TIA <sup>4</sup>	5,940	7.6%
Breast Cancer	1,467	1.9%
Colorectal Cancer	1,284	1.6%
Prostate Cancer	2,563	3.3%
Lung Cancer	1,039	1.3%
Endometrial Cancer	323	0.4%
Acquired Hypothyroidism	13,596	17.4%
Anemia	59,566	76.3%
Asthma	4,677	6.0%
Benign Prostatic Hyperplasia	8,076	10.3%
Chronic Kidney Disease	70,910	90.8%
COPD <sup>5</sup> and Bronchiectasis	14,111	18.1%
Glaucoma	8,907	11.4%
Osteoporosis	3,650	4.7%
Obesity: diagnosed or identified by weight management procedures	23,214	29.7%
Obesity: identified by weight management-related prescriptions	936	1.2%
Overweight	8,634	11.1%
Smoking: diagnosed or identified by smoking cessation procedures	26,009	33.3%
Smoking: identified by smoking-related prescriptions	350	0.4%
Alcohol Abuse or Dependence	2,960	3.8%
Drug Abuse or Dependence	4,551	5.8%
History of Cardiac Arrest	745	1.0%
History of Coronary Angioplasty or Bypass	11,325	14.5%

**Table 11. Aggregated Characteristics of Sodium zirconium cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	38.5	36.1
Mean number of emergency room encounters	1.0	2.4
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	17.1	23.4
Mean number of filled prescriptions	30.2	24.6
Mean number of generics dispensed	11.6	5.8
Mean number of unique drug classes dispensed	10.7	5.1

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	2,406	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	62.0	12.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	180	7.5%
41-64 years	1,059	44.0%
≥ 65 years	1,121	46.6%
Sex		
Female	1,174	48.8%
Male	1,232	51.2%
Race <sup>3</sup>		
American Indian or Alaska Native	16	0.7%
Asian	66	2.7%
Black or African American	146	6.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	781	32.5%
White	1,386	57.6%
Hispanic origin		
Yes	197	8.2%
No	1,519	63.1%
Unknown	690	28.7%
Year		
2018	251	10.4%
2019	503	20.9%
2020	586	24.4%
2021	436	18.1%
2022	585	24.3%
2023	45	1.9%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	33	1.4%
Alzheimer's Disease and related conditions	96	4.0%
Atrial Fibrillation	205	8.5%
Diabetes Mellitus	879	36.5%
Heart Failure	355	14.8%
Hyperlipidemia	742	30.8%
Hypertension	1,238	51.5%

**Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	577	24.0%
Ischemic Heart Disease	532	22.1%
Rheumatoid Arthritis/Osteoarthritis	500	20.8%
Stroke/TIA <sup>4</sup>	86	3.6%
Breast Cancer	74	3.1%
Colorectal Cancer	52	2.2%
Prostate Cancer	52	2.2%
Lung Cancer	28	1.2%
Endometrial Cancer	15	0.6%
Acquired Hypothyroidism	344	14.3%
Anemia	1,474	61.3%
Asthma	142	5.9%
Benign Prostatic Hyperplasia	138	5.7%
Chronic Kidney Disease	586	24.4%
COPD <sup>5</sup> and Bronchiectasis	273	11.3%
Glaucoma	185	7.7%
Osteoporosis	117	4.9%
Obesity: diagnosed or identified by weight management procedures	677	28.1%
Obesity: identified by weight management-related prescriptions	29	1.2%
Overweight	226	9.4%
Smoking: diagnosed or identified by smoking cessation procedures	733	30.5%
Smoking: identified by smoking-related prescriptions	31	1.3%
Alcohol Abuse or Dependence	541	22.5%
Drug Abuse or Dependence	176	7.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	139	5.8%

**Table 1m. Aggregated Characteristics of Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	24.1	19.6
Mean number of emergency room encounters	0.8	1.7
Mean number of inpatient hospital encounters	0.7	1.3
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	11.3	20.1
Mean number of filled prescriptions	26.9	22.5
Mean number of generics dispensed	10.3	6.1
Mean number of unique drug classes dispensed	9.5	5.4

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



**Table 1n. Aggregated Characteristics of Pegvaliase-pqz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	528	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	32.2	10.9
Age		
0-17 years	*****	*****
18-24 years	139	26.3%
25-40 years	230	43.6%
41-64 years	120	22.7%
≥ 65 years	*****	*****
Sex		
Female	276	52.3%
Male	252	47.7%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	290	54.9%
White	226	42.8%
Hispanic origin		
Yes	12	2.3%
No	204	38.6%
Unknown	312	59.1%
Year		
2018	71	13.4%
2019	169	32.0%
2020	135	25.6%
2021	74	14.0%
2022	68	12.9%
2023	11	2.1%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	16	3.0%
Heart Failure	*****	*****
Hyperlipidemia	14	2.7%
Hypertension	26	4.9%

**Table 1n. Aggregated Characteristics of Pegvaliase-pqz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	95	18.0%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA <sup>4</sup>	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	14	2.7%
Asthma	16	3.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	81	15.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	11	2.1%
Smoking: diagnosed or identified by smoking cessation procedures	34	6.4%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

**Table 1n. Aggregated Characteristics of Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	6.9	8.4
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.9	11.1
Mean number of filled prescriptions	11.4	12.7
Mean number of generics dispensed	4.7	4.3
Mean number of unique drug classes dispensed	4.4	3.9

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	51,437	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.6	12.1
Age		
0-17 years	81	0.2%
18-24 years	257	0.5%
25-40 years	2,083	4.0%
41-64 years	13,732	26.7%
≥ 65 years	35,284	68.6%
Sex		
Female	24,881	48.4%
Male	26,556	51.6%
Race <sup>3</sup>		
American Indian or Alaska Native	264	0.5%
Asian	508	1.0%
Black or African American	3,502	6.8%
Multi-racial	126	0.2%
Native Hawaiian or Other Pacific Islander	112	0.2%
Unknown	13,299	25.9%
White	33,626	65.4%
Hispanic origin		
Yes	1,292	2.5%
No	35,167	68.4%
Unknown	14,978	29.1%
Year		
2018	407	0.8%
2019	1,266	2.5%
2020	1,123	2.2%
2021	30,833	59.9%
2022	17,430	33.9%
2023	378	0.7%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	671	1.3%
Alzheimer's Disease and related conditions	3,390	6.6%
Atrial Fibrillation	5,781	11.2%
Diabetes Mellitus	15,343	29.8%
Heart Failure	8,909	17.3%
Hyperlipidemia	18,733	36.4%
Hypertension	25,874	50.3%

**Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	9,895	19.2%
Ischemic Heart Disease	12,697	24.7%
Rheumatoid Arthritis/Osteoarthritis	11,925	23.2%
Stroke/TIA <sup>4</sup>	1,682	3.3%
Breast Cancer	921	1.8%
Colorectal Cancer	469	0.9%
Prostate Cancer	1,104	2.1%
Lung Cancer	765	1.5%
Endometrial Cancer	130	0.3%
Acquired Hypothyroidism	6,522	12.7%
Anemia	10,576	20.6%
Asthma	2,566	5.0%
Benign Prostatic Hyperplasia	2,995	5.8%
Chronic Kidney Disease	10,110	19.7%
COPD <sup>5</sup> and Bronchiectasis	8,640	16.8%
Glaucoma	3,705	7.2%
Osteoporosis	2,092	4.1%
Obesity: diagnosed or identified by weight management procedures	14,837	28.8%
Obesity: identified by weight management-related prescriptions	432	0.8%
Overweight	4,102	8.0%
Smoking: diagnosed or identified by smoking cessation procedures	12,620	24.5%
Smoking: identified by smoking-related prescriptions	146	0.3%
Alcohol Abuse or Dependence	923	1.8%
Drug Abuse or Dependence	1,831	3.6%
History of Cardiac Arrest	105	0.2%
History of Coronary Angioplasty or Bypass	4,141	8.1%

**Table 1o. Aggregated Characteristics of Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.0	11.8
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	5.2	11.5
Mean number of filled prescriptions	20.7	20.6
Mean number of generics dispensed	8.5	6.0
Mean number of unique drug classes dispensed	8.0	5.5

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	0	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race <sup>3</sup>		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2018	.	.
2019	.	.
2020	.	.
2021	.	.
2022	.	.
2023	.	.
<b>Health Characteristics</b>		
Acute Myocardial Infarction	.	.
Alzheimer's Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

**Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA <sup>4</sup>	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD <sup>5</sup> and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.



**Table 1p. Aggregated Characteristics of Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*Data presented by a dash or period is due to their inability to be calculated. This table may not use all data representations.

**Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	20,980	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	20.4	10.8
Age		
0-17 years	11,082	52.8%
18-24 years	3,471	16.5%
25-40 years	4,318	20.6%
41-64 years	1,950	9.3%
≥ 65 years	159	0.8%
Sex		
Female	9,510	45.3%
Male	11,470	54.7%
Race <sup>3</sup>		
American Indian or Alaska Native	118	0.6%
Asian	433	2.1%
Black or African American	1,577	7.5%
Multi-racial	91	0.4%
Native Hawaiian or Other Pacific Islander	41	0.2%
Unknown	8,841	42.1%
White	9,879	47.1%
Hispanic origin		
Yes	2,783	13.3%
No	11,884	56.6%
Unknown	6,313	30.1%
Year		
2018	797	3.8%
2019	12,138	57.9%
2020	5,691	27.1%
2021	1,186	5.7%
2022	1,096	5.2%
2023	72	0.3%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	348	1.7%
Atrial Fibrillation	36	0.2%
Diabetes Mellitus	313	1.5%
Heart Failure	190	0.9%
Hyperlipidemia	594	2.8%
Hypertension	794	3.8%
Depression	1,403	6.7%

**Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	148	0.7%
Rheumatoid Arthritis/Osteoarthritis	197	0.9%
Stroke/TIA <sup>4</sup>	252	1.2%
Breast Cancer	15	0.1%
Colorectal Cancer	19	0.1%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	795	3.8%
Anemia	1,333	6.4%
Asthma	1,148	5.5%
Benign Prostatic Hyperplasia	57	0.3%
Chronic Kidney Disease	556	2.7%
COPD <sup>5</sup> and Bronchiectasis	435	2.1%
Glaucoma	179	0.9%
Osteoporosis	298	1.4%
Obesity: diagnosed or identified by weight management procedures	948	4.5%
Obesity: identified by weight management-related prescriptions	18	0.1%
Overweight	452	2.2%
Smoking: diagnosed or identified by smoking cessation procedures	433	2.1%
Smoking: identified by smoking-related prescriptions	21	0.1%
Alcohol Abuse or Dependence	73	0.3%
Drug Abuse or Dependence	211	1.0%
History of Cardiac Arrest	41	0.2%
History of Coronary Angioplasty or Bypass	22	0.1%

**Table 1q. Aggregated Characteristics of Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	16.0	22.8
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.3	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	48.2	54.6
Mean number of filled prescriptions	30.2	23.3
Mean number of generics dispensed	7.9	5.2
Mean number of unique drug classes dispensed	7.5	4.8

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	249	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	72.0	12.3
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	189	75.9%
Sex		
Female	164	65.9%
Male	85	34.1%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	48	19.3%
White	187	75.1%
Hispanic origin		
Yes	*****	*****
No	190	76.3%
Unknown	*****	*****
Year		
2018	*****	*****
2019	51	20.5%
2020	76	30.5%
2021	71	28.5%
2022	37	14.9%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	27	10.8%
Atrial Fibrillation	56	22.5%
Diabetes Mellitus	88	35.3%
Heart Failure	62	24.9%
Hyperlipidemia	126	50.6%
Hypertension	162	65.1%
Depression	80	32.1%

**Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	77	30.9%
Rheumatoid Arthritis/Osteoarthritis	84	33.7%
Stroke/TIA <sup>4</sup>	14	5.6%
Breast Cancer	21	8.4%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	56	22.5%
Anemia	101	40.6%
Asthma	25	10.0%
Benign Prostatic Hyperplasia	43	17.3%
Chronic Kidney Disease	94	37.8%
COPD <sup>5</sup> and Bronchiectasis	44	17.7%
Glaucoma	27	10.8%
Osteoporosis	27	10.8%
Obesity: diagnosed or identified by weight management procedures	79	31.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	27	10.8%
Smoking: diagnosed or identified by smoking cessation procedures	79	31.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	19	7.6%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	28	11.2%

**Table 1r. Aggregated Characteristics of Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	30.6	23.2
Mean number of emergency room encounters	1.1	1.9
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.2	0.7
Mean number of other ambulatory encounters	16.3	24.7
Mean number of filled prescriptions	29.7	30.8
Mean number of generics dispensed	12.6	6.2
Mean number of unique drug classes dispensed	11.4	5.5

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	2,872	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	63.3	12.2
Age		
0-17 years	23	0.8%
18-24 years	32	1.1%
25-40 years	224	7.8%
41-64 years	943	32.8%
≥ 65 years	1,650	57.5%
Sex		
Female	1,259	43.8%
Male	1,613	56.2%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	23	0.8%
Black or African American	32	1.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	881	30.7%
White	1,920	66.9%
Hispanic origin		
Yes	49	1.7%
No	1,866	65.0%
Unknown	957	33.3%
Year		
2018	306	10.7%
2019	643	22.4%
2020	799	27.8%
2021	571	19.9%
2022	529	18.4%
2023	24	0.8%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	24	0.8%
Alzheimer's Disease and related conditions	89	3.1%
Atrial Fibrillation	287	10.0%
Diabetes Mellitus	596	20.8%
Heart Failure	307	10.7%
Hyperlipidemia	1,005	35.0%
Hypertension	1,433	49.9%
Depression	569	19.8%



**Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	567	19.7%
Rheumatoid Arthritis/Osteoarthritis	414	14.4%
Stroke/TIA <sup>4</sup>	282	9.8%
Breast Cancer	101	3.5%
Colorectal Cancer	290	10.1%
Prostate Cancer	114	4.0%
Lung Cancer	208	7.2%
Endometrial Cancer	12	0.4%
Acquired Hypothyroidism	605	21.1%
Anemia	1,036	36.1%
Asthma	137	4.8%
Benign Prostatic Hyperplasia	225	7.8%
Chronic Kidney Disease	584	20.3%
COPD <sup>5</sup> and Bronchiectasis	253	8.8%
Glaucoma	193	6.7%
Osteoporosis	98	3.4%
Obesity: diagnosed or identified by weight management procedures	570	19.8%
Obesity: identified by weight management-related prescriptions	16	0.6%
Overweight	287	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	1,028	35.8%
Smoking: identified by smoking-related prescriptions	29	1.0%
Alcohol Abuse or Dependence	68	2.4%
Drug Abuse or Dependence	115	4.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	183	6.4%

**Table 1s. Aggregated Characteristics of Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	25.6	12.9
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.2	12.7
Mean number of filled prescriptions	22.9	16.9
Mean number of generics dispensed	10.2	5.7
Mean number of unique drug classes dispensed	9.4	5.0

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	3,371	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	64.5	11.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	244	7.2%
41-64 years	1,109	32.9%
≥ 65 years	1,991	59.1%
Sex		
Female	1,556	46.2%
Male	1,815	53.8%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	36	1.1%
Black or African American	52	1.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,033	30.6%
White	2,232	66.2%
Hispanic origin		
Yes	43	1.3%
No	2,174	64.5%
Unknown	1,154	34.2%
Year		
2018	298	8.8%
2019	623	18.5%
2020	911	27.0%
2021	792	23.5%
2022	707	21.0%
2023	40	1.2%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	30	0.9%
Alzheimer's Disease and related conditions	112	3.3%
Atrial Fibrillation	349	10.4%
Diabetes Mellitus	716	21.2%
Heart Failure	374	11.1%
Hyperlipidemia	1,196	35.5%
Hypertension	1,701	50.5%
Depression	683	20.3%

**Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Ischemic Heart Disease	706	20.9%
Rheumatoid Arthritis/Osteoarthritis	491	14.6%
Stroke/TIA <sup>4</sup>	297	8.8%
Breast Cancer	119	3.5%
Colorectal Cancer	965	28.6%
Prostate Cancer	125	3.7%
Lung Cancer	218	6.5%
Endometrial Cancer	14	0.4%
Acquired Hypothyroidism	672	19.9%
Anemia	1,360	40.3%
Asthma	161	4.8%
Benign Prostatic Hyperplasia	262	7.8%
Chronic Kidney Disease	725	21.5%
COPD <sup>5</sup> and Bronchiectasis	308	9.1%
Glaucoma	226	6.7%
Osteoporosis	120	3.6%
Obesity: diagnosed or identified by weight management procedures	670	19.9%
Obesity: identified by weight management-related prescriptions	16	0.5%
Overweight	343	10.2%
Smoking: diagnosed or identified by smoking cessation procedures	1,224	36.3%
Smoking: identified by smoking-related prescriptions	33	1.0%
Alcohol Abuse or Dependence	69	2.0%
Drug Abuse or Dependence	138	4.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	220	6.5%

**Table 1t. Aggregated Characteristics of Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	26.2	13.0
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	0.7	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.6	12.6
Mean number of filled prescriptions	22.8	16.7
Mean number of generics dispensed	10.3	5.6
Mean number of unique drug classes dispensed	9.4	4.9

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	27	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	35.1	10.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	0	0.0%
No	*****	*****
Unknown	*****	*****
Year		
2018	0	0.0%
2019	0	0.0%
2020	0	0.0%
2021	0	0.0%
2022	27	100.0%
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	*****	*****
Depression	*****	*****

**Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA <sup>4</sup>	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

**Table 1u. Aggregated Characteristics of Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	5.8	4.1
Mean number of emergency room encounters	0.9	1.1
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	3.4	2.8
Mean number of filled prescriptions	11.6	9.2
Mean number of generics dispensed	4.9	3.0
Mean number of unique drug classes dispensed	4.7	2.8

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*NaN: Not a number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



**Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	1,476	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	68.8	11.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	313	21.2%
≥ 65 years	1,075	72.8%
Sex		
Female	750	50.8%
Male	726	49.2%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	82	5.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	391	26.5%
White	967	65.5%
Hispanic origin		
Yes	44	3.0%
No	1,012	68.6%
Unknown	420	28.5%
Year		
2018	111	7.5%
2019	187	12.7%
2020	327	22.2%
2021	376	25.5%
2022	450	30.5%
2023	25	1.7%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	21	1.4%
Alzheimer's Disease and related conditions	73	4.9%
Atrial Fibrillation	212	14.4%
Diabetes Mellitus	335	22.7%
Heart Failure	261	17.7%
Hyperlipidemia	614	41.6%
Hypertension	869	58.9%
Depression	321	21.7%

**Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	386	26.2%
Rheumatoid Arthritis/Osteoarthritis	248	16.8%
Stroke/TIA <sup>4</sup>	88	6.0%
Breast Cancer	89	6.0%
Colorectal Cancer	38	2.6%
Prostate Cancer	70	4.7%
Lung Cancer	27	1.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	235	15.9%
Anemia	1,099	74.5%
Asthma	82	5.6%
Benign Prostatic Hyperplasia	126	8.5%
Chronic Kidney Disease	428	29.0%
COPD <sup>5</sup> and Bronchiectasis	182	12.3%
Glaucoma	106	7.2%
Osteoporosis	88	6.0%
Obesity: diagnosed or identified by weight management procedures	287	19.4%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	174	11.8%
Smoking: diagnosed or identified by smoking cessation procedures	529	35.8%
Smoking: identified by smoking-related prescriptions	12	0.8%
Alcohol Abuse or Dependence	49	3.3%
Drug Abuse or Dependence	48	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	121	8.2%

**Table 1v. Aggregated Characteristics of Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	34.7	19.9
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	1.0	1.4
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	14.9	18.0
Mean number of filled prescriptions	23.6	15.6
Mean number of generics dispensed	10.9	5.9
Mean number of unique drug classes dispensed	10.1	5.3

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	197	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	44.9	13.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	53	26.9%
41-64 years	101	51.3%
≥ 65 years	21	10.7%
Sex		
Female	124	62.9%
Male	73	37.1%
Race <sup>3</sup>		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	161	81.7%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	170	86.3%
Year		
2018	0	0.0%
2019	68	34.5%
2020	36	18.3%
2021	*****	*****
2022	53	26.9%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	11	5.6%
Hypertension	14	7.1%
Depression	34	17.3%

**Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	21	10.7%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	19	9.6%
Anemia	22	11.2%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

**Table 1w. Aggregated Characteristics of Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.1	12.0
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.1	12.8
Mean number of filled prescriptions	20.2	22.1
Mean number of generics dispensed	7.9	6.6
Mean number of unique drug classes dispensed	7.2	5.9

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*NaN: Not a number

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Unique patients	25,153	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	33.3	8.2
Age		
0-17 years	*****	*****
18-24 years	4,359	17.3%
25-40 years	15,403	61.2%
41-64 years	5,053	20.1%
≥ 65 years	*****	*****
Sex		
Female	25,123	99.9%
Male	30	0.1%
Race <sup>3</sup>		
American Indian or Alaska Native	111	0.4%
Asian	235	0.9%
Black or African American	1,487	5.9%
Multi-racial	252	1.0%
Native Hawaiian or Other Pacific Islander	24	0.1%
Unknown	16,853	67.0%
White	6,191	24.6%
Hispanic origin		
Yes	1,260	5.0%
No	6,827	27.1%
Unknown	17,066	67.8%
Year		
2018	1,111	4.4%
2019	7,912	31.5%
2020	8,257	32.8%
2021	3,793	15.1%
2022	3,606	14.3%
2023	474	1.9%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	27	0.1%
Atrial Fibrillation	23	0.1%
Diabetes Mellitus	776	3.1%
Heart Failure	128	0.5%
Hyperlipidemia	852	3.4%
Hypertension	1,654	6.6%

**Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

<b>Patient Characteristics</b>	<b>Number/Mean</b>	<b>Percent/ Standard Deviation<sup>1</sup></b>
Depression	6,368	25.3%
Ischemic Heart Disease	187	0.7%
Rheumatoid Arthritis/Osteoarthritis	1,026	4.1%
Stroke/TIA <sup>4</sup>	51	0.2%
Breast Cancer	56	0.2%
Colorectal Cancer	11	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,040	4.1%
Anemia	2,448	9.7%
Asthma	1,293	5.1%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	316	1.3%
COPD <sup>5</sup> and Bronchiectasis	166	0.7%
Glaucoma	254	1.0%
Osteoporosis	17	0.1%
Obesity: diagnosed or identified by weight management procedures	4,133	16.4%
Obesity: identified by weight management-related prescriptions	240	1.0%
Overweight	1,398	5.6%
Smoking: diagnosed or identified by smoking cessation procedures	2,632	10.5%
Smoking: identified by smoking-related prescriptions	300	1.2%
Alcohol Abuse or Dependence	256	1.0%
Drug Abuse or Dependence	789	3.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	17	0.1%



**Table 1x. Aggregated Characteristics of Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	11.3	10.8
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.1	8.2
Mean number of filled prescriptions	15.4	16.3
Mean number of generics dispensed	7.2	5.6
Mean number of unique drug classes dispensed	6.7	5.0

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	141	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	13.0	13.0
Age		
0-17 years	110	78.0%
18-24 years	*****	*****
25-40 years	12	8.5%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	81	57.4%
Male	60	42.6%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	77	54.6%
White	38	27.0%
Hispanic origin		
Yes	21	14.9%
No	60	42.6%
Unknown	60	42.6%
Year		
2018	*****	*****
2019	27	19.1%
2020	76	53.9%
2021	*****	*****
2022	18	12.8%
2023	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	17	12.1%

**Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	12	8.5%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	82	58.2%
Asthma	12	8.5%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	22	15.6%
COPD <sup>5</sup> and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	20	14.2%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****

**Table 1y. Aggregated Characteristics of Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	23.6	28.1
Mean number of emergency room encounters	1.2	2.0
Mean number of inpatient hospital encounters	1.4	1.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	86.1	57.1
Mean number of filled prescriptions	51.7	79.9
Mean number of generics dispensed	8.8	8.7
Mean number of unique drug classes dispensed	8.0	7.3

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Unique patients	390	N/A <sup>2</sup>
<b>Demographic Characteristics</b>		
Age (years)	57.4	9.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	282	72.3%
≥ 65 years	86	22.1%
Sex		
Female	175	44.9%
Male	215	55.1%
Race <sup>3</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	14	3.6%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	183	46.9%
White	176	45.1%
Hispanic origin		
Yes	63	16.2%
No	199	51.0%
Unknown	128	32.8%
Year		
2018	*****	*****
2019	205	52.6%
2020	122	31.3%
2021	31	7.9%
2022	*****	*****
2023	0	0.0%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	15	3.8%
Atrial Fibrillation	12	3.1%
Diabetes Mellitus	139	35.6%
Heart Failure	39	10.0%
Hyperlipidemia	70	17.9%
Hypertension	159	40.8%

**Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
Depression	95	24.4%
Ischemic Heart Disease	60	15.4%
Rheumatoid Arthritis/Osteoarthritis	68	17.4%
Stroke/TIA <sup>4</sup>	*****	*****
Breast Cancer	12	3.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	*****	*****
Anemia	225	57.7%
Asthma	18	4.6%
Benign Prostatic Hyperplasia	11	2.8%
Chronic Kidney Disease	63	16.2%
COPD <sup>5</sup> and Bronchiectasis	30	7.7%
Glaucoma	17	4.4%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	121	31.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	39	10.0%
Smoking: diagnosed or identified by smoking cessation procedures	120	30.8%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	165	42.3%
Drug Abuse or Dependence	52	13.3%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	3.6%

**Table 1z. Aggregated Characteristics of Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

Patient Characteristics	Number/Mean	Percent/ Standard Deviation <sup>1</sup>
<b>Health Service Utilization Intensity Metrics</b>		
Mean number of ambulatory encounters	18.8	16.5
Mean number of emergency room encounters	1.1	3.0
Mean number of inpatient hospital encounters	0.7	1.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	10.9	17.9
Mean number of filled prescriptions	28.9	22.6
Mean number of generics dispensed	10.5	5.8
Mean number of unique drug classes dispensed	9.7	5.2

<sup>1</sup>Value represents standard deviation where n % follows the value

<sup>2</sup>N/A: Not Applicable

<sup>3</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

<sup>4</sup>TIA: Transient Ischemic Attack

<sup>5</sup>COPD: Chronic Obstructive Pulmonary Disease

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

**Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Lutetium Lu 177 dotatate</i>	13,931	13,931	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate</i>	2,430,596	2,333,808	96.0%	16,260	0.7%	79,227	3.3%	1,301	0.1%
<i>Tezacaftor and ivacaftor</i>	42,423	41,541	97.9%	351	0.8%	504	1.2%	27	0.1%
<i>Apalutamide</i>	116,929	115,315	98.6%	911	0.8%	666	0.6%	37	0.0%
<i>Ibalizumab-uiyk</i>	7,138	7,106	99.6%	14	0.2%	18	0.3%	0	0.0%
<i>Tildrakizumab</i>	38,286	35,824	93.6%	****	****	2,211	5.8%	****	****
<i>Burosumab-twza</i>	18,387	17,461	95.0%	908	4.9%	18	0.1%	0	0.0%
<i>Fostamatinib</i>	8,019	7,910	98.6%	73	0.9%	****	****	****	****
<i>palonosetron</i>	133,889	****	100.0%	****	****	****	****	0	0.0%
<i>Lofexidine hydrochloride</i>	7,866	7,800	99.2%	55	0.7%	****	****	****	****
<i>Erenumab-aooe</i>	1,484,002	1,397,126	94.1%	14,234	1.0%	72,487	4.9%	155	0.0%
<i>Sodium zirconium cyclosilicate</i>	270,097	225,079	83.3%	17,413	6.4%	27,508	10.2%	97	0.0%
<i>Avatrombopag</i>	9,359	9,009	96.3%	235	2.5%	****	****	****	****
<i>Pegvaliase-pqpz</i>	7,489	7,188	96.0%	259	3.5%	30	0.4%	12	0.2%
<i>Baricitinib</i>	77,774	76,110	97.9%	****	****	1,429	1.8%	****	****
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.
<i>Cannabidiol</i>	268,214	249,026	92.8%	16,942	6.3%	1,942	0.7%	304	0.1%
<i>Plazomicin</i>	1,409	****	****	0	0.0%	0	0.0%	****	****
<i>Binimetinib</i>	19,042	18,919	99.4%	108	0.6%	****	****	****	****
<i>Encorafenib</i>	21,646	21,369	98.7%	252	1.2%	25	0.1%	0	0.0%
<i>Tecovirimat</i>	39	39	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ivosidenib</i>	9,090	9,056	99.6%	****	****	****	****	0	0.0%
<i>Tafenoquine</i>	536	506	94.4%	19	3.5%	****	****	****	****
<i>Elagolix sodium</i>	124,342	117,858	94.8%	1,165	0.9%	5,266	4.2%	53	0.0%
<i>Fish oil triglycerides</i>	4,549	4,549	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lusutrombopag</i>	568	****	****	****	****	0	0.0%	0	0.0%

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash or period is due to their inability to be calculated. This table may not use all data representations.



**Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	13,931	1	1	1	1	1	1.0	0.0
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	2,430,596	1	30	30	30	899	31.3	12.0
<i>Tezacaftor and ivacaftor</i>	42,423	1	28	28	28	280	28.5	7.8
<i>Apalutamide</i>	116,929	1	30	30	30	250	29.9	6.2
<i>Ibalizumab-uiyk</i>	7,138	1	1	14	28	84	12.8	12.3
<i>Tildrakizumab</i>	38,286	1	1	1	1	168	6.9	20.0
<i>Burosumab-twza</i>	18,387	1	1	1	28	90	12.9	15.9
<i>Fostamatinib</i>	8,019	1	30	30	30	101	29.6	6.4
<i>Fosnetupitant and palonosetron</i>	133,889	1	1	1	1	90	1.3	2.5
<i>Lofexidine hydrochloride</i>	7,866	1	8	9	14	126	11.6	6.9
<i>Erenumab-aooe</i>	1,484,002	1	28	30	30	389	31.8	13.6
<i>Sodium zirconium cyclosilicate</i>	270,097	1	25	30	30	450	31.7	21.4
<i>Avatrombopag</i>	9,359	1	15	30	30	105	24.1	12.3
<i>Pegvaliase-pqyz</i>	7,489	1	28	30	30	152	28.7	8.6
<i>Baricitinib</i>	77,774	1	1	1	30	180	12.6	17.3
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	268,214	1	30	30	30	658	29.6	8.0
<i>Plazomicin</i>	1,409	1	1	1	1	554	1.5	14.8
<i>Binimetinib</i>	19,042	1	30	30	30	180	29.2	4.8
<i>Encorafenib</i>	21,646	1	30	30	30	90	29.2	4.9
<i>Tecovirimat</i>	39	8	14	14	14	14	13.6	1.5
<i>Ivosidenib</i>	9,090	1	30	30	30	90	28.9	5.1
<i>Tafenoquine</i>	536	1	1	14	28	365	17.1	23.9
<i>Elagolix sodium</i>	124,342	1	28	28	28	280	29.9	12.6
<i>Fish oil triglycerides</i>	4,549	1	1	1	4	21	2.6	2.5
<i>Lusutrombopag</i>	568	1	7	7	7	37	7.8	3.6

~Data presented by a dash or period is due to their inability to be calculated. This table may not use all data representations.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Lutetium Lu 177 dotatate</b>	<b>13,931</b>	<b>13,931</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	6,873	6,873	49.3%	0	NaN	0	NaN	0	NaN
Male	7,058	7,058	50.7%	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir</b>	<b>2,430,596</b>	<b>2,333,808</b>	<b>100.0%</b>	<b>16,260</b>	<b>100.0%</b>	<b>79,227</b>	<b>100.0%</b>	<b>1,301</b>	<b>100.0%</b>
Female	606,019	589,688	25.3%	3,409	21.0%	12,676	16.0%	246	18.9%
Male	1,824,577	1,744,120	74.7%	12,851	79.0%	66,551	84.0%	1,055	81.1%
<b>Tezacaftor and ivacaftor</b>	<b>42,423</b>	<b>41,541</b>	<b>100.0%</b>	<b>351</b>	<b>100.0%</b>	<b>504</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
Female	20,741	20,315	48.9%	174	49.6%	236	46.8%	16	59.3%
Male	21,682	21,226	51.1%	177	50.4%	268	53.2%	11	40.7%
<b>Apalutamide</b>	<b>116,929</b>	<b>115,315</b>	<b>100.0%</b>	<b>911</b>	<b>100.0%</b>	<b>666</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>
Female	****	****	****	0	0.0%	0	0.0%	0	0.0%
Male	****	****	****	911	100.0%	666	100.0%	37	100.0%
<b>Ibalizumab-uiyk</b>	<b>7,138</b>	<b>7,106</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	1,556	****	****	****	****	****	****	0	NaN
Male	5,582	****	****	****	****	****	****	0	NaN
<b>Tildrakizumab</b>	<b>38,286</b>	<b>35,824</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>2,211</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	19,684	18,428	51.4%	****	****	****	****	****	****
Male	18,602	17,396	48.6%	****	****	****	****	****	****
<b>Burosumab-twza</b>	<b>18,387</b>	<b>17,461</b>	<b>100.0%</b>	<b>908</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	11,586	10,880	62.3%	****	****	****	****	0	NaN
Male	6,801	6,581	37.7%	****	****	****	****	0	NaN
<b>Fostamatinib</b>	<b>8,019</b>	<b>7,910</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	4,699	4,633	58.6%	52	71.2%	****	37.1%	****	100.0%
Male	3,320	3,277	41.4%	21	28.8%	****	62.9%	0	0.0%
<b>Fosnetupitant and palonosetron</b>	<b>133,889</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>****</b>	<b>0</b>	<b>NaN</b>
Female	74,806	****	55.9%	0	0.0%	****	****	0	NaN
Male	59,083	****	44.1%	****	100.0%	****	****	0	NaN
<b>Lofexidine hydrochloride</b>	<b>7,866</b>	<b>7,800</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	4,048	4,029	51.7%	****	****	****	****	0	****
Male	3,818	3,771	48.3%	****	****	****	****	****	****
<b>Erenumab-aooe</b>	<b>1,484,002</b>	<b>1,397,126</b>	<b>100.0%</b>	<b>14,234</b>	<b>100.0%</b>	<b>72,487</b>	<b>100.0%</b>	<b>155</b>	<b>100.0%</b>
Female	1,267,611	1,193,366	85.4%	12,153	85.4%	61,964	85.5%	128	82.6%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

Number of Dispensings by Days Supplied									
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	216,391	203,760	14.6%	2,081	14.6%	10,523	14.5%	27	17.4%
<b>Sodium zirconium cyclosilicate</b>	<b>270,097</b>	<b>225,079</b>	<b>100.0%</b>	<b>17,413</b>	<b>100.0%</b>	<b>27,508</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>
Female	111,607	93,487	41.5%	7,248	41.6%	10,834	39.4%	38	39.2%
Male	158,490	131,592	58.5%	10,165	58.4%	16,674	60.6%	59	60.8%
<b>Avatrombopag</b>	<b>9,359</b>	<b>9,009</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	4,782	4,577	50.8%	147	62.6%	58	****	0	0.0%
Male	4,577	4,432	49.2%	88	37.4%	****	****	****	100.0%
<b>Pegvaliase-pqpz</b>	<b>7,489</b>	<b>7,188</b>	<b>100.0%</b>	<b>259</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
Female	3,552	3,414	47.5%	117	45.2%	****	****	****	****
Male	3,937	3,774	52.5%	142	54.8%	****	****	****	****
<b>Baricitinib</b>	<b>77,774</b>	<b>76,110</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>1,429</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	45,959	44,631	58.6%	****	****	1,154	80.8%	****	****
Male	31,815	31,479	41.4%	61	****	275	19.2%	0	0.0%
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>268,214</b>	<b>249,026</b>	<b>100.0%</b>	<b>16,942</b>	<b>100.0%</b>	<b>1,942</b>	<b>100.0%</b>	<b>304</b>	<b>100.0%</b>
Female	119,795	110,918	44.5%	7,786	46.0%	932	48.0%	159	52.3%
Male	148,419	138,108	55.5%	9,156	54.0%	1,010	52.0%	145	47.7%
<b>Plazomicin</b>	<b>1,409</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>****</b>	<b>100.0%</b>
Female	1,001	1,001	71.1%	0	NaN	0	NaN	0	0.0%
Male	408	****	****	0	NaN	0	NaN	****	****
<b>Binimetinib</b>	<b>19,042</b>	<b>18,919</b>	<b>100.0%</b>	<b>108</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	8,633	8,568	45.3%	****	****	****	****	****	****
Male	10,409	10,351	54.7%	****	****	****	****	****	****
<b>Encorafenib</b>	<b>21,646</b>	<b>21,369</b>	<b>100.0%</b>	<b>252</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	10,156	10,004	46.8%	****	****	****	****	0	NaN
Male	11,490	11,365	53.2%	****	****	****	****	0	NaN
<b>Tecovirimat</b>	<b>39</b>	<b>39</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	0	NaN	0	NaN	0	NaN

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Ivosidenib</b>	<b>9,090</b>	<b>9,056</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	4,695	4,674	51.6%	*****	*****	*****	*****	0	NaN
Male	4,395	4,382	48.4%	*****	*****	*****	*****	0	NaN
<b>Tafenoquine</b>	<b>536</b>	<b>506</b>	<b>100.0%</b>	<b>19</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	355	346	68.4%	*****	*****	*****	*****	0	0.0%
Male	181	160	31.6%	*****	*****	*****	*****	*****	*****
<b>Elagolix sodium</b>	<b>124,342</b>	<b>117,858</b>	<b>100.0%</b>	<b>1,165</b>	<b>100.0%</b>	<b>5,266</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>
Female	124,199	*****	99.9%	*****	*****	*****	*****	53	100.0%
Male	143	*****	0.1%	*****	*****	*****	*****	0	0.0%
<b>Fish oil triglycerides</b>	<b>4,549</b>	<b>4,549</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	2,539	2,539	55.8%	0	NaN	0	NaN	0	NaN
Male	2,010	2,010	44.2%	0	NaN	0	NaN	0	NaN
<b>Lusutrombopag</b>	<b>568</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	280	*****	*****	0	*****	0	NaN	0	NaN
Male	288	*****	*****	*****	*****	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>13,931</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	6,873	1	1	1	1	1	1.0	0.0
Male	7,058	1	1	1	1	1	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>2,430,596</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>899</b>	<b>31.3</b>	<b>12.0</b>
Female	606,019	1	30	30	30	518	30.5	10.1
Male	1,824,577	1	30	30	30	899	31.6	12.6
<b>Tezacaftor and ivacaftor</b>	<b>42,423</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>280</b>	<b>28.5</b>	<b>7.8</b>
Female	20,741	1	28	28	28	280	28.5	7.8
Male	21,682	1	28	28	28	280	28.5	7.9
<b>Apalutamide</b>	<b>116,929</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>250</b>	<b>29.9</b>	<b>6.2</b>
Female	*****	30	30	30	30	30	30.0	0.0
Male	*****	1	30	30	30	250	29.9	6.2
<b>Ibalizumab-uiyk</b>	<b>7,138</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>28</b>	<b>84</b>	<b>12.8</b>	<b>12.3</b>
Female	1,556	1	1	1	14	84	9.9	11.8
Male	5,582	1	1	14	28	84	13.6	12.4
<b>Tildrakizumab</b>	<b>38,286</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>6.9</b>	<b>20.0</b>
Female	19,684	1	1	1	1	168	7.0	19.9
Male	18,602	1	1	1	1	147	6.9	20.0
<b>Burosumab-twza</b>	<b>18,387</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>90</b>	<b>12.9</b>	<b>15.9</b>
Female	11,586	1	1	1	28	90	13.9	16.4
Male	6,801	1	1	1	28	84	11.3	14.8
<b>Fostamatinib</b>	<b>8,019</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>101</b>	<b>29.6</b>	<b>6.4</b>
Female	4,699	1	30	30	30	101	29.6	6.0
Male	3,320	1	30	30	30	90	29.5	6.9
<b>Fosnetupitant and palonosetron</b>	<b>133,889</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>90</b>	<b>1.3</b>	<b>2.5</b>
Female	74,806	1	1	1	1	90	1.3	2.5
Male	59,083	1	1	1	1	90	1.3	2.5
<b>Lofexidine hydrochloride</b>	<b>7,866</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>126</b>	<b>11.6</b>	<b>6.9</b>
Female	4,048	1	8	9	14	90	11.5	6.3
Male	3,818	1	8	9	14	126	11.8	7.5
<b>Erenumab-aooe</b>	<b>1,484,002</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>30</b>	<b>389</b>	<b>31.8</b>	<b>13.6</b>
Female	1,267,611	1	28	30	30	389	31.8	13.6
Male	216,391	1	28	30	30	360	31.8	13.6
<b>Sodium zirconium cyclosilicate</b>	<b>270,097</b>	<b>1</b>	<b>25</b>	<b>30</b>	<b>30</b>	<b>450</b>	<b>31.7</b>	<b>21.4</b>
Female	111,607	1	20	30	30	180	30.9	21.4
Male	158,490	1	28	30	30	450	32.4	21.5
<b>Avatrombopag</b>	<b>9,359</b>	<b>1</b>	<b>15</b>	<b>30</b>	<b>30</b>	<b>105</b>	<b>24.1</b>	<b>12.3</b>
Female	4,782	1	18	30	30	90	24.6	12.0
Male	4,577	1	14	30	30	105	23.7	12.6
<b>Pegvaliase-pqpz</b>	<b>7,489</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>30</b>	<b>152</b>	<b>28.7</b>	<b>8.6</b>
Female	3,552	1	28	30	30	152	28.5	8.7
Male	3,937	1	28	30	30	105	28.9	8.5
<b>Baricitinib</b>	<b>77,774</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>30</b>	<b>180</b>	<b>12.6</b>	<b>17.3</b>
Female	45,959	1	1	21	30	180	17.2	18.5
Male	31,815	1	1	1	1	90	6.0	12.9
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>268,214</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>658</b>	<b>29.6</b>	<b>8.0</b>
Female	119,795	1	30	30	30	447	29.7	8.1
Male	148,419	1	30	30	30	658	29.4	7.9
<b>Plazomicin</b>	<b>1,409</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>554</b>	<b>1.5</b>	<b>14.8</b>
Female	1,001	1	1	1	1	10	1.1	0.7
Male	408	1	1	1	1	554	2.5	27.4
<b>Binimetinib</b>	<b>19,042</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>29.2</b>	<b>4.8</b>
Female	8,633	1	30	30	30	180	29.3	5.0
Male	10,409	1	30	30	30	180	29.2	4.7
<b>Encorafenib</b>	<b>21,646</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>4.9</b>
Female	10,156	1	30	30	30	90	29.2	4.7
Male	11,490	1	30	30	30	90	29.2	5.0
<b>Tecovirimat</b>	<b>39</b>	<b>8</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>13.6</b>	<b>1.5</b>
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	8	14	14	14	14	13.6	1.6
<b>Ivosidenib</b>	<b>9,090</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>28.9</b>	<b>5.1</b>
Female	4,695	1	30	30	30	90	28.9	5.1
Male	4,395	1	30	30	30	90	28.9	5.1
<b>Tafenoquine</b>	<b>536</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>28</b>	<b>365</b>	<b>17.1</b>	<b>23.9</b>
Female	355	1	1	14	28	84	15.5	13.7
Male	181	1	2	14	28	365	20.4	36.2
<b>Elagolix sodium</b>	<b>124,342</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>280</b>	<b>29.9</b>	<b>12.6</b>
Female	124,199	1	28	28	28	280	29.9	12.6
Male	143	1	28	28	28	84	28.7	9.3
<b>Fish oil triglycerides</b>	<b>4,549</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>21</b>	<b>2.6</b>	<b>2.5</b>
Female	2,539	1	1	1	4	21	2.6	2.5
Male	2,010	1	1	1	4	14	2.5	2.4
<b>Lusutrombopag</b>	<b>568</b>	<b>1</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>37</b>	<b>7.8</b>	<b>3.6</b>
Female	280	1	7	7	7	30	8.0	3.6
Male	288	3	7	7	7	37	7.5	3.5

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Lutetium Lu 177 dotatate</b>	<b>13,931</b>	<b>13,931</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.1%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	0.1%	0	NaN	0	NaN	0	NaN
25-40 years	259	259	1.9%	0	NaN	0	NaN	0	NaN
41-64 years	3,298	3,298	23.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	10,347	10,347	74.3%	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>2,430,596</b>	<b>2,333,808</b>	<b>100.0%</b>	<b>16,260</b>	<b>100.0%</b>	<b>79,227</b>	<b>100.0%</b>	<b>1,301</b>	<b>100.0%</b>
0-17 years	9,786	9,425	0.4%	*****	0.6%	259	0.3%	*****	*****
18-24 years	79,679	76,351	3.3%	931	5.7%	2,286	2.9%	111	8.5%
25-40 years	549,410	525,764	22.5%	5,337	32.8%	17,859	22.5%	450	34.6%
41-64 years	1,437,653	1,379,231	59.1%	9,165	56.4%	48,557	61.3%	700	53.8%
≥ 65 years	354,068	343,037	14.7%	*****	4.5%	10,266	13.0%	*****	*****
<b>Tezacaftor and ivacaftor</b>	<b>42,423</b>	<b>41,541</b>	<b>100.0%</b>	<b>351</b>	<b>100.0%</b>	<b>504</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
0-17 years	14,822	14,491	34.9%	185	52.7%	*****	*****	*****	*****
18-24 years	7,556	7,394	17.8%	81	23.1%	*****	*****	*****	*****
25-40 years	13,734	13,512	32.5%	51	14.5%	159	31.5%	12	44.4%
41-64 years	5,526	5,414	13.0%	20	5.7%	92	18.3%	0	0.0%
≥ 65 years	785	730	1.8%	14	4.0%	41	8.1%	0	0.0%
<b>Apalutamide</b>	<b>116,929</b>	<b>115,315</b>	<b>100.0%</b>	<b>911</b>	<b>100.0%</b>	<b>666</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	15	15	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	11,393	11,296	9.8%	56	6.1%	41	6.2%	0	0.0%
≥ 65 years	105,521	104,004	90.2%	855	93.9%	625	93.8%	37	100.0%
<b>Ibalizumab-uiyk</b>	<b>7,138</b>	<b>7,106</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	856	856	12.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	5,158	*****	*****	14	100.0%	*****	*****	0	NaN
≥ 65 years	991	*****	*****	0	0.0%	*****	*****	0	NaN
<b>Tildrakizumab</b>	<b>38,286</b>	<b>35,824</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>2,211</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	14	*****	0.0%	0	0.0%	*****	*****	0	0.0%
18-24 years	228	*****	0.4%	*****	*****	*****	*****	0	0.0%
25-40 years	1,325	950	2.7%	40	16.4%	335	15.2%	0	0.0%
41-64 years	4,223	3,157	8.8%	*****	*****	911	41.2%	*****	100.0%
≥ 65 years	32,496	31,550	88.1%	47	19.3%	899	40.7%	0	0.0%
<b>Burosumab-twza</b>	<b>18,387</b>	<b>17,461</b>	<b>100.0%</b>	<b>908</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	10,752	10,481	60.0%	*****	*****	*****	*****	0	NaN
18-24 years	840	730	4.2%	*****	*****	*****	*****	0	NaN
25-40 years	2,258	2,082	11.9%	*****	*****	*****	*****	0	NaN
41-64 years	2,958	2,711	15.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,579	1,457	8.3%	*****	*****	*****	*****	0	NaN
<b>Fostamatinib</b>	<b>8,019</b>	<b>7,910</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	21	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	230	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	884	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,957	2,930	37.0%	*****	*****	*****	*****	*****	*****
≥ 65 years	3,927	3,854	48.7%	49	67.1%	24	68.6%	0	0.0%
<b>Fosnetupitant and palonosetron</b>	<b>133,889</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	387	387	0.3%	0	0.0%	0	0.0%	0	NaN
25-40 years	2,945	2,945	2.2%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	20.6%	0	0.0%	*****	66.7%	0	NaN
≥ 65 years	102,956	*****	76.9%	*****	100.0%	*****	33.3%	0	NaN
<b>Lofexidine hydrochloride</b>	<b>7,866</b>	<b>7,800</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	15	15	0.2%	0	0.0%	0	0.0%	0	0.0%
18-24 years	380	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	2,774	2,762	35.4%	*****	*****	*****	*****	0	0.0%
41-64 years	3,804	3,773	48.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	893	871	11.2%	*****	*****	*****	*****	0	0.0%
<b>Erenumab-aoee</b>	<b>1,484,002</b>	<b>1,397,126</b>	<b>100.0%</b>	<b>14,234</b>	<b>100.0%</b>	<b>72,487</b>	<b>100.0%</b>	<b>155</b>	<b>100.0%</b>
0-17 years	7,577	7,209	0.5%	83	0.6%	285	0.4%	0	0.0%
18-24 years	66,408	63,986	4.6%	*****	3.3%	1,941	2.7%	*****	*****



**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	358,901	344,496	24.7%	2,987	21.0%	11,391	15.7%	27	17.4%
41-64 years	803,699	757,014	54.2%	7,505	52.7%	39,080	53.9%	100	64.5%
≥ 65 years	247,417	224,421	16.1%	*****	22.4%	19,790	27.3%	*****	*****
<b>Sodium zirconium cyclosilicate</b>	<b>270,097</b>	<b>225,079</b>	<b>100.0%</b>	<b>17,413</b>	<b>100.0%</b>	<b>27,508</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>
0-17 years	99	*****	0.0%	0	0.0%	*****	0.0%	0	0.0%
18-24 years	768	661	0.3%	*****	0.3%	*****	0.2%	0	0.0%
25-40 years	12,153	10,293	4.6%	*****	4.5%	1,062	3.9%	*****	*****
41-64 years	83,618	70,745	31.4%	*****	31.3%	7,398	26.9%	*****	*****
≥ 65 years	173,459	143,288	63.7%	11,128	63.9%	18,983	69.0%	60	61.9%
<b>Avatrombopag</b>	<b>9,359</b>	<b>9,009</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	26	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	298	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	734	704	7.8%	*****	*****	*****	*****	0	0.0%
41-64 years	3,779	3,675	40.8%	82	34.9%	22	19.8%	0	0.0%
≥ 65 years	4,522	4,310	47.8%	130	55.3%	*****	*****	*****	100.0%
<b>Pegvaliase-pqpz</b>	<b>7,489</b>	<b>7,188</b>	<b>100.0%</b>	<b>259</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
0-17 years	561	536	7.5%	*****	*****	*****	*****	0	0.0%
18-24 years	1,746	1,671	23.2%	64	24.7%	*****	*****	*****	*****
25-40 years	3,137	2,998	41.7%	118	45.6%	*****	*****	*****	*****
41-64 years	2,026	1,965	27.3%	56	21.6%	*****	*****	*****	*****
≥ 65 years	19	*****	*****	*****	*****	0	0.0%	0	0.0%
<b>Baricitinib</b>	<b>77,774</b>	<b>76,110</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>1,429</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	518	468	0.6%	*****	*****	*****	*****	0	0.0%
18-24 years	720	709	0.9%	*****	*****	*****	*****	0	0.0%
25-40 years	4,463	4,388	5.8%	*****	*****	*****	*****	0	0.0%
41-64 years	28,773	28,081	36.9%	*****	*****	603	42.2%	*****	50.0%
≥ 65 years	43,300	42,464	55.8%	*****	*****	748	52.3%	*****	50.0%
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Cannabidiol</b>	<b>268,214</b>	<b>249,026</b>	<b>100.0%</b>	<b>16,942</b>	<b>100.0%</b>	<b>1,942</b>	<b>100.0%</b>	<b>304</b>	<b>100.0%</b>
0-17 years	127,219	116,798	46.9%	9,397	55.5%	803	41.3%	221	72.7%
18-24 years	40,949	38,703	15.5%	1,992	11.8%	226	11.6%	28	9.2%
25-40 years	63,391	59,510	23.9%	3,343	19.7%	510	26.3%	28	9.2%
41-64 years	34,800	32,253	13.0%	2,133	12.6%	*****	*****	*****	*****
≥ 65 years	1,855	1,762	0.7%	77	0.5%	*****	*****	*****	*****
<b>Plazomicin</b>	<b>1,409</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%
25-40 years	43	*****	*****	0	NaN	0	NaN	*****	100.0%
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%
≥ 65 years	1,150	1,150	81.7%	0	NaN	0	NaN	0	0.0%
<b>Binimetinib</b>	<b>19,042</b>	<b>18,919</b>	<b>100.0%</b>	<b>108</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	123	104	0.5%	*****	*****	*****	*****	*****	75.0%
18-24 years	219	*****	*****	*****	*****	0	0.0%	*****	25.0%
25-40 years	1,528	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	6,447	6,419	33.9%	*****	*****	*****	*****	0	0.0%
≥ 65 years	10,725	10,658	56.3%	*****	*****	*****	*****	0	0.0%
<b>Encorafenib</b>	<b>21,646</b>	<b>21,369</b>	<b>100.0%</b>	<b>252</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	18	18	0.1%	0	0.0%	0	0.0%	0	NaN
18-24 years	180	180	0.8%	0	0.0%	0	0.0%	0	NaN
25-40 years	1,674	1,658	7.8%	16	6.3%	0	0.0%	0	NaN
41-64 years	7,282	7,194	33.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	12,492	12,319	57.6%	*****	*****	*****	*****	0	NaN
<b>Tecovirimat</b>	<b>39</b>	<b>39</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	22	22	56.4%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>9,090</b>	<b>9,056</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	76	76	0.8%	0	0.0%	0	0.0%	0	NaN

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	505	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,828	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	6,673	6,651	73.4%	*****	*****	*****	*****	0	NaN
<b>Tafenoquine</b>	<b>536</b>	<b>506</b>	<b>100.0%</b>	<b>19</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	30	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	27	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	151	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	289	270	53.4%	*****	*****	*****	*****	*****	100.0%
≥ 65 years	39	*****	*****	0	0.0%	*****	*****	0	0.0%
<b>Elagolix sodium</b>	<b>124,342</b>	<b>117,858</b>	<b>100.0%</b>	<b>1,165</b>	<b>100.0%</b>	<b>5,266</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>
0-17 years	2,231	*****	1.8%	*****	*****	*****	*****	0	0.0%
18-24 years	21,698	20,586	17.5%	*****	*****	905	17.2%	*****	*****
25-40 years	74,283	70,587	59.9%	743	63.8%	2,918	55.4%	35	66.0%
41-64 years	26,076	24,521	20.8%	*****	*****	1,335	25.4%	*****	*****
≥ 65 years	54	*****	0.0%	0	0.0%	*****	*****	0	0.0%
<b>Fish oil triglycerides</b>	<b>4,549</b>	<b>4,549</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	4,001	4,001	88.0%	0	NaN	0	NaN	0	NaN
18-24 years	293	293	6.4%	0	NaN	0	NaN	0	NaN
25-40 years	51	51	1.1%	0	NaN	0	NaN	0	NaN
41-64 years	54	54	1.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	150	150	3.3%	0	NaN	0	NaN	0	NaN
<b>Lusutrombopag</b>	<b>568</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	28	28	4.9%	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	100.0%	0	NaN	0	NaN
≥ 65 years	111	111	19.6%	0	0.0%	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>13,931</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	259	1	1	1	1	1	1.0	0.0
41-64 years	3,298	1	1	1	1	1	1.0	0.0
≥ 65 years	10,347	1	1	1	1	1	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>2,430,596</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>899</b>	<b>31.3</b>	<b>12.0</b>
0-17 years	9,786	1	30	30	30	210	30.9	11.5
18-24 years	79,679	1	30	30	30	300	31.1	12.3
25-40 years	549,410	1	30	30	30	360	31.3	12.3
41-64 years	1,437,653	1	30	30	30	899	31.4	12.1
≥ 65 years	354,068	1	30	30	30	518	31.0	11.0
<b>Tezacaftor and ivacaftor</b>	<b>42,423</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>280</b>	<b>28.5</b>	<b>7.8</b>
0-17 years	14,822	1	28	28	28	224	28.3	7.4
18-24 years	7,556	1	28	28	28	280	28.4	9.2
25-40 years	13,734	1	28	28	28	210	28.5	7.1
41-64 years	5,526	1	28	28	28	90	28.8	7.7
≥ 65 years	785	4	28	28	28	84	31.3	13.0
<b>Apalutamide</b>	<b>116,929</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>250</b>	<b>29.9</b>	<b>6.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	15	24	30	30	30	30	29.6	1.5
41-64 years	11,393	1	30	30	30	90	29.4	5.5
≥ 65 years	105,521	1	30	30	30	250	30.0	6.3
<b>Ibalizumab-uiyk</b>	<b>7,138</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>28</b>	<b>84</b>	<b>12.8</b>	<b>12.3</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	14	84	9.4	15.5
25-40 years	856	1	1	14	16	30	11.4	10.9
41-64 years	5,158	1	1	14	28	84	13.2	12.5
≥ 65 years	991	1	1	14	28	84	12.1	12.0
<b>Tildrakizumab</b>	<b>38,286</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>6.9</b>	<b>20.0</b>
0-17 years	14	1	28	84	84	84	55.8	34.9
18-24 years	228	1	1	1	65	84	27.8	34.5
25-40 years	1,325	1	1	1	71	90	27.0	34.9
41-64 years	4,223	1	1	1	31	168	24.6	33.4
≥ 65 years	32,496	1	1	1	1	90	3.7	13.9
<b>Burosumab-twza</b>	<b>18,387</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>90</b>	<b>12.9</b>	<b>15.9</b>
0-17 years	10,752	1	1	1	28	90	13.9	14.6
18-24 years	840	1	1	1	28	84	14.3	19.9
25-40 years	2,258	1	1	1	28	72	11.1	16.9
41-64 years	2,958	1	1	1	28	84	11.8	17.4
≥ 65 years	1,579	1	1	1	28	84	10.4	17.1
<b>Fostamatinib</b>	<b>8,019</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>101</b>	<b>29.6</b>	<b>6.4</b>
0-17 years	21	8	30	30	30	42	28.5	7.2
18-24 years	230	5	30	30	30	50	28.1	5.4
25-40 years	884	1	30	30	30	90	29.3	5.2

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	2,957	1	30	30	30	101	29.2	6.3
≥ 65 years	3,927	1	30	30	30	90	30.0	6.7
<b>Fosnetupitant and palonosetron</b>	<b>133,889</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>90</b>	<b>1.3</b>	<b>2.5</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	2,945	1	1	1	1	28	1.2	1.9
41-64 years	27,597	1	1	1	1	90	1.2	2.2
≥ 65 years	102,956	1	1	1	1	90	1.3	2.6
<b>Lofexidine hydrochloride</b>	<b>7,866</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>126</b>	<b>11.6</b>	<b>6.9</b>
0-17 years	15	2	8	12	14	14	11.2	3.7
18-24 years	380	1	8	9	12	32	10.4	4.6
25-40 years	2,774	1	8	9	14	90	11.3	6.1
41-64 years	3,804	1	8	9	14	126	11.7	6.8
≥ 65 years	893	1	8	9	14	90	12.7	9.8
<b>Erenumab-aooe</b>	<b>1,484,002</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>30</b>	<b>389</b>	<b>31.8</b>	<b>13.6</b>
0-17 years	7,577	1	28	30	30	90	30.8	12.4
18-24 years	66,408	1	28	30	30	180	30.4	11.1
25-40 years	358,901	1	28	30	30	360	30.6	11.4
41-64 years	803,699	1	28	30	30	389	31.8	13.6
≥ 65 years	247,417	1	30	30	30	365	34.1	16.6
<b>Sodium zirconium cyclosilicate</b>	<b>270,097</b>	<b>1</b>	<b>25</b>	<b>30</b>	<b>30</b>	<b>450</b>	<b>31.7</b>	<b>21.4</b>
0-17 years	99	5	30	30	30	90	31.9	16.6
18-24 years	768	1	28	30	30	90	31.6	19.5
25-40 years	12,153	1	28	30	30	180	32.1	19.5
41-64 years	83,618	1	28	30	30	180	31.6	20.1
≥ 65 years	173,459	1	22	30	30	450	31.8	22.2
<b>Avatrombopag</b>	<b>9,359</b>	<b>1</b>	<b>15</b>	<b>30</b>	<b>30</b>	<b>105</b>	<b>24.1</b>	<b>12.3</b>
0-17 years	26	16	28	30	30	30	28.2	3.6
18-24 years	298	2	30	30	30	90	27.7	8.2
25-40 years	734	1	28	30	30	84	26.1	10.9
41-64 years	3,779	1	5	30	30	90	21.3	12.4
≥ 65 years	4,522	1	28	30	30	105	25.9	12.3
<b>Pegvaliase-pqpz</b>	<b>7,489</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>30</b>	<b>152</b>	<b>28.7</b>	<b>8.6</b>
0-17 years	561	1	28	30	30	86	28.1	9.7
18-24 years	1,746	1	28	30	30	152	28.4	9.3
25-40 years	3,137	1	28	30	30	105	29.0	8.9
41-64 years	2,026	1	28	30	30	93	28.6	7.1
≥ 65 years	19	5	30	30	30	42	27.9	8.5
<b>Baricitinib</b>	<b>77,774</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>30</b>	<b>180</b>	<b>12.6</b>	<b>17.3</b>
0-17 years	518	1	30	30	30	90	30.9	12.6
18-24 years	720	1	15	30	30	90	23.5	13.4
25-40 years	4,463	1	1	30	30	90	19.3	16.3
41-64 years	28,773	1	1	30	30	120	18.8	17.6
≥ 65 years	43,300	1	1	1	1	180	7.5	15.4
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>268,214</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>658</b>	<b>29.6</b>	<b>8.0</b>
0-17 years	127,219	1	30	30	30	658	29.9	8.3
18-24 years	40,949	1	30	30	30	366	29.5	7.2
25-40 years	63,391	1	30	30	30	243	29.4	7.3
41-64 years	34,800	1	30	30	30	300	28.9	8.8
≥ 65 years	1,855	1	29	30	30	100	28.1	8.4
<b>Plazomicin</b>	<b>1,409</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>554</b>	<b>1.5</b>	<b>14.8</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	43	1	1	1	1	554	13.9	84.3
41-64 years	216	1	1	1	1	7	1.3	1.2
≥ 65 years	1,150	1	1	1	1	10	1.1	0.7
<b>Binimetinib</b>	<b>19,042</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>180</b>	<b>29.2</b>	<b>4.8</b>
0-17 years	123	3	30	30	30	180	35.3	26.1
18-24 years	219	2	30	30	30	120	29.5	8.2
25-40 years	1,528	1	30	30	30	60	29.1	4.1
41-64 years	6,447	1	30	30	30	79	29.0	4.3
≥ 65 years	10,725	1	30	30	30	90	29.2	4.2
<b>Encorafenib</b>	<b>21,646</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>29.2</b>	<b>4.9</b>
0-17 years	18	12	30	30	30	30	27.4	6.0
18-24 years	180	7	30	30	30	30	29.1	3.7
25-40 years	1,674	1	30	30	30	60	29.0	4.5
41-64 years	7,282	1	30	30	30	90	29.1	5.3
≥ 65 years	12,492	1	30	30	30	90	29.3	4.7
<b>Tecovirimat</b>	<b>39</b>	<b>8</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>13.6</b>	<b>1.5</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	14	14	14	14	13.5	1.5
25-40 years	22	8	14	14	14	14	13.5	1.8
41-64 years	*****	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>9,090</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>28.9</b>	<b>5.1</b>
0-17 years	*****	14	24	28	28	30	25.4	5.3
18-24 years	*****	2	30	30	30	30	28.5	5.5
25-40 years	505	1	30	30	30	60	28.8	6.2
41-64 years	1,828	1	30	30	30	84	28.7	5.0
≥ 65 years	6,673	1	30	30	30	90	29.0	5.0
<b>Tafenoquine</b>	<b>536</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>28</b>	<b>365</b>	<b>17.1</b>	<b>23.9</b>
0-17 years	30	1	1	11	30	90	18.8	21.1
18-24 years	27	1	1	28	30	90	20.3	20.8
25-40 years	151	1	1	3	21	84	11.5	13.2
41-64 years	289	1	1	21	28	365	19.5	28.5
≥ 65 years	39	1	3	16	28	79	17.6	18.8
<b>Elagolix sodium</b>	<b>124,342</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>28</b>	<b>280</b>	<b>29.9</b>	<b>12.6</b>

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	2,231	1	28	28	28	90	30.0	12.4
18-24 years	21,698	1	28	28	28	168	29.9	12.2
25-40 years	74,283	1	28	28	28	280	29.7	12.4
41-64 years	26,076	1	28	28	28	280	30.4	13.2
≥ 65 years	54	1	28	28	28	84	32.7	16.9
<b>Fish oil triglycerides</b>	<b>4,549</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>21</b>	<b>2.6</b>	<b>2.5</b>
0-17 years	4,001	1	1	1	4	21	2.6	2.4
18-24 years	293	1	1	1	7	14	3.1	2.9
25-40 years	51	1	1	1	1	14	1.3	1.8
41-64 years	54	1	1	1	1	7	1.4	1.4
≥ 65 years	150	1	1	1	1	6	1.0	0.4
<b>Lusutrombopag</b>	<b>568</b>	<b>1</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>37</b>	<b>7.8</b>	<b>3.6</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	7	7	7	7	7.0	0.0
25-40 years	*****	7	7	7	7	30	7.8	4.3
41-64 years	426	1	7	7	7	37	7.9	3.9
≥ 65 years	111	7	7	7	7	14	7.2	1.0

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Lutetium Lu 177 dotatate</i>	4,522	4,522	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	175,440	14,826	8.5%	22,121	12.6%	60,466	34.5%	42,926	24.5%	35,101	20.0%
<i>Tezacaftor and ivacaftor</i>	3,794	269	7.1%	503	13.3%	1,662	43.8%	1,172	30.9%	188	5.0%
<i>Apalutamide</i>	11,580	1,494	12.9%	2,100	18.1%	4,643	40.1%	2,208	19.1%	1,135	9.8%
<i>Ibalizumab-uiyk</i>	307	97	31.6%	57	18.6%	75	24.4%	34	11.1%	44	14.3%
<i>Tildrakizumab</i>	7,837	6,963	88.8%	210	2.7%	470	6.0%	151	1.9%	43	0.5%
<i>Burosumab-twza</i>	1,038	473	45.6%	142	13.7%	164	15.8%	149	14.4%	110	10.6%
<i>Fostamatinib</i>	1,120	236	21.1%	314	28.0%	375	33.5%	126	11.3%	69	6.2%
<i>palonosetron</i>	24,863	24,315	97.8%	393	1.6%	*****	0.6%	*****	0.0%	0	0.0%
<i>Lofexidine hydrochloride</i>	5,773	5,411	93.7%	310	5.4%	*****	*****	*****	*****	*****	*****
<i>Erenumab-aooe</i>	158,717	22,702	14.3%	31,338	19.7%	59,809	37.7%	27,777	17.5%	17,091	10.8%
<i>Sodium zirconium cyclosilicate</i>	78,091	35,102	45.0%	18,202	23.3%	19,434	24.9%	4,430	5.7%	923	1.2%
<i>Avatrombopag</i>	2,406	1,500	62.3%	317	13.2%	414	17.2%	122	5.1%	53	2.2%
<i>Pegvaliase-pqpz</i>	528	43	8.1%	77	14.6%	195	36.9%	109	20.6%	104	19.7%
<i>Baricitinib</i>	51,437	48,051	93.4%	1,024	2.0%	1,594	3.1%	501	1.0%	267	0.5%
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Cannabidiol</i>	20,980	1,828	8.7%	2,951	14.1%	7,387	35.2%	6,487	30.9%	2,327	11.1%
<i>Plazomicin</i>	249	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Binimetinib</i>	2,872	663	23.1%	716	24.9%	1,072	37.3%	297	10.3%	124	4.3%
<i>Encorafenib</i>	3,371	802	23.8%	801	23.8%	1,305	38.7%	334	9.9%	129	3.8%
<i>Tecovirimat</i>	27	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	1,476	310	21.0%	444	30.1%	532	36.0%	134	9.1%	56	3.8%
<i>Tafenoquine</i>	197	130	66.0%	45	22.8%	*****	*****	*****	*****	*****	*****
<i>Elagolix sodium</i>	25,153	7,020	27.9%	6,718	26.7%	9,036	35.9%	2,021	8.0%	358	1.4%
<i>Fish oil triglycerides</i>	141	72	51.1%	40	28.4%	*****	*****	*****	*****	0	0.0%
<i>Lusutrombopag</i>	390	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	4,522	1	2	4	4	8	3.1	1.2
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	175,440	1	120	315	630	1,898	433.6	398.6
<i>Tezacaftor and ivacaftor</i>	3,794	3	112	279	468	1,820	318.7	257.1
<i>Apalutamide</i>	11,580	1	85	180	420	1,752	302.1	309.5
<i>Ibalizumab-uiyk</i>	307	1	19	90	383	1,683	296.5	415.4
<i>Tildrakizumab</i>	7,837	1	3	5	9	1,367	33.9	110.9
<i>Burosumab-twza</i>	1,038	1	12	40	365	1,658	229.0	335.0
<i>Fostamatinib</i>	1,120	1	60	104	240	1,740	211.7	271.6
<i>Fosnetupitant and palonosetron</i>	24,863	1	2	4	6	488	6.9	14.8
<i>Lofexidine hydrochloride</i>	5,773	1	9	10	15	816	15.8	25.5
<i>Erenumab-aooe</i>	158,717	1	68	178	418	1,716	297.4	316.0
<i>Sodium zirconium cyclosilicate</i>	78,091	1	25	52	130	1,560	109.8	155.3
<i>Avatrombopag</i>	2,406	1	5	15	90	1,167	93.9	176.7
<i>Pegvaliase-pqpz</i>	528	3	100	269	620	1,552	407.2	384.5
<i>Baricitinib</i>	51,437	1	1	1	1	1,566	19.1	97.7
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	20,980	1	112	293	568	1,627	378.1	335.5
<i>Plazomicin</i>	249	1	3	5	7	554	8.6	35.7
<i>Binimetinib</i>	2,872	1	44	111	240	1,664	193.6	234.3
<i>Encorafenib</i>	3,371	1	41	113	240	1,664	187.7	225.9
<i>Tecovirimat</i>	27	9	14	14	14	112	19.6	19.2
<i>Ivosidenib</i>	1,476	1	47	90	210	1,582	178.0	217.2
<i>Tafenoquine</i>	197	1	4	21	59	861	46.6	89.1
<i>Elagolix sodium</i>	25,153	1	28	84	195	1,441	147.9	168.2
<i>Fish oil triglycerides</i>	141	1	6	28	77	723	82.9	152.2
<i>Lusutrombopag</i>	390	3	7	7	7	280	11.3	17.9

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>4,522</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	2,218	2,218	49.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,304	2,304	51.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir</b>	<b>175,440</b>	<b>14,826</b>	<b>100.0%</b>	<b>22,121</b>	<b>100.0%</b>	<b>60,466</b>	<b>100.0%</b>	<b>42,926</b>	<b>100.0%</b>	<b>35,101</b>	<b>100.0%</b>
Female	45,683	4,245	28.6%	6,127	27.7%	15,766	26.1%	11,482	26.7%	8,063	23.0%
Male	129,757	10,581	71.4%	15,994	72.3%	44,700	73.9%	31,444	73.3%	27,038	77.0%
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>269</b>	<b>100.0%</b>	<b>503</b>	<b>100.0%</b>	<b>1,662</b>	<b>100.0%</b>	<b>1,172</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>
Female	1,889	132	49.1%	269	53.5%	834	50.2%	568	48.5%	86	45.7%
Male	1,905	137	50.9%	234	46.5%	828	49.8%	604	51.5%	102	54.3%
<b>Apalutamide</b>	<b>11,580</b>	<b>1,494</b>	<b>100.0%</b>	<b>2,100</b>	<b>100.0%</b>	<b>4,643</b>	<b>100.0%</b>	<b>2,208</b>	<b>100.0%</b>	<b>1,135</b>	<b>100.0%</b>
Female	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Male	*****	1,494	100.0%	2,100	100.0%	*****	*****	2,208	100.0%	1,135	100.0%
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>97</b>	<b>100.0%</b>	<b>57</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>44</b>	<b>100.0%</b>
Female	72	28	28.9%	16	28.1%	16	21.3%	*****	*****	*****	*****
Male	235	69	71.1%	41	71.9%	59	78.7%	*****	*****	*****	*****
<b>Tildrakizumab</b>	<b>7,837</b>	<b>6,963</b>	<b>100.0%</b>	<b>210</b>	<b>100.0%</b>	<b>470</b>	<b>100.0%</b>	<b>151</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>
Female	4,152	3,687	53.0%	113	53.8%	249	53.0%	82	54.3%	21	48.8%
Male	3,685	3,276	47.0%	97	46.2%	221	47.0%	69	45.7%	22	51.2%
<b>Burosumab-twza</b>	<b>1,038</b>	<b>473</b>	<b>100.0%</b>	<b>142</b>	<b>100.0%</b>	<b>164</b>	<b>100.0%</b>	<b>149</b>	<b>100.0%</b>	<b>110</b>	<b>100.0%</b>
Female	673	304	64.3%	84	59.2%	109	66.5%	103	69.1%	73	66.4%
Male	365	169	35.7%	58	40.8%	55	33.5%	46	30.9%	37	33.6%
<b>Fostamatinib</b>	<b>1,120</b>	<b>236</b>	<b>100.0%</b>	<b>314</b>	<b>100.0%</b>	<b>375</b>	<b>100.0%</b>	<b>126</b>	<b>100.0%</b>	<b>69</b>	<b>100.0%</b>
Female	621	121	51.3%	173	55.1%	214	57.1%	68	54.0%	45	65.2%
Male	499	115	48.7%	141	44.9%	161	42.9%	58	46.0%	24	34.8%
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>24,315</b>	<b>100.0%</b>	<b>393</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	14,012	13,696	56.3%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	10,851	10,619	43.7%	168	42.7%	*****	*****	*****	*****	0	NaN
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>5,411</b>	<b>100.0%</b>	<b>310</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	2,998	2,817	52.1%	162	52.3%	*****	*****	*****	*****	*****	*****
Male	2,775	2,594	47.9%	148	47.7%	*****	*****	*****	*****	0	0.0%

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>22,702</b>	<b>100.0%</b>	<b>31,338</b>	<b>100.0%</b>	<b>59,809</b>	<b>100.0%</b>	<b>27,777</b>	<b>100.0%</b>	<b>17,091</b>	<b>100.0%</b>
Female	135,234	19,072	84.0%	26,518	84.6%	51,250	85.7%	23,906	86.1%	14,488	84.8%
Male	23,483	3,630	16.0%	4,820	15.4%	8,559	14.3%	3,871	13.9%	2,603	15.2%
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>35,102</b>	<b>100.0%</b>	<b>18,202</b>	<b>100.0%</b>	<b>19,434</b>	<b>100.0%</b>	<b>4,430</b>	<b>100.0%</b>	<b>923</b>	<b>100.0%</b>
Female	33,612	15,787	45.0%	7,855	43.2%	7,919	40.7%	1,699	38.4%	352	38.1%
Male	44,479	19,315	55.0%	10,347	56.8%	11,515	59.3%	2,731	61.6%	571	61.9%
<b>Avatrombopag</b>	<b>2,406</b>	<b>1,500</b>	<b>100.0%</b>	<b>317</b>	<b>100.0%</b>	<b>414</b>	<b>100.0%</b>	<b>122</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>
Female	1,174	692	46.1%	166	52.4%	226	54.6%	63	51.6%	27	50.9%
Male	1,232	808	53.9%	151	47.6%	188	45.4%	59	48.4%	26	49.1%
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>43</b>	<b>100.0%</b>	<b>77</b>	<b>100.0%</b>	<b>195</b>	<b>100.0%</b>	<b>109</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>
Female	276	23	53.5%	43	55.8%	111	56.9%	54	49.5%	45	43.3%
Male	252	20	46.5%	34	44.2%	84	43.1%	55	50.5%	59	56.7%
<b>Baricitinib</b>	<b>51,437</b>	<b>48,051</b>	<b>100.0%</b>	<b>1,024</b>	<b>100.0%</b>	<b>1,594</b>	<b>100.0%</b>	<b>501</b>	<b>100.0%</b>	<b>267</b>	<b>100.0%</b>
Female	24,881	22,120	46.0%	799	78.0%	1,320	82.8%	425	84.8%	217	81.3%
Male	26,556	25,931	54.0%	225	22.0%	274	17.2%	76	15.2%	50	18.7%
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1,828</b>	<b>100.0%</b>	<b>2,951</b>	<b>100.0%</b>	<b>7,387</b>	<b>100.0%</b>	<b>6,487</b>	<b>100.0%</b>	<b>2,327</b>	<b>100.0%</b>
Female	9,510	876	47.9%	1,341	45.4%	3,347	45.3%	2,898	44.7%	1,048	45.0%
Male	11,470	952	52.1%	1,610	54.6%	4,040	54.7%	3,589	55.3%	1,279	55.0%
<b>Plazomicin</b>	<b>249</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	164	*****	*****	*****	100.0%	0	NaN	0	0.0%	0	NaN
Male	85	*****	*****	0	0.0%	0	NaN	*****	100.0%	0	NaN
<b>Binimetinib</b>	<b>2,872</b>	<b>663</b>	<b>100.0%</b>	<b>716</b>	<b>100.0%</b>	<b>1,072</b>	<b>100.0%</b>	<b>297</b>	<b>100.0%</b>	<b>124</b>	<b>100.0%</b>
Female	1,259	293	44.2%	320	44.7%	440	41.0%	145	48.8%	61	49.2%
Male	1,613	370	55.8%	396	55.3%	632	59.0%	152	51.2%	63	50.8%
<b>Encorafenib</b>	<b>3,371</b>	<b>802</b>	<b>100.0%</b>	<b>801</b>	<b>100.0%</b>	<b>1,305</b>	<b>100.0%</b>	<b>334</b>	<b>100.0%</b>	<b>129</b>	<b>100.0%</b>
Female	1,556	383	47.8%	376	46.9%	573	43.9%	163	48.8%	61	47.3%
Male	1,815	419	52.2%	425	53.1%	732	56.1%	171	51.2%	68	52.7%
<b>Tecovirimat</b>	<b>27</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>

**Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>1,476</b>	<b>310</b>	<b>100.0%</b>	<b>444</b>	<b>100.0%</b>	<b>532</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>	<b>56</b>	<b>100.0%</b>
Female	750	163	52.6%	225	50.7%	264	49.6%	67	50.0%	31	55.4%
Male	726	147	47.4%	219	49.3%	268	50.4%	67	50.0%	25	44.6%
<b>Tafenoquine</b>	<b>197</b>	<b>130</b>	<b>100.0%</b>	<b>45</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>
Female	124	81	62.3%	*****	*****	*****	*****	*****	*****	0	0.0%
Male	73	49	37.7%	*****	*****	*****	*****	0	0.0%	*****	*****
<b>Elagolix sodium</b>	<b>25,153</b>	<b>7,020</b>	<b>100.0%</b>	<b>6,718</b>	<b>100.0%</b>	<b>9,036</b>	<b>100.0%</b>	<b>2,021</b>	<b>100.0%</b>	<b>358</b>	<b>100.0%</b>
Female	25,123	*****	*****	6,707	99.8%	*****	*****	*****	*****	*****	*****
Male	30	*****	*****	11	0.2%	*****	*****	*****	*****	*****	*****
<b>Fish oil triglycerides</b>	<b>141</b>	<b>72</b>	<b>100.0%</b>	<b>40</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	81	44	61.1%	21	52.5%	*****	*****	*****	*****	0	NaN
Male	60	28	38.9%	19	47.5%	*****	*****	*****	*****	0	NaN
<b>Lusutrombopag</b>	<b>390</b>	<b>379</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	175	*****	*****	*****	*****	*****	100.0%	0	NaN	0	NaN
Male	215	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>4</b>	<b>8</b>	<b>3.1</b>	<b>1.2</b>
Female	2,218	1	2	4	4	8	3.1	1.2
Male	2,304	1	2	4	4	8	3.1	1.3
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>1</b>	<b>120</b>	<b>315</b>	<b>630</b>	<b>1,898</b>	<b>433.6</b>	<b>398.6</b>
Female	45,683	1	110	300	596	1,894	404.9	371.8
Male	129,757	1	120	323	645	1,898	443.7	407.2
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>3</b>	<b>112</b>	<b>279</b>	<b>468</b>	<b>1,820</b>	<b>318.7</b>	<b>257.1</b>
Female	1,889	3	112	252	462	1,760	312.6	257.8
Male	1,905	3	114	280	476	1,820	324.8	256.4
<b>Apalutamide</b>	<b>11,580</b>	<b>1</b>	<b>85</b>	<b>180</b>	<b>420</b>	<b>1,752</b>	<b>302.1</b>	<b>309.5</b>
Female	*****	120	120	120	120	120	120.0	NaN
Male	*****	1	85	180	420	1,752	302.1	309.5
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>1</b>	<b>19</b>	<b>90</b>	<b>383</b>	<b>1,683</b>	<b>296.5</b>	<b>415.4</b>
Female	72	1	11	44	252	1,560	212.9	338.3
Male	235	1	25	112	446	1,683	322.1	433.8
<b>Tildrakizumab</b>	<b>7,837</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>9</b>	<b>1,367</b>	<b>33.9</b>	<b>110.9</b>
Female	4,152	1	3	4	8	1,367	33.1	107.6
Male	3,685	1	3	5	9	1,291	34.8	114.6
<b>Burosumab-twza</b>	<b>1,038</b>	<b>1</b>	<b>12</b>	<b>40</b>	<b>365</b>	<b>1,658</b>	<b>229.0</b>	<b>335.0</b>
Female	673	1	12	43	384	1,539	239.5	344.2
Male	365	1	13	36	322	1,658	209.8	316.9
<b>Fostatinib</b>	<b>1,120</b>	<b>1</b>	<b>60</b>	<b>104</b>	<b>240</b>	<b>1,740</b>	<b>211.7</b>	<b>271.6</b>
Female	621	1	60	120	270	1,740	224.1	289.7
Male	499	2	44	90	240	1,613	196.4	246.5
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>6</b>	<b>488</b>	<b>6.9</b>	<b>14.8</b>
Female	14,012	1	3	4	6	337	6.8	14.2
Male	10,851	1	2	4	7	488	6.9	15.7
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>1</b>	<b>9</b>	<b>10</b>	<b>15</b>	<b>816</b>	<b>15.8</b>	<b>25.5</b>
Female	2,998	1	9	10	16	816	15.5	24.8
Male	2,775	1	9	10	15	709	16.2	26.2
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>1</b>	<b>68</b>	<b>178</b>	<b>418</b>	<b>1,716</b>	<b>297.4</b>	<b>316.0</b>
Female	135,234	1	70	180	420	1,706	298.2	315.4
Male	23,483	1	60	168	410	1,716	293.3	319.5
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>1</b>	<b>25</b>	<b>52</b>	<b>130</b>	<b>1,560</b>	<b>109.8</b>	<b>155.3</b>
Female	33,612	1	20	42	120	1,435	102.4	148.5
Male	44,479	1	28	57	146	1,560	115.3	160.0
<b>Avatrombopag</b>	<b>2,406</b>	<b>1</b>	<b>5</b>	<b>15</b>	<b>90</b>	<b>1,167</b>	<b>93.9</b>	<b>176.7</b>
Female	1,174	1	5	27	111	1,167	100.1	178.8
Male	1,232	1	5	10	77	1,134	87.9	174.6
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>3</b>	<b>100</b>	<b>269</b>	<b>620</b>	<b>1,552</b>	<b>407.2</b>	<b>384.5</b>
Female	276	4	93	217	533	1,552	366.8	364.8
Male	252	3	112	323	686	1,524	451.4	401.0
<b>Baricitinib</b>	<b>51,437</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,566</b>	<b>19.1</b>	<b>97.7</b>
Female	24,881	1	1	1	1	1,530	31.9	125.2
Male	26,556	1	1	1	1	1,566	7.2	59.2
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.

**Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1</b>	<b>112</b>	<b>293</b>	<b>568</b>	<b>1,627</b>	<b>378.1</b>	<b>335.5</b>
Female	9,510	1	106	283	559	1,611	374.7	335.6
Male	11,470	1	114	298	570	1,627	380.8	335.5
<b>Plazomicin</b>	<b>249</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>7</b>	<b>554</b>	<b>8.6</b>	<b>35.7</b>
Female	164	1	3	5	7	84	6.7	9.6
Male	85	1	2	5	7	554	12.1	59.7
<b>Binimetinib</b>	<b>2,872</b>	<b>1</b>	<b>44</b>	<b>111</b>	<b>240</b>	<b>1,664</b>	<b>193.6</b>	<b>234.3</b>
Female	1,259	2	42	105	270	1,664	200.6	239.9
Male	1,613	1	45	118	236	1,626	188.1	229.8
<b>Encorafenib</b>	<b>3,371</b>	<b>1</b>	<b>41</b>	<b>113</b>	<b>240</b>	<b>1,664</b>	<b>187.7</b>	<b>225.9</b>
Female	1,556	2	35	101	240	1,664	190.7	228.5
Male	1,815	1	45	120	228	1,626	185.1	223.6
<b>Tecovirimat</b>	<b>27</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>19.6</b>	<b>19.2</b>
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	19.8	19.6
<b>Ivosidenib</b>	<b>1,476</b>	<b>1</b>	<b>47</b>	<b>90</b>	<b>210</b>	<b>1,582</b>	<b>178.0</b>	<b>217.2</b>
Female	750	1	47	90	210	1,442	181.2	223.0
Male	726	4	48	90	210	1,582	174.8	211.1
<b>Tafenoquine</b>	<b>197</b>	<b>1</b>	<b>4</b>	<b>21</b>	<b>59</b>	<b>861</b>	<b>46.6</b>	<b>89.1</b>
Female	124	1	5	24	58	528	44.3	71.6
Male	73	1	2	17	60	861	50.6	113.4
<b>Elagolix sodium</b>	<b>25,153</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>195</b>	<b>1,441</b>	<b>147.9</b>	<b>168.2</b>
Female	25,123	1	28	84	195	1,441	147.9	168.2
Male	30	4	28	84	168	784	136.7	166.4
<b>Fish oil triglycerides</b>	<b>141</b>	<b>1</b>	<b>6</b>	<b>28</b>	<b>77</b>	<b>723</b>	<b>82.9</b>	<b>152.2</b>
Female	81	1	5	19	70	721	81.9	161.4
Male	60	1	8	44	78	723	84.2	140.2
<b>Lusutrombopag</b>	<b>390</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>280</b>	<b>11.3</b>	<b>17.9</b>
Female	175	7	7	7	14	280	12.8	25.3
Male	215	3	7	7	7	56	10.1	7.7

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>4,522</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	94	94	2.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,121	1,121	24.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,294	3,294	72.8%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>14,826</b>	<b>100.0%</b>	<b>22,121</b>	<b>100.0%</b>	<b>60,466</b>	<b>100.0%</b>	<b>42,926</b>	<b>100.0%</b>	<b>35,101</b>	<b>100.0%</b>
0-17 years	966	101	0.7%	129	0.6%	401	0.7%	267	0.6%	68	0.2%
18-24 years	8,703	1,105	7.5%	1,476	6.7%	3,550	5.9%	1,940	4.5%	632	1.8%
25-40 years	52,127	5,574	37.6%	8,132	36.8%	20,627	34.1%	12,055	28.1%	5,739	16.3%
41-64 years	94,953	6,854	46.2%	10,595	47.9%	30,661	50.7%	24,566	57.2%	22,277	63.5%
≥ 65 years	18,691	1,192	8.0%	1,789	8.1%	5,227	8.6%	4,098	9.5%	6,385	18.2%
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>269</b>	<b>100.0%</b>	<b>503</b>	<b>100.0%</b>	<b>1,662</b>	<b>100.0%</b>	<b>1,172</b>	<b>100.0%</b>	<b>188</b>	<b>100.0%</b>
0-17 years	1,360	87	32.3%	174	34.6%	615	37.0%	435	37.1%	49	26.1%
18-24 years	787	67	24.9%	128	25.4%	377	22.7%	185	15.8%	30	16.0%
25-40 years	1,229	81	30.1%	159	31.6%	540	32.5%	398	34.0%	51	27.1%
41-64 years	365	*****	*****	*****	*****	*****	*****	130	11.1%	*****	*****
≥ 65 years	53	*****	*****	*****	*****	*****	*****	24	2.0%	*****	*****
<b>Apalutamide</b>	<b>11,580</b>	<b>1,494</b>	<b>100.0%</b>	<b>2,100</b>	<b>100.0%</b>	<b>4,643</b>	<b>100.0%</b>	<b>2,208</b>	<b>100.0%</b>	<b>1,135</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	148	9.9%	195	9.3%	497	10.7%	*****	*****	95	8.4%
≥ 65 years	10,415	1,346	90.1%	1,905	90.7%	4,146	89.3%	1,978	89.6%	1,040	91.6%
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>97</b>	<b>100.0%</b>	<b>57</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>44</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	*****	22	22.7%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	214	61	62.9%	40	70.2%	57	76.0%	*****	*****	*****	*****

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	39	****	****	****	****	****	****	****	****	****	****
<b>Tildrakizumab</b>	<b>7,837</b>	<b>6,963</b>	<b>100.0%</b>	<b>210</b>	<b>100.0%</b>	<b>470</b>	<b>100.0%</b>	<b>151</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>
0-17 years	****	****	****	0	0.0%	0	0.0%	0	0.0%	****	****
18-24 years	****	****	****	****	****	17	3.6%	****	****	****	****
25-40 years	343	195	2.8%	****	****	88	18.7%	****	****	****	****
41-64 years	1,038	639	9.2%	107	51.0%	211	44.9%	****	****	****	****
≥ 65 years	6,395	6,098	87.6%	64	30.5%	154	32.8%	57	37.7%	22	51.2%
<b>Burosumab-twza</b>	<b>1,038</b>	<b>473</b>	<b>100.0%</b>	<b>142</b>	<b>100.0%</b>	<b>164</b>	<b>100.0%</b>	<b>149</b>	<b>100.0%</b>	<b>110</b>	<b>100.0%</b>
0-17 years	582	223	47.1%	69	48.6%	116	70.7%	110	73.8%	64	58.2%
18-24 years	75	47	9.9%	****	****	****	****	****	****	****	****
25-40 years	137	77	16.3%	21	14.8%	14	8.5%	12	8.1%	13	11.8%
41-64 years	161	80	16.9%	28	19.7%	18	11.0%	17	11.4%	18	16.4%
≥ 65 years	83	46	9.7%	****	****	****	****	****	****	****	****
<b>Fostamatinib</b>	<b>1,120</b>	<b>236</b>	<b>100.0%</b>	<b>314</b>	<b>100.0%</b>	<b>375</b>	<b>100.0%</b>	<b>126</b>	<b>100.0%</b>	<b>69</b>	<b>100.0%</b>
0-17 years	****	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
18-24 years	****	****	****	11	3.5%	****	****	****	****	****	****
25-40 years	129	****	****	34	10.8%	55	14.7%	****	****	****	****
41-64 years	374	65	27.5%	102	32.5%	135	36.0%	****	****	****	****
≥ 65 years	579	140	59.3%	167	53.2%	173	46.1%	63	50.0%	36	52.2%
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>24,315</b>	<b>100.0%</b>	<b>393</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	****	****	****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	****	****	****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	659	****	****	****	****	****	****	0	0.0%	0	NaN
41-64 years	5,418	5,329	21.9%	****	****	****	****	0	0.0%	0	NaN
≥ 65 years	18,709	18,255	75.1%	321	81.7%	****	****	****	****	0	NaN
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>5,411</b>	<b>100.0%</b>	<b>310</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>
0-17 years	****	****	****	0	0.0%	****	2.2%	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
25-40 years	2,011	1,886	34.9%	105	33.9%	****	****	****	****	0	0.0%
41-64 years	2,821	2,633	48.7%	165	53.2%	****	****	****	****	****	****
≥ 65 years	637	598	11.1%	****	****	****	****	****	****	0	0.0%



**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>22,702</b>	<b>100.0%</b>	<b>31,338</b>	<b>100.0%</b>	<b>59,809</b>	<b>100.0%</b>	<b>27,777</b>	<b>100.0%</b>	<b>17,091</b>	<b>100.0%</b>
0-17 years	900	106	0.5%	191	0.6%	403	0.7%	139	0.5%	61	0.4%
18-24 years	8,287	1,258	5.5%	1,742	5.6%	3,465	5.8%	1,361	4.9%	461	2.7%
25-40 years	40,874	5,906	26.0%	8,354	26.7%	16,345	27.3%	7,029	25.3%	3,240	19.0%
41-64 years	81,933	11,053	48.7%	15,536	49.6%	30,556	51.1%	15,075	54.3%	9,713	56.8%
≥ 65 years	26,723	4,379	19.3%	5,515	17.6%	9,040	15.1%	4,173	15.0%	3,616	21.2%
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>35,102</b>	<b>100.0%</b>	<b>18,202</b>	<b>100.0%</b>	<b>19,434</b>	<b>100.0%</b>	<b>4,430</b>	<b>100.0%</b>	<b>923</b>	<b>100.0%</b>
0-17 years	25	*****	0.0%	*****	0.0%	*****	0.1%	*****	*****	0	0.0%
18-24 years	284	*****	0.4%	*****	0.4%	*****	0.4%	*****	*****	*****	*****
25-40 years	3,800	1,699	4.8%	986	5.4%	895	4.6%	*****	*****	*****	*****
41-64 years	23,205	9,526	27.1%	5,835	32.1%	6,277	32.3%	1,312	29.6%	255	27.6%
≥ 65 years	50,777	23,739	67.6%	11,302	62.1%	12,178	62.7%	2,923	66.0%	635	68.8%
<b>Avatrombopag</b>	<b>2,406</b>	<b>1,500</b>	<b>100.0%</b>	<b>317</b>	<b>100.0%</b>	<b>414</b>	<b>100.0%</b>	<b>122</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	180	*****	*****	*****	*****	48	11.6%	*****	*****	*****	*****
41-64 years	1,059	738	49.2%	112	35.3%	148	35.7%	*****	*****	*****	*****
≥ 65 years	1,121	666	44.4%	160	50.5%	199	48.1%	63	51.6%	33	62.3%
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>43</b>	<b>100.0%</b>	<b>77</b>	<b>100.0%</b>	<b>195</b>	<b>100.0%</b>	<b>109</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	139	*****	*****	19	24.7%	51	26.2%	41	37.6%	*****	*****
25-40 years	230	20	46.5%	35	45.5%	93	47.7%	38	34.9%	44	42.3%
41-64 years	120	*****	*****	*****	*****	36	18.5%	*****	*****	34	32.7%
≥ 65 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
<b>Baricitinib</b>	<b>51,437</b>	<b>48,051</b>	<b>100.0%</b>	<b>1,024</b>	<b>100.0%</b>	<b>1,594</b>	<b>100.0%</b>	<b>501</b>	<b>100.0%</b>	<b>267</b>	<b>100.0%</b>
0-17 years	81	23	0.0%	18	1.8%	*****	*****	*****	*****	*****	*****
18-24 years	257	146	0.3%	54	5.3%	*****	*****	*****	*****	*****	*****
25-40 years	2,083	1,660	3.5%	159	15.5%	213	13.4%	*****	*****	*****	*****
41-64 years	13,732	11,819	24.6%	556	54.3%	920	57.7%	292	58.3%	145	54.3%
≥ 65 years	35,284	34,403	71.6%	237	23.1%	386	24.2%	156	31.1%	102	38.2%

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1,828</b>	<b>100.0%</b>	<b>2,951</b>	<b>100.0%</b>	<b>7,387</b>	<b>100.0%</b>	<b>6,487</b>	<b>100.0%</b>	<b>2,327</b>	<b>100.0%</b>
0-17 years	11,082	940	51.4%	1,577	53.4%	4,059	54.9%	3,865	59.6%	641	27.5%
18-24 years	3,471	351	19.2%	518	17.6%	1,279	17.3%	1,011	15.6%	312	13.4%
25-40 years	4,318	350	19.1%	564	19.1%	1,453	19.7%	1,178	18.2%	773	33.2%
41-64 years	1,950	156	8.5%	261	8.8%	555	7.5%	403	6.2%	575	24.7%
≥ 65 years	159	31	1.7%	31	1.1%	41	0.6%	30	0.5%	26	1.1%
<b>Plazomicin</b>	<b>249</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	2.0%	0	0.0%	0	NaN	*****	100.0%	0	NaN
41-64 years	*****	*****	22.0%	0	0.0%	0	NaN	0	0.0%	0	NaN
≥ 65 years	189	*****	75.9%	*****	100.0%	0	NaN	0	0.0%	0	NaN
<b>Binimetinib</b>	<b>2,872</b>	<b>663</b>	<b>100.0%</b>	<b>716</b>	<b>100.0%</b>	<b>1,072</b>	<b>100.0%</b>	<b>297</b>	<b>100.0%</b>	<b>124</b>	<b>100.0%</b>
0-17 years	23	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	32	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	224	*****	*****	*****	*****	97	9.0%	*****	*****	*****	*****
41-64 years	943	185	27.9%	243	33.9%	378	35.3%	*****	*****	*****	*****
≥ 65 years	1,650	433	65.3%	403	56.3%	571	53.3%	168	56.6%	75	60.5%
<b>Encorafenib</b>	<b>3,371</b>	<b>802</b>	<b>100.0%</b>	<b>801</b>	<b>100.0%</b>	<b>1,305</b>	<b>100.0%</b>	<b>334</b>	<b>100.0%</b>	<b>129</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	244	*****	*****	*****	*****	108	8.3%	*****	*****	*****	*****
41-64 years	1,109	239	29.8%	259	32.3%	458	35.1%	*****	*****	*****	*****
≥ 65 years	1,991	524	65.3%	472	58.9%	725	55.6%	193	57.8%	77	59.7%
<b>Tecovirimat</b>	<b>27</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>1,476</b>	<b>310</b>	<b>100.0%</b>	<b>444</b>	<b>100.0%</b>	<b>532</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>	<b>56</b>	<b>100.0%</b>
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	0.4%	0	0.0%	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	313	61	19.7%	95	21.4%	119	22.4%	*****	*****	*****	*****
≥ 65 years	1,075	234	75.5%	321	72.3%	381	71.6%	*****	*****	*****	*****
<b>Tafenoquine</b>	<b>197</b>	<b>130</b>	<b>100.0%</b>	<b>45</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	53	41	31.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	101	62	47.7%	26	57.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<b>Elagolix sodium</b>	<b>25,153</b>	<b>7,020</b>	<b>100.0%</b>	<b>6,718</b>	<b>100.0%</b>	<b>9,036</b>	<b>100.0%</b>	<b>2,021</b>	<b>100.0%</b>	<b>358</b>	<b>100.0%</b>
0-17 years	*****	61	0.9%	90	1.3%	130	1.4%	*****	*****	15	4.2%
18-24 years	4,359	1,188	16.9%	1,147	17.1%	1,634	18.1%	337	16.7%	53	14.8%
25-40 years	15,403	4,416	62.9%	4,183	62.3%	5,399	59.7%	1,204	59.6%	201	56.1%
41-64 years	5,053	1,355	19.3%	1,298	19.3%	1,873	20.7%	438	21.7%	89	24.9%
≥ 65 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
<b>Fish oil triglycerides</b>	<b>141</b>	<b>72</b>	<b>100.0%</b>	<b>40</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	110	47	65.3%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	12	12	16.7%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<b>Lusutrombopag</b>	<b>390</b>	<b>379</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

**Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	282	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	86	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>4</b>	<b>8</b>	<b>3.1</b>	<b>1.2</b>
0-17 years	*****	1	1	1	1	2	1.2	0.4
18-24 years	*****	1	1	3	4	4	2.9	1.3
25-40 years	94	1	1	3	4	4	2.8	1.3
41-64 years	1,121	1	2	3	4	8	2.9	1.3
≥ 65 years	3,294	1	2	4	4	8	3.1	1.2
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>1</b>	<b>120</b>	<b>315</b>	<b>630</b>	<b>1,898</b>	<b>433.6</b>	<b>398.6</b>
0-17 years	966	3	101	270	450	1,500	312.7	262.0
18-24 years	8,703	1	81	201	418	1,770	284.9	265.5
25-40 years	52,127	1	90	232	474	1,898	329.9	316.3
41-64 years	94,953	1	137	360	702	1,894	475.2	413.8
≥ 65 years	18,691	1	167	452	949	1,872	586.8	483.0
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>3</b>	<b>112</b>	<b>279</b>	<b>468</b>	<b>1,820</b>	<b>318.7</b>	<b>257.1</b>
0-17 years	1,360	3	121	280	448	1,820	308.2	228.2
18-24 years	787	7	93	196	392	1,724	273.0	236.9
25-40 years	1,229	4	122	280	476	1,760	318.8	246.7
41-64 years	365	3	155	364	616	1,770	435.5	360.5
≥ 65 years	53	28	112	504	620	1,213	463.2	337.3
<b>Apalutamide</b>	<b>11,580</b>	<b>1</b>	<b>85</b>	<b>180</b>	<b>420</b>	<b>1,752</b>	<b>302.1</b>	<b>309.5</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	444	444	444	444	444	444.0	NaN
41-64 years	*****	1	88	193	402	1,616	287.6	281.4
≥ 65 years	10,415	1	84	180	422	1,752	303.7	312.5
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>1</b>	<b>19</b>	<b>90</b>	<b>383</b>	<b>1,683</b>	<b>296.5</b>	<b>415.4</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	28	30	182	966	206.2	377.8
25-40 years	47	1	8	62	266	1,466	207.6	334.8
41-64 years	214	1	25	108	414	1,683	317.9	435.7
≥ 65 years	*****	1	28	113	446	1,610	307.7	394.1
<b>Tildrakizumab</b>	<b>7,837</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>9</b>	<b>1,367</b>	<b>33.9</b>	<b>110.9</b>
0-17 years	*****	1	1	1	779	779	260.3	449.2
18-24 years	*****	1	4	34	171	1,036	109.3	169.3
25-40 years	343	1	3	12	151	1,008	104.3	161.6
41-64 years	1,038	1	3	8	114	1,252	99.9	178.8
≥ 65 years	6,395	1	3	4	8	1,367	18.6	83.1
<b>Burosumab-twza</b>	<b>1,038</b>	<b>1</b>	<b>12</b>	<b>40</b>	<b>365</b>	<b>1,658</b>	<b>229.0</b>	<b>335.0</b>
0-17 years	582	1	17	84	445	1,658	256.8	322.2
18-24 years	75	1	7	19	156	1,539	159.9	313.6
25-40 years	137	1	8	23	184	1,435	182.4	325.7
41-64 years	161	1	11	31	231	1,492	216.3	365.0
≥ 65 years	83	1	10	26	151	1,408	198.5	380.1
<b>Fostatinib</b>	<b>1,120</b>	<b>1</b>	<b>60</b>	<b>104</b>	<b>240</b>	<b>1,740</b>	<b>211.7</b>	<b>271.6</b>
0-17 years	*****	219	219	300	380	380	299.5	113.8
18-24 years	*****	5	42	90	215	905	179.8	205.0
25-40 years	129	1	60	120	240	1,404	200.7	233.4
41-64 years	374	2	60	120	270	1,740	230.6	296.2

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	579	5	38	90	240	1,613	203.7	266.7
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>6</b>	<b>488</b>	<b>6.9</b>	<b>14.8</b>
0-17 years	*****	1	1	1	2	2	1.3	0.6
18-24 years	*****	1	2	5	7	13	5.2	3.6
25-40 years	659	1	2	4	6	126	5.2	8.6
41-64 years	5,418	1	2	4	6	315	6.1	12.1
≥ 65 years	18,709	1	3	4	6	488	7.1	15.7
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>1</b>	<b>9</b>	<b>10</b>	<b>15</b>	<b>816</b>	<b>15.8</b>	<b>25.5</b>
0-17 years	*****	8	11	13	14	110	28.0	40.2
18-24 years	*****	2	9	12	14	90	13.3	9.5
25-40 years	2,011	1	9	11	15	411	15.6	20.3
41-64 years	2,821	1	9	9	16	816	15.8	25.1
≥ 65 years	637	1	9	9	16	709	17.8	41.6
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>1</b>	<b>68</b>	<b>178</b>	<b>418</b>	<b>1,716</b>	<b>297.4</b>	<b>316.0</b>
0-17 years	900	1	84	171	344	1,633	259.5	266.5
18-24 years	8,287	1	60	150	335	1,614	243.2	250.9
25-40 years	40,874	1	60	168	368	1,648	268.8	283.3
41-64 years	81,933	1	80	180	445	1,716	311.8	324.1
≥ 65 years	26,723	1	60	168	445	1,698	315.3	351.0
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>1</b>	<b>25</b>	<b>52</b>	<b>130</b>	<b>1,560</b>	<b>109.8</b>	<b>155.3</b>
0-17 years	25	9	45	120	159	390	126.2	100.2
18-24 years	284	1	30	42	109	960	85.4	110.0
25-40 years	3,800	1	30	48	120	1,038	102.6	140.3
41-64 years	23,205	1	30	60	142	1,445	114.0	152.7
≥ 65 years	50,777	1	17	44	125	1,560	108.5	157.7
<b>Avatrombopag</b>	<b>2,406</b>	<b>1</b>	<b>5</b>	<b>15</b>	<b>90</b>	<b>1,167</b>	<b>93.9</b>	<b>176.7</b>
0-17 years	*****	87	104	167	264	314	183.5	102.1
18-24 years	*****	5	46	120	240	939	196.7	231.3
25-40 years	180	3	10	35	121	1,029	106.5	156.7
41-64 years	1,059	1	5	10	60	1,145	76.2	162.3
≥ 65 years	1,121	1	5	30	106	1,167	104.4	188.2
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>3</b>	<b>100</b>	<b>269</b>	<b>620</b>	<b>1,552</b>	<b>407.2</b>	<b>384.5</b>
0-17 years	*****	22	107	329	733	1,245	426.8	375.9
18-24 years	139	3	94	220	550	1,524	356.8	333.5
25-40 years	230	10	106	251	599	1,552	396.2	387.6
41-64 years	120	8	100	357	788	1,503	483.0	429.2
≥ 65 years	*****	225	225	265	305	305	265.0	56.6
<b>Baricitinib</b>	<b>51,437</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,566</b>	<b>19.1</b>	<b>97.7</b>
0-17 years	81	1	30	90	260	1,173	197.4	265.2
18-24 years	257	1	1	20	90	982	65.8	114.4
25-40 years	2,083	1	1	1	3	1,510	41.2	121.7
41-64 years	13,732	1	1	1	1	1,548	39.4	138.5
≥ 65 years	35,284	1	1	1	1	1,566	9.2	70.3
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1</b>	<b>112</b>	<b>293</b>	<b>568</b>	<b>1,627</b>	<b>378.1</b>	<b>335.5</b>
0-17 years	11,082	1	112	280	536	1,623	342.9	280.6
18-24 years	3,471	1	90	255	516	1,627	347.5	317.2
25-40 years	4,318	1	120	317	615	1,526	432.2	388.7
41-64 years	1,950	1	119	368	873	1,495	516.5	453.2
≥ 65 years	159	7	51	161	549	1,442	327.3	356.2
<b>Plazomicin</b>	<b>249</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>7</b>	<b>554</b>	<b>8.6</b>	<b>35.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	7	27	554	99.3	223.0
41-64 years	*****	1	2	5	7	21	5.1	4.1
≥ 65 years	189	1	3	5	7	84	6.6	9.1
<b>Binimetinib</b>	<b>2,872</b>	<b>1</b>	<b>44</b>	<b>111</b>	<b>240</b>	<b>1,664</b>	<b>193.6</b>	<b>234.3</b>
0-17 years	23	11	60	144	288	640	188.6	173.7
18-24 years	32	10	60	142	247	775	201.8	197.5
25-40 years	224	2	60	120	257	1,326	198.4	214.5
41-64 years	943	1	59	120	240	1,664	198.4	235.7
≥ 65 years	1,650	1	30	90	240	1,626	190.1	237.6
<b>Encorafenib</b>	<b>3,371</b>	<b>1</b>	<b>41</b>	<b>113</b>	<b>240</b>	<b>1,664</b>	<b>187.7</b>	<b>225.9</b>
0-17 years	*****	12	36	97	211	288	123.5	120.6
18-24 years	*****	30	90	149	330	775	227.4	220.7
25-40 years	244	2	60	120	270	1,296	198.8	209.3
41-64 years	1,109	1	49	120	240	1,664	191.3	228.1
≥ 65 years	1,991	2	30	90	240	1,626	183.9	226.8
<b>Tecovirimat</b>	<b>27</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>19.6</b>	<b>19.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	12	14	63	112	37.3	49.9
25-40 years	*****	14	14	14	14	30	16.4	5.6
41-64 years	*****	14	14	14	14	28	16.8	6.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>1,476</b>	<b>1</b>	<b>47</b>	<b>90</b>	<b>210</b>	<b>1,582</b>	<b>178.0</b>	<b>217.2</b>
0-17 years	*****	86	86	102	117	117	101.5	21.9
18-24 years	*****	9	25	198	869	870	361.3	407.3
25-40 years	*****	19	51	92	246	1,221	181.8	215.2
41-64 years	313	4	50	91	227	1,235	167.6	186.7
≥ 65 years	1,075	1	45	90	210	1,582	179.9	224.1
<b>Tafenoquine</b>	<b>197</b>	<b>1</b>	<b>4</b>	<b>21</b>	<b>59</b>	<b>861</b>	<b>46.6</b>	<b>89.1</b>
0-17 years	*****	1	5	25	65	282	56.4	84.8
18-24 years	*****	1	6	26	70	180	45.8	56.2
25-40 years	53	1	2	15	30	248	32.8	51.6
41-64 years	101	1	4	28	60	861	55.9	112.3
≥ 65 years	21	1	1	12	54	136	32.6	42.1
<b>Elagolix sodium</b>	<b>25,153</b>	<b>1</b>	<b>28</b>	<b>84</b>	<b>195</b>	<b>1,441</b>	<b>147.9</b>	<b>168.2</b>
0-17 years	*****	2	56	112	252	1,254	199.7	226.3
18-24 years	4,359	1	28	84	196	1,258	149.1	162.4
25-40 years	15,403	1	28	84	170	1,441	143.4	164.8
41-64 years	5,053	1	28	84	196	1,265	156.9	177.4

**Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	476	476	560	729	729	588.3	128.9
<b>Fish oil triglycerides</b>	<b>141</b>	<b>1</b>	<b>6</b>	<b>28</b>	<b>77</b>	<b>723</b>	<b>82.9</b>	<b>152.2</b>
0-17 years	110	1	9	45	83	723	95.3	156.7
18-24 years	*****	1	10	31	133	707	152.2	276.1
25-40 years	12	1	1	1	8	25	5.3	7.9
41-64 years	*****	1	1	6	13	33	9.1	10.9
≥ 65 years	*****	1	4	6	34	110	31.0	46.1
<b>Lusutrombopag</b>	<b>390</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>280</b>	<b>11.3</b>	<b>17.9</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	7	7	7	7	7.0	0.0
25-40 years	*****	7	7	7	7	44	11.5	10.0
41-64 years	282	3	7	7	14	280	12.0	20.7
≥ 65 years	86	7	7	7	7	42	9.3	5.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lutetium Lu 177 dotatate</i>	13,921	13,921	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir sodium/emtricitabine/ tenofovir alafenamide fumarate</i>	699,595	355,211	50.8%	179,959	25.7%	121,777	17.4%	27,830	4.0%	14,818	2.1%
<i>Tezacaftor and ivacaftor</i>	14,644	8,221	56.1%	3,615	24.7%	2,283	15.6%	391	2.7%	134	0.9%
<i>Apalutamide</i>	36,365	17,966	49.4%	9,633	26.5%	7,209	19.8%	1,210	3.3%	347	1.0%
<i>Ibalizumab-uiyk</i>	3,797	3,367	88.7%	193	5.1%	192	5.1%	30	0.8%	15	0.4%
<i>Tildrakizumab</i>	36,842	35,187	95.5%	1,105	3.0%	492	1.3%	****	****	****	****
<i>Burosumab-twza</i>	12,760	11,714	91.8%	549	4.3%	358	2.8%	84	0.7%	55	0.4%
<i>Fostamatinib</i>	2,950	1,563	53.0%	837	28.4%	467	15.8%	63	2.1%	20	0.7%
<i>palonosetron</i>	132,350	131,985	99.7%	303	0.2%	62	0.0%	0	0.0%	0	0.0%
<i>Lofexidine hydrochloride</i>	7,235	7,077	97.8%	137	1.9%	****	****	****	****	0	0.0%
<i>Erenumab-aooe</i>	577,165	313,080	54.2%	154,270	26.7%	91,997	15.9%	13,269	2.3%	4,549	0.8%
<i>Sodium zirconium cyclosilicate</i>	175,266	118,777	67.8%	41,461	23.7%	13,564	7.7%	1,260	0.7%	204	0.1%
<i>Avatrombopag</i>	4,942	3,678	74.4%	768	15.5%	423	8.6%	57	1.2%	16	0.3%
<i>Pegvaliase-pqz</i>	2,920	1,840	63.0%	685	23.5%	309	10.6%	48	1.6%	38	1.3%
<i>Baricitinib</i>	59,846	54,417	90.9%	3,165	5.3%	1,938	3.2%	266	0.4%	60	0.1%
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Cannabidiol</i>	61,573	28,221	45.8%	15,503	25.2%	12,055	19.6%	4,405	7.2%	1,389	2.3%
<i>Plazomicin</i>	674	****	****	0	0.0%	0	0.0%	****	****	0	0.0%
<i>Binimetinib</i>	8,279	4,942	59.7%	2,138	25.8%	1,045	12.6%	128	1.5%	26	0.3%
<i>Encorafenib</i>	9,319	5,435	58.3%	2,448	26.3%	1,272	13.6%	137	1.5%	27	0.3%
<i>Tecovirimat</i>	29	****	****	0	0.0%	****	****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	3,355	1,650	49.2%	1,011	30.1%	620	18.5%	60	1.8%	14	0.4%
<i>Tafenoquine</i>	366	298	81.4%	54	14.8%	****	****	****	****	0	0.0%
<i>Elagolix sodium</i>	60,829	37,578	61.8%	14,992	24.6%	7,490	12.3%	651	1.1%	118	0.2%
<i>Fish oil triglycerides</i>	2,843	2,772	97.5%	52	1.8%	****	****	****	****	0	0.0%
<i>Lusutrombopag</i>	528	****	****	****	****	0	0.0%	0	0.0%	0	0.0%

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	13,921	1	1	1	1	3	1.0	0.0
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	699,595	1	30	30	90	1,898	108.7	184.7
<i>Tezacaftor and ivacaftor</i>	14,644	1	28	28	84	1,820	82.6	136.0
<i>Apalutamide</i>	36,365	1	30	40	90	1,752	96.2	138.2
<i>Ibalizumab-uiyk</i>	3,797	1	1	1	1	1,655	24.0	92.1
<i>Tildrakizumab</i>	36,842	1	1	1	1	1,146	7.2	34.6
<i>Burosumab-twza</i>	12,760	1	1	1	1	1,484	18.6	85.7
<i>Fostamatinib</i>	2,950	1	30	30	90	1,613	80.4	118.2
<i>Fosnetupitant and palonosetron</i>	132,350	1	1	1	1	270	1.3	4.4
<i>Lofexidine hydrochloride</i>	7,235	1	8	9	14	644	12.6	14.5
<i>Erenumab-aooe</i>	577,165	1	30	30	90	1,688	81.8	123.4
<i>Sodium zirconium cyclosilicate</i>	175,266	1	22	30	60	1,415	48.9	68.3
<i>Avatrombopag</i>	4,942	1	5	30	34	1,115	45.7	85.7
<i>Pegvaliase-pqz</i>	2,920	1	30	30	60	1,503	73.6	144.3
<i>Baricitinib</i>	59,846	1	1	1	1	1,476	16.4	58.7
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	61,573	1	30	45	120	1,627	128.8	203.7
<i>Plazomicin</i>	674	1	1	1	3	554	3.2	21.4
<i>Binimetinib</i>	8,279	1	30	30	60	1,626	67.2	91.5
<i>Encorafenib</i>	9,319	1	30	30	60	1,626	67.9	91.2
<i>Tecovirimat</i>	29	9	14	14	14	112	18.2	18.5
<i>Ivosidenib</i>	3,355	1	30	35	90	1,139	78.3	99.8
<i>Tafenoquine</i>	366	1	1	5	28	531	25.1	53.5
<i>Elagolix sodium</i>	60,829	1	28	28	56	1,360	61.2	79.5
<i>Fish oil triglycerides</i>	2,843	1	1	1	1	716	4.1	25.2
<i>Lusutrombopag</i>	528	3	7	7	7	57	8.4	5.2

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lutetium Lu 177 dotatate</b>	<b>13,921</b>	<b>13,921</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	6,868	6,868	49.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	7,053	7,053	50.7%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>699,595</b>	<b>355,211</b>	<b>100.0%</b>	<b>179,959</b>	<b>100.0%</b>	<b>121,777</b>	<b>100.0%</b>	<b>27,830</b>	<b>100.0%</b>	<b>14,818</b>	<b>100.0%</b>
Female	184,377	96,943	27.3%	47,006	26.1%	30,474	25.0%	6,874	24.7%	3,080	20.8%
Male	515,218	258,268	72.7%	132,953	73.9%	91,303	75.0%	20,956	75.3%	11,738	79.2%
<b>Tezacaftor and ivacaftor</b>	<b>14,644</b>	<b>8,221</b>	<b>100.0%</b>	<b>3,615</b>	<b>100.0%</b>	<b>2,283</b>	<b>100.0%</b>	<b>391</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>
Female	7,351	4,211	51.2%	1,780	49.2%	1,104	48.4%	193	49.4%	63	47.0%
Male	7,293	4,010	48.8%	1,835	50.8%	1,179	51.6%	198	50.6%	71	53.0%
<b>Apalutamide</b>	<b>36,365</b>	<b>17,966</b>	<b>100.0%</b>	<b>9,633</b>	<b>100.0%</b>	<b>7,209</b>	<b>100.0%</b>	<b>1,210</b>	<b>100.0%</b>	<b>347</b>	<b>100.0%</b>
Female	*****	0	0.0%	0	0.0%	*****	0.0%	0	0.0%	0	0.0%
Male	*****	17,966	100.0%	9,633	100.0%	*****	100.0%	1,210	100.0%	347	100.0%
<b>Ibalizumab-uiyk</b>	<b>3,797</b>	<b>3,367</b>	<b>100.0%</b>	<b>193</b>	<b>100.0%</b>	<b>192</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>15</b>	<b>100.0%</b>
Female	1,075	989	29.4%	41	21.2%	*****	*****	*****	*****	0	0.0%
Male	2,722	2,378	70.6%	152	78.8%	*****	*****	*****	*****	15	100.0%
<b>Tildrakizumab</b>	<b>36,842</b>	<b>35,187</b>	<b>100.0%</b>	<b>1,105</b>	<b>100.0%</b>	<b>492</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	18,945	18,071	51.4%	584	52.9%	262	53.3%	*****	*****	*****	*****
Male	17,897	17,116	48.6%	521	47.1%	230	46.7%	*****	*****	*****	*****
<b>Burosumab-twza</b>	<b>12,760</b>	<b>11,714</b>	<b>100.0%</b>	<b>549</b>	<b>100.0%</b>	<b>358</b>	<b>100.0%</b>	<b>84</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>
Female	7,775	7,077	60.4%	355	64.7%	253	70.7%	50	59.5%	40	72.7%
Male	4,985	4,637	39.6%	194	35.3%	105	29.3%	34	40.5%	15	27.3%
<b>Fostamatinib</b>	<b>2,950</b>	<b>1,563</b>	<b>100.0%</b>	<b>837</b>	<b>100.0%</b>	<b>467</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>
Female	1,775	952	60.9%	504	60.2%	272	58.2%	*****	*****	*****	*****
Male	1,175	611	39.1%	333	39.8%	195	41.8%	*****	*****	*****	*****
<b>Fosnetupitant and</b>	<b>132,350</b>	<b>131,985</b>	<b>100.0%</b>	<b>303</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	74,032	73,826	55.9%	174	57.4%	32	51.6%	0	NaN	0	NaN
Male	58,318	58,159	44.1%	129	42.6%	30	48.4%	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>7,235</b>	<b>7,077</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	3,716	3,646	51.5%	*****	*****	*****	*****	*****	*****	0	NaN
Male	3,519	3,431	48.5%	*****	*****	*****	*****	0	0.0%	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Erenumab-aooe</b>	<b>577,165</b>	<b>313,080</b>	<b>100.0%</b>	<b>154,270</b>	<b>100.0%</b>	<b>91,997</b>	<b>100.0%</b>	<b>13,269</b>	<b>100.0%</b>	<b>4,549</b>	<b>100.0%</b>
Female	493,702	267,710	85.5%	132,178	85.7%	78,644	85.5%	11,304	85.2%	3,866	85.0%
Male	83,463	45,370	14.5%	22,092	14.3%	13,353	14.5%	1,965	14.8%	683	15.0%
<b>Sodium zirconium cyclosilicate</b>	<b>175,266</b>	<b>118,777</b>	<b>100.0%</b>	<b>41,461</b>	<b>100.0%</b>	<b>13,564</b>	<b>100.0%</b>	<b>1,260</b>	<b>100.0%</b>	<b>204</b>	<b>100.0%</b>
Female	73,741	50,934	42.9%	16,928	40.8%	5,335	39.3%	465	36.9%	79	38.7%
Male	101,525	67,843	57.1%	24,533	59.2%	8,229	60.7%	795	63.1%	125	61.3%
<b>Avatrombopag</b>	<b>4,942</b>	<b>3,678</b>	<b>100.0%</b>	<b>768</b>	<b>100.0%</b>	<b>423</b>	<b>100.0%</b>	<b>57</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>
Female	2,521	1,872	50.9%	398	51.8%	213	50.4%	****	****	****	****
Male	2,421	1,806	49.1%	370	48.2%	210	49.6%	****	****	****	****
<b>Pegvaliase-pqpz</b>	<b>2,920</b>	<b>1,840</b>	<b>100.0%</b>	<b>685</b>	<b>100.0%</b>	<b>309</b>	<b>100.0%</b>	<b>48</b>	<b>100.0%</b>	<b>38</b>	<b>100.0%</b>
Female	1,384	837	45.5%	346	50.5%	163	52.8%	24	50.0%	14	36.8%
Male	1,536	1,003	54.5%	339	49.5%	146	47.2%	24	50.0%	24	63.2%
<b>Baricitinib</b>	<b>59,846</b>	<b>54,417</b>	<b>100.0%</b>	<b>3,165</b>	<b>100.0%</b>	<b>1,938</b>	<b>100.0%</b>	<b>266</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>
Female	31,398	26,919	49.5%	2,625	82.9%	1,589	82.0%	216	81.2%	49	81.7%
Male	28,448	27,498	50.5%	540	17.1%	349	18.0%	50	18.8%	11	18.3%
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>61,573</b>	<b>28,221</b>	<b>100.0%</b>	<b>15,503</b>	<b>100.0%</b>	<b>12,055</b>	<b>100.0%</b>	<b>4,405</b>	<b>100.0%</b>	<b>1,389</b>	<b>100.0%</b>
Female	27,556	12,685	44.9%	6,908	44.6%	5,358	44.4%	1,973	44.8%	632	45.5%
Male	34,017	15,536	55.1%	8,595	55.4%	6,697	55.6%	2,432	55.2%	757	54.5%
<b>Plazomicin</b>	<b>674</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	485	****	****	0	NaN	0	NaN	0	0.0%	0	NaN
Male	189	****	****	0	NaN	0	NaN	****	****	0	NaN
<b>Binimetinib</b>	<b>8,279</b>	<b>4,942</b>	<b>100.0%</b>	<b>2,138</b>	<b>100.0%</b>	<b>1,045</b>	<b>100.0%</b>	<b>128</b>	<b>100.0%</b>	<b>26</b>	<b>100.0%</b>
Female	3,828	2,330	47.1%	970	45.4%	453	43.3%	****	****	****	****
Male	4,451	2,612	52.9%	1,168	54.6%	592	56.7%	****	****	****	****
<b>Encorafenib</b>	<b>9,319</b>	<b>5,435</b>	<b>100.0%</b>	<b>2,448</b>	<b>100.0%</b>	<b>1,272</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
Female	4,436	2,633	48.4%	1,138	46.5%	587	46.1%	67	48.9%	11	40.7%
Male	4,883	2,802	51.6%	1,310	53.5%	685	53.9%	70	51.1%	16	59.3%
<b>Tecovirimat</b>	<b>29</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	****	****	****	0	NaN	0	0.0%	0	NaN	0	NaN

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>3,355</b>	<b>1,650</b>	<b>100.0%</b>	<b>1,011</b>	<b>100.0%</b>	<b>620</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>
Female	1,786	920	55.8%	511	50.5%	312	50.3%	*****	*****	*****	*****
Male	1,569	730	44.2%	500	49.5%	308	49.7%	*****	*****	*****	*****
<b>Tafenoquine</b>	<b>366</b>	<b>298</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	236	192	64.4%	*****	*****	*****	*****	*****	*****	0	NaN
Male	130	106	35.6%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Elagolix sodium</b>	<b>60,829</b>	<b>37,578</b>	<b>100.0%</b>	<b>14,992</b>	<b>100.0%</b>	<b>7,490</b>	<b>100.0%</b>	<b>651</b>	<b>100.0%</b>	<b>118</b>	<b>100.0%</b>
Female	60,748	37,520	99.8%	*****	*****	*****	*****	*****	*****	118	100.0%
Male	81	58	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
<b>Fish oil triglycerides</b>	<b>2,843</b>	<b>2,772</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	1,615	1,573	56.7%	30	57.7%	*****	*****	*****	*****	0	NaN
Male	1,228	1,199	43.3%	22	42.3%	*****	*****	*****	*****	0	NaN
<b>Lusutrombopag</b>	<b>528</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	262	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	266	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>13,921</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.0</b>
Female	6,868	1	1	1	1	2	1.0	0.0
Male	7,053	1	1	1	1	3	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>699,595</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,898</b>	<b>108.7</b>	<b>184.7</b>
Female	184,377	1	30	30	90	1,836	100.3	166.4
Male	515,218	1	30	30	90	1,898	111.7	190.7
<b>Tezacaftor and ivacaftor</b>	<b>14,644</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>1,820</b>	<b>82.6</b>	<b>136.0</b>
Female	7,351	1	28	28	84	1,724	80.3	133.6
Male	7,293	1	28	28	84	1,820	84.8	138.3
<b>Apalutamide</b>	<b>36,365</b>	<b>1</b>	<b>30</b>	<b>40</b>	<b>90</b>	<b>1,752</b>	<b>96.2</b>	<b>138.2</b>
Female	*****	120	120	120	120	120	120.0	NaN
Male	*****	1	30	40	90	1,752	96.2	138.2
<b>Ibalizumab-uiyk</b>	<b>3,797</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,655</b>	<b>24.0</b>	<b>92.1</b>
Female	1,075	1	1	1	1	602	14.3	53.4
Male	2,722	1	1	1	1	1,655	27.8	103.2
<b>Tildrakizumab</b>	<b>36,842</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,146</b>	<b>7.2</b>	<b>34.6</b>
Female	18,945	1	1	1	1	924	7.3	33.1
Male	17,897	1	1	1	1	1,146	7.2	36.1
<b>Burosumab-twza</b>	<b>12,760</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,484</b>	<b>18.6</b>	<b>85.7</b>
Female	7,775	1	1	1	1	1,484	20.7	91.5
Male	4,985	1	1	1	1	1,367	15.4	75.7
<b>Fostamatinib</b>	<b>2,950</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,613</b>	<b>80.4</b>	<b>118.2</b>
Female	1,775	1	30	30	90	1,470	78.4	110.9
Male	1,175	2	30	30	90	1,613	83.4	128.6
<b>Fosnetupitant and palonosetron</b>	<b>132,350</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>270</b>	<b>1.3</b>	<b>4.4</b>
Female	74,032	1	1	1	1	226	1.3	4.2
Male	58,318	1	1	1	1	270	1.3	4.6
<b>Lofexidine hydrochloride</b>	<b>7,235</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>644</b>	<b>12.6</b>	<b>14.5</b>
Female	3,716	1	8	9	14	644	12.5	15.9
Male	3,519	1	8	9	14	348	12.7	12.9
<b>Erenumab-aooe</b>	<b>577,165</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,688</b>	<b>81.8</b>	<b>123.4</b>
Female	493,702	1	30	30	90	1,687	81.7	123.2
Male	83,463	1	30	30	90	1,688	82.5	124.7
<b>Sodium zirconium cyclosilicate</b>	<b>175,266</b>	<b>1</b>	<b>22</b>	<b>30</b>	<b>60</b>	<b>1,415</b>	<b>48.9</b>	<b>68.3</b>
Female	73,741	1	19	30	56	1,349	46.7	65.7
Male	101,525	1	26	30	60	1,415	50.5	70.1
<b>Avatrombopag</b>	<b>4,942</b>	<b>1</b>	<b>5</b>	<b>30</b>	<b>34</b>	<b>1,115</b>	<b>45.7</b>	<b>85.7</b>
Female	2,521	1	5	30	33	1,115	46.6	89.6
Male	2,421	1	5	30	35	960	44.8	81.4
<b>Pegvaliase-pqpz</b>	<b>2,920</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,503</b>	<b>73.6</b>	<b>144.3</b>
Female	1,384	1	30	30	60	1,487	73.2	136.6
Male	1,536	1	30	30	60	1,503	74.1	151.0
<b>Baricitinib</b>	<b>59,846</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,476</b>	<b>16.4</b>	<b>58.7</b>
Female	31,398	1	1	1	30	1,476	25.2	71.9
Male	28,448	1	1	1	1	1,350	6.7	36.9
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>61,573</b>	<b>1</b>	<b>30</b>	<b>45</b>	<b>120</b>	<b>1,627</b>	<b>128.8</b>	<b>203.7</b>
Female	27,556	1	30	44	120	1,611	129.3	204.9
Male	34,017	1	30	46	120	1,627	128.4	202.7
<b>Plazomicin</b>	<b>674</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>554</b>	<b>3.2</b>	<b>21.4</b>
Female	485	1	1	1	3	20	2.3	2.3
Male	189	1	1	1	4	554	5.5	40.2
<b>Binimetinib</b>	<b>8,279</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,626</b>	<b>67.2</b>	<b>91.5</b>
Female	3,828	1	30	30	60	1,332	66.0	88.3
Male	4,451	1	30	30	60	1,626	68.2	94.1
<b>Encorafenib</b>	<b>9,319</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,626</b>	<b>67.9</b>	<b>91.2</b>
Female	4,436	1	30	30	60	1,332	66.9	88.4
Male	4,883	1	30	30	60	1,626	68.8	93.7
<b>Tecovirimat</b>	<b>29</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>18.2</b>	<b>18.5</b>
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	18.4	18.8
<b>Ivosidenib</b>	<b>3,355</b>	<b>1</b>	<b>30</b>	<b>35</b>	<b>90</b>	<b>1,139</b>	<b>78.3</b>	<b>99.8</b>
Female	1,786	1	30	30	90	991	76.1	95.8
Male	1,569	1	30	50	90	1,139	80.9	104.1
<b>Tafenoquine</b>	<b>366</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>28</b>	<b>531</b>	<b>25.1</b>	<b>53.5</b>
Female	236	1	1	4	30	528	23.3	47.3
Male	130	1	1	7	28	531	28.4	63.3
<b>Elagolix sodium</b>	<b>60,829</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,360</b>	<b>61.2</b>	<b>79.5</b>
Female	60,748	1	28	28	56	1,360	61.2	79.5
Male	81	4	28	28	56	476	50.6	61.1
<b>Fish oil triglycerides</b>	<b>2,843</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>716</b>	<b>4.1</b>	<b>25.2</b>
Female	1,615	1	1	1	1	643	4.1	25.1
Male	1,228	1	1	1	1	716	4.1	25.4
<b>Lusutrombopag</b>	<b>528</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>57</b>	<b>8.4</b>	<b>5.2</b>
Female	262	6	7	7	7	57	8.6	5.2
Male	266	3	7	7	7	56	8.2	5.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lutetium Lu 177 dotatate</b>	<b>13,921</b>	<b>13,921</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	0.1%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	256	256	1.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	3,292	3,292	23.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	10,346	10,346	74.3%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>699,595</b>	<b>355,211</b>	<b>100.0%</b>	<b>179,959</b>	<b>100.0%</b>	<b>121,777</b>	<b>100.0%</b>	<b>27,830</b>	<b>100.0%</b>	<b>14,818</b>	<b>100.0%</b>
0-17 years	3,088	1,610	0.5%	751	0.4%	559	0.5%	138	0.5%	30	0.2%
18-24 years	31,388	17,925	5.0%	7,983	4.4%	4,495	3.7%	785	2.8%	200	1.3%
25-40 years	199,668	110,986	31.2%	50,848	28.3%	30,270	24.9%	5,528	19.9%	2,036	13.7%
41-64 years	386,411	189,320	53.3%	99,712	55.4%	70,411	57.8%	17,389	62.5%	9,579	64.6%
≥ 65 years	79,040	35,370	10.0%	20,665	11.5%	16,042	13.2%	3,990	14.3%	2,973	20.1%
<b>Tezacaftor and ivacaftor</b>	<b>14,644</b>	<b>8,221</b>	<b>100.0%</b>	<b>3,615</b>	<b>100.0%</b>	<b>2,283</b>	<b>100.0%</b>	<b>391</b>	<b>100.0%</b>	<b>134</b>	<b>100.0%</b>
0-17 years	4,846	2,604	31.7%	1,220	33.7%	834	36.5%	148	37.9%	40	29.9%
18-24 years	2,903	1,736	21.1%	700	19.4%	385	16.9%	55	14.1%	27	20.1%
25-40 years	5,212	3,055	37.2%	1,282	35.5%	718	31.4%	123	31.5%	34	25.4%
41-64 years	1,509	765	9.3%	372	10.3%	288	12.6%	*****	*****	*****	*****
≥ 65 years	174	61	0.7%	41	1.1%	58	2.5%	*****	*****	*****	*****
<b>Apalutamide</b>	<b>36,365</b>	<b>17,966</b>	<b>100.0%</b>	<b>9,633</b>	<b>100.0%</b>	<b>7,209</b>	<b>100.0%</b>	<b>1,210</b>	<b>100.0%</b>	<b>347</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	10.3%	*****	*****	*****	*****	126	10.4%	36	10.4%
≥ 65 years	32,737	16,107	89.7%	8,664	89.9%	6,571	91.1%	1,084	89.6%	311	89.6%
<b>Ibalizumab-uiyk</b>	<b>3,797</b>	<b>3,367</b>	<b>100.0%</b>	<b>193</b>	<b>100.0%</b>	<b>192</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>15</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	512	451	13.4%	30	15.5%	*****	*****	*****	*****	0	0.0%



**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	2,655	2,340	69.5%	147	76.2%	133	69.3%	*****	*****	*****	*****
≥ 65 years	532	484	14.4%	*****	*****	*****	*****	*****	*****	*****	*****
<b>Tildrakizumab</b>	<b>36,842</b>	<b>35,187</b>	<b>100.0%</b>	<b>1,105</b>	<b>100.0%</b>	<b>492</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	11	*****	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	189	*****	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	1,133	855	2.4%	192	17.4%	*****	*****	*****	*****	0	0.0%
41-64 years	3,591	2,851	8.1%	519	47.0%	195	39.6%	*****	*****	*****	*****
≥ 65 years	31,918	31,332	89.0%	360	32.6%	201	40.9%	*****	*****	*****	*****
<b>Burosumab-twza</b>	<b>12,760</b>	<b>11,714</b>	<b>100.0%</b>	<b>549</b>	<b>100.0%</b>	<b>358</b>	<b>100.0%</b>	<b>84</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>
0-17 years	7,030	6,290	53.7%	396	72.1%	269	75.1%	54	64.3%	21	38.2%
18-24 years	599	560	4.8%	20	3.6%	*****	*****	*****	*****	*****	*****
25-40 years	1,720	1,630	13.9%	48	8.7%	24	6.7%	*****	*****	*****	*****
41-64 years	2,169	2,046	17.5%	60	10.9%	38	10.6%	14	16.7%	11	20.0%
≥ 65 years	1,242	1,188	10.1%	25	4.6%	*****	*****	*****	*****	*****	*****
<b>Fostamatinib</b>	<b>2,950</b>	<b>1,563</b>	<b>100.0%</b>	<b>837</b>	<b>100.0%</b>	<b>467</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	388	242	15.5%	87	10.4%	*****	*****	*****	*****	*****	*****
41-64 years	1,050	563	36.0%	287	34.3%	169	36.2%	*****	*****	*****	*****
≥ 65 years	1,397	688	44.0%	433	51.7%	232	49.7%	*****	*****	*****	*****
<b>Fosnetupitant and palonosetron</b>	<b>132,350</b>	<b>131,985</b>	<b>100.0%</b>	<b>303</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	0.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	2,925	*****	2.2%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	27,438	27,386	20.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	101,596	101,287	76.7%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>7,235</b>	<b>7,077</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	2,529	2,476	35.0%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	3,505	3,422	48.4%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	824	805	11.4%	*****	*****	*****	*****	0	0.0%	0	NaN
<b>Erenumab-aoee</b>	<b>577,165</b>	<b>313,080</b>	<b>100.0%</b>	<b>154,270</b>	<b>100.0%</b>	<b>91,997</b>	<b>100.0%</b>	<b>13,269</b>	<b>100.0%</b>	<b>4,549</b>	<b>100.0%</b>
0-17 years	2,893	1,581	0.5%	753	0.5%	466	0.5%	74	0.6%	19	0.4%
18-24 years	28,183	16,166	5.2%	7,422	4.8%	3,960	4.3%	520	3.9%	115	2.5%
25-40 years	143,121	79,534	25.4%	38,009	24.6%	21,803	23.7%	2,899	21.8%	876	19.3%
41-64 years	306,014	165,459	52.8%	81,169	52.6%	49,253	53.5%	7,480	56.4%	2,653	58.3%
≥ 65 years	96,954	50,340	16.1%	26,917	17.4%	16,515	18.0%	2,296	17.3%	886	19.5%
<b>Sodium zirconium cyclosilicate</b>	<b>175,266</b>	<b>118,777</b>	<b>100.0%</b>	<b>41,461</b>	<b>100.0%</b>	<b>13,564</b>	<b>100.0%</b>	<b>1,260</b>	<b>100.0%</b>	<b>204</b>	<b>100.0%</b>
0-17 years	46	27	0.0%	*****	0.0%	*****	0.1%	*****	*****	0	0.0%
18-24 years	540	371	0.3%	*****	0.3%	*****	0.3%	*****	*****	0	0.0%
25-40 years	8,027	5,518	4.6%	1,877	4.5%	566	4.2%	*****	*****	*****	*****
41-64 years	52,503	35,210	29.6%	12,659	30.5%	4,152	30.6%	*****	*****	*****	*****
≥ 65 years	114,150	77,651	65.4%	26,789	64.6%	8,797	64.9%	779	61.8%	134	65.7%
<b>Avatrombopag</b>	<b>4,942</b>	<b>3,678</b>	<b>100.0%</b>	<b>768</b>	<b>100.0%</b>	<b>423</b>	<b>100.0%</b>	<b>57</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>
0-17 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	164	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	382	275	7.5%	64	8.3%	*****	*****	*****	*****	0	0.0%
41-64 years	2,074	1,634	44.4%	260	33.9%	153	36.2%	*****	*****	*****	*****
≥ 65 years	2,307	1,641	44.6%	409	53.3%	218	51.5%	*****	*****	*****	*****
<b>Pegvaliase-pqpz</b>	<b>2,920</b>	<b>1,840</b>	<b>100.0%</b>	<b>685</b>	<b>100.0%</b>	<b>309</b>	<b>100.0%</b>	<b>48</b>	<b>100.0%</b>	<b>38</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	784	521	28.3%	179	26.1%	65	21.0%	*****	*****	*****	*****
25-40 years	1,196	776	42.2%	262	38.2%	120	38.8%	19	39.6%	19	50.0%
41-64 years	774	446	24.2%	213	31.1%	96	31.1%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<b>Baricitinib</b>	<b>59,846</b>	<b>54,417</b>	<b>100.0%</b>	<b>3,165</b>	<b>100.0%</b>	<b>1,938</b>	<b>100.0%</b>	<b>266</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Number of Treatment Episodes by Duration											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
0-17 years	167	95	0.2%	32	1.0%	*****	*****	*****	*****	*****	*****
18-24 years	456	339	0.6%	81	2.6%	*****	*****	*****	*****	0	0.0%
25-40 years	2,935	2,378	4.4%	367	11.6%	173	8.9%	*****	*****	*****	*****
41-64 years	18,265	15,238	28.0%	1,726	54.5%	1,118	57.7%	150	56.4%	33	55.0%
≥ 65 years	38,023	36,367	66.8%	959	30.3%	582	30.0%	*****	*****	*****	*****
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>61,573</b>	<b>28,221</b>	<b>100.0%</b>	<b>15,503</b>	<b>100.0%</b>	<b>12,055</b>	<b>100.0%</b>	<b>4,405</b>	<b>100.0%</b>	<b>1,389</b>	<b>100.0%</b>
0-17 years	29,613	13,301	47.1%	7,367	47.5%	5,987	49.7%	2,559	58.1%	399	28.7%
18-24 years	10,116	4,778	16.9%	2,505	16.2%	2,021	16.8%	*****	*****	*****	*****
25-40 years	14,066	6,604	23.4%	3,556	22.9%	2,599	21.6%	826	18.8%	481	34.6%
41-64 years	7,290	3,288	11.7%	1,955	12.6%	1,363	11.3%	360	8.2%	324	23.3%
≥ 65 years	488	250	0.9%	120	0.8%	85	0.7%	*****	*****	*****	*****
<b>Plazomicin</b>	<b>674</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	*****	100.0%	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
≥ 65 years	565	565	*****	0	NaN	0	NaN	0	0.0%	0	NaN
<b>Binimetinib</b>	<b>8,279</b>	<b>4,942</b>	<b>100.0%</b>	<b>2,138</b>	<b>100.0%</b>	<b>1,045</b>	<b>100.0%</b>	<b>128</b>	<b>100.0%</b>	<b>26</b>	<b>100.0%</b>
0-17 years	41	22	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	73	38	0.8%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	695	423	8.6%	181	8.5%	79	7.6%	*****	*****	*****	*****
41-64 years	2,807	1,696	34.3%	708	33.1%	354	33.9%	*****	*****	*****	*****
≥ 65 years	4,663	2,763	55.9%	1,222	57.2%	591	56.6%	73	57.0%	14	53.8%
<b>Encorafenib</b>	<b>9,319</b>	<b>5,435</b>	<b>100.0%</b>	<b>2,448</b>	<b>100.0%</b>	<b>1,272</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	731	424	7.8%	197	8.0%	97	7.6%	*****	*****	*****	*****
41-64 years	3,060	1,766	32.5%	812	33.2%	425	33.4%	*****	*****	*****	*****
≥ 65 years	5,462	3,210	59.1%	1,423	58.1%	738	58.0%	77	56.2%	14	51.9%
<b>Tecovirimat</b>	<b>29</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	*****	*****	0	NaN	0	NaN
25-40 years	19	19	67.9%	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>3,355</b>	<b>1,650</b>	<b>100.0%</b>	<b>1,011</b>	<b>100.0%</b>	<b>620</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	176	86	5.2%	47	4.6%	*****	*****	*****	*****	*****	*****
41-64 years	670	339	20.5%	196	19.4%	114	18.4%	*****	*****	*****	*****
≥ 65 years	2,474	1,205	73.0%	756	74.8%	466	75.2%	*****	*****	*****	*****
<b>Tafenoquine</b>	<b>366</b>	<b>298</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	109	95	31.9%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	186	148	49.7%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	32	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<b>Elagolix sodium</b>	<b>60,829</b>	<b>37,578</b>	<b>100.0%</b>	<b>14,992</b>	<b>100.0%</b>	<b>7,490</b>	<b>100.0%</b>	<b>651</b>	<b>100.0%</b>	<b>118</b>	<b>100.0%</b>
0-17 years	*****	*****	1.7%	*****	1.6%	*****	*****	*****	*****	*****	*****
18-24 years	10,823	6,828	18.2%	2,620	17.5%	1,233	16.5%	*****	*****	*****	*****
25-40 years	36,573	22,698	60.4%	8,958	59.8%	4,479	59.8%	371	57.0%	67	56.8%
41-64 years	12,415	7,428	19.8%	3,168	21.1%	1,654	22.1%	142	21.8%	23	19.5%
≥ 65 years	*****	*****	0.0%	*****	0.0%	*****	*****	*****	*****	0	0.0%

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Fish oil triglycerides</b>	<b>2,843</b>	<b>2,772</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	2,528	2,460	88.7%	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	187	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	51	51	1.8%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	53	53	1.9%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	24	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
<b>Lusutrombopag</b>	<b>528</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	393	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	106	106	*****	0	0.0%	0	NaN	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>13,921</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	256	1	1	1	1	3	1.0	0.1
41-64 years	3,292	1	1	1	1	3	1.0	0.0
≥ 65 years	10,346	1	1	1	1	2	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>699,595</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,898</b>	<b>108.7</b>	<b>184.7</b>
0-17 years	3,088	1	30	30	90	1,447	97.8	144.9
18-24 years	31,388	1	30	30	81	1,770	79.0	118.5
25-40 years	199,668	1	30	30	90	1,898	86.1	138.7
41-64 years	386,411	1	30	43	95	1,849	116.8	196.4
≥ 65 years	79,040	1	30	60	120	1,862	138.8	235.3
<b>Tezacaftor and ivacaftor</b>	<b>14,644</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>1,820</b>	<b>82.6</b>	<b>136.0</b>
0-17 years	4,846	1	28	28	84	1,820	86.5	135.9
18-24 years	2,903	1	28	28	56	1,724	74.0	128.6
25-40 years	5,212	1	28	28	56	1,652	75.2	121.4
41-64 years	1,509	3	28	28	84	1,770	105.3	180.1
≥ 65 years	174	28	28	56	168	1,064	141.1	177.7
<b>Apalutamide</b>	<b>36,365</b>	<b>1</b>	<b>30</b>	<b>40</b>	<b>90</b>	<b>1,752</b>	<b>96.2</b>	<b>138.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	24	30	60	60	120	55.5	30.6
41-64 years	*****	1	30	30	90	1,262	92.5	135.8
≥ 65 years	32,737	1	30	41	90	1,752	96.6	138.5
<b>Ibalizumab-uiyk</b>	<b>3,797</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,655</b>	<b>24.0</b>	<b>92.1</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	406	12.8	56.1
25-40 years	512	1	1	1	1	420	19.1	53.6
41-64 years	2,655	1	1	1	1	1,655	25.6	100.5
≥ 65 years	532	1	1	1	1	1,056	22.6	82.2
<b>Tildrakizumab</b>	<b>36,842</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,146</b>	<b>7.2</b>	<b>34.6</b>
0-17 years	11	1	28	84	84	252	71.0	70.3
18-24 years	189	1	1	1	30	700	33.5	73.6
25-40 years	1,133	1	1	1	30	534	31.6	61.2
41-64 years	3,591	1	1	1	28	952	28.9	66.0
≥ 65 years	31,918	1	1	1	1	1,146	3.7	25.2
<b>Burosumab-twza</b>	<b>12,760</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,484</b>	<b>18.6</b>	<b>85.7</b>
0-17 years	7,030	1	1	1	1	1,376	21.3	79.2
18-24 years	599	1	1	1	1	1,315	20.0	105.9
25-40 years	1,720	1	1	1	1	1,435	14.5	89.2
41-64 years	2,169	1	1	1	1	1,484	16.1	92.7
≥ 65 years	1,242	1	1	1	1	1,334	13.3	91.7
<b>Fostamatinib</b>	<b>2,950</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,613</b>	<b>80.4</b>	<b>118.2</b>
0-17 years	*****	30	30	51	109	189	74.9	58.7
18-24 years	*****	5	30	30	60	690	60.5	80.4
25-40 years	388	1	30	30	60	861	66.7	90.6
41-64 years	1,050	1	30	30	90	1,504	82.1	130.3

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,397	1	30	38	90	1,613	84.4	117.9
<b>Fosnetupitant and palonosetron</b>	<b>132,350</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>270</b>	<b>1.3</b>	<b>4.4</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	2,925	1	1	1	1	105	1.2	3.2
41-64 years	27,438	1	1	1	1	168	1.2	3.3
≥ 65 years	101,596	1	1	1	1	270	1.3	4.7
<b>Lofexidine hydrochloride</b>	<b>7,235</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>644</b>	<b>12.6</b>	<b>14.5</b>
0-17 years	*****	8	11	14	14	70	18.7	19.4
18-24 years	*****	1	8	9	12	48	10.7	5.2
25-40 years	2,529	1	8	9	14	411	12.4	12.3
41-64 years	3,505	1	8	9	14	644	12.7	15.4
≥ 65 years	824	1	8	9	14	348	13.8	18.7
<b>Erenumab-aooe</b>	<b>577,165</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,688</b>	<b>81.8</b>	<b>123.4</b>
0-17 years	2,893	1	28	30	88	1,228	80.7	116.2
18-24 years	28,183	1	29	30	82	1,474	71.5	101.6
25-40 years	143,121	1	30	30	84	1,619	76.8	113.6
41-64 years	306,014	1	30	30	90	1,688	83.5	127.1
≥ 65 years	96,954	1	30	30	90	1,630	86.9	130.8
<b>Sodium zirconium cyclosilicate</b>	<b>175,266</b>	<b>1</b>	<b>22</b>	<b>30</b>	<b>60</b>	<b>1,415</b>	<b>48.9</b>	<b>68.3</b>
0-17 years	46	9	30	30	90	390	68.6	73.0
18-24 years	540	1	27	30	56	480	44.9	48.6
25-40 years	8,027	1	28	30	56	998	48.6	65.7
41-64 years	52,503	1	28	30	60	1,415	50.4	70.4
≥ 65 years	114,150	1	20	30	60	1,396	48.3	67.6
<b>Avatrombopag</b>	<b>4,942</b>	<b>1</b>	<b>5</b>	<b>30</b>	<b>34</b>	<b>1,115</b>	<b>45.7</b>	<b>85.7</b>
0-17 years	15	16	30	30	56	172	48.9	42.7
18-24 years	164	5	30	30	60	641	50.4	71.3
25-40 years	382	2	14	30	60	600	50.2	73.9
41-64 years	2,074	1	5	15	30	1,115	38.9	82.3
≥ 65 years	2,307	1	5	30	60	1,077	50.7	91.1
<b>Pegvaliase-pqpz</b>	<b>2,920</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,503</b>	<b>73.6</b>	<b>144.3</b>
0-17 years	*****	3	30	30	86	1,214	98.1	184.2
18-24 years	784	1	28	30	60	1,487	63.3	117.9
25-40 years	1,196	1	30	30	60	1,488	76.2	157.7
41-64 years	774	1	30	30	60	1,503	74.9	136.9
≥ 65 years	*****	5	30	70	125	300	106.0	117.5
<b>Baricitinib</b>	<b>59,846</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,476</b>	<b>16.4</b>	<b>58.7</b>
0-17 years	167	1	30	30	90	840	95.7	156.0
18-24 years	456	1	1	30	42	420	37.1	45.3
25-40 years	2,935	1	1	1	30	1,476	29.3	64.0
41-64 years	18,265	1	1	1	30	1,447	29.6	77.3
≥ 65 years	38,023	1	1	1	1	1,460	8.5	43.8
<b>Moxidectin</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>61,573</b>	<b>1</b>	<b>30</b>	<b>45</b>	<b>120</b>	<b>1,627</b>	<b>128.8</b>	<b>203.7</b>
0-17 years	29,613	1	30	50	128	1,611	128.3	186.7
18-24 years	10,116	1	30	40	120	1,627	119.2	186.8
25-40 years	14,066	1	30	42	120	1,526	132.7	226.5
41-64 years	7,290	1	30	44	120	1,495	138.2	243.5
≥ 65 years	488	2	30	30	90	1,399	106.6	174.2
<b>Plazomicin</b>	<b>674</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>554</b>	<b>3.2</b>	<b>21.4</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	33	1	1	1	1	554	18.1	96.2
41-64 years	76	1	1	3	7	13	3.7	2.7
≥ 65 years	565	1	1	1	3	20	2.2	2.3
<b>Binimetinib</b>	<b>8,279</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,626</b>	<b>67.2</b>	<b>91.5</b>
0-17 years	41	11	30	30	144	640	105.8	138.9
18-24 years	73	10	30	30	90	771	88.4	127.1
25-40 years	695	1	30	30	60	960	64.0	85.4
41-64 years	2,807	1	30	30	60	1,599	66.7	93.5
≥ 65 years	4,663	1	30	30	60	1,626	67.3	89.8
<b>Encorafenib</b>	<b>9,319</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,626</b>	<b>67.9</b>	<b>91.2</b>
0-17 years	*****	12	30	30	90	120	54.9	43.5
18-24 years	*****	22	30	30	90	771	91.8	136.6
25-40 years	731	1	30	30	60	960	66.4	86.8
41-64 years	3,060	1	30	30	60	1,599	69.3	96.8
≥ 65 years	5,462	1	30	30	60	1,626	67.0	88.0
<b>Tecovirimat</b>	<b>29</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>18.2</b>	<b>18.5</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	12	14	63	112	37.3	49.9
25-40 years	*****	14	14	14	14	30	15.6	4.7
41-64 years	*****	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>3,355</b>	<b>1</b>	<b>30</b>	<b>35</b>	<b>90</b>	<b>1,139</b>	<b>78.3</b>	<b>99.8</b>
0-17 years	*****	28	32	45	70	86	50.8	25.9
18-24 years	*****	2	30	30	60	750	69.9	132.0
25-40 years	176	3	30	36	90	961	82.6	108.6
41-64 years	670	4	30	30	90	1,087	78.3	100.9
≥ 65 years	2,474	1	30	40	90	1,139	78.2	98.4
<b>Tafenoquine</b>	<b>366</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>28</b>	<b>531</b>	<b>25.1</b>	<b>53.5</b>
0-17 years	21	1	1	2	21	282	26.9	62.8
18-24 years	18	1	1	6	38	180	30.5	47.1
25-40 years	109	1	1	2	28	154	16.0	27.0
41-64 years	186	1	1	14	30	531	30.3	66.0
≥ 65 years	32	1	1	3	28	112	21.4	29.2
<b>Elagolix sodium</b>	<b>60,829</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,360</b>	<b>61.2</b>	<b>79.5</b>
0-17 years	*****	1	28	28	56	1,094	66.2	103.8
18-24 years	10,823	1	28	28	56	1,258	60.0	79.2
25-40 years	36,573	1	28	28	56	1,360	60.4	77.8
41-64 years	12,415	1	28	28	70	1,265	63.9	82.0



**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	28	42	112	350	729	220.6	246.9
<b>Fish oil triglycerides</b>	<b>2,843</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>716</b>	<b>4.1</b>	<b>25.2</b>
0-17 years	2,528	1	1	1	1	716	4.1	23.4
18-24 years	187	1	1	1	1	643	4.9	47.1
25-40 years	51	1	1	1	1	14	1.3	1.8
41-64 years	53	1	1	1	1	14	1.4	2.0
≥ 65 years	24	1	1	1	6	96	6.5	19.3
<b>Lusutrombopag</b>	<b>528</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>57</b>	<b>8.4</b>	<b>5.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	7	7	7	7	7.0	0.0
25-40 years	*****	7	7	7	7	30	8.4	5.2
41-64 years	393	3	7	7	7	57	8.6	5.8
≥ 65 years	106	7	7	7	7	14	7.5	1.8

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Lutetium Lu 177 dotatate</i>	4,522	4,522	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	175,440	72,301	41.2%	41,877	23.9%	39,241	22.4%	12,929	7.4%	9,092	5.2%
<i>Tezacaftor and ivacaftor</i>	3,794	1,737	45.8%	851	22.4%	815	21.5%	271	7.1%	120	3.2%
<i>Apalutamide</i>	11,580	4,968	42.9%	2,912	25.1%	2,863	24.7%	627	5.4%	210	1.8%
<i>Ibalizumab-uiyk</i>	307	228	74.3%	42	13.7%	*****	*****	*****	*****	*****	*****
<i>Tildrakizumab</i>	7,837	7,394	94.3%	250	3.2%	171	2.2%	*****	*****	*****	*****
<i>Burosumab-twza</i>	1,038	799	77.0%	105	10.1%	73	7.0%	30	2.9%	31	3.0%
<i>Fostamatinib</i>	1,120	558	49.8%	324	28.9%	194	17.3%	32	2.9%	12	1.1%
<i>Fosnetupitant and palonosetron</i>	24,863	24,726	99.4%	117	0.5%	20	0.1%	0	0.0%	0	0.0%
<i>Lofexidine hydrochloride</i>	5,773	5,680	98.4%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Erenumab-aooe</i>	158,717	83,119	52.4%	40,102	25.3%	28,263	17.8%	5,024	3.2%	2,209	1.4%
<i>Sodium zirconium cyclosilicate</i>	78,091	54,883	70.3%	16,719	21.4%	5,752	7.4%	613	0.8%	124	0.2%
<i>Avatrombopag</i>	2,406	1,896	78.8%	288	12.0%	180	7.5%	*****	*****	*****	*****
<i>Pegvaliase-pqyz</i>	528	249	47.2%	162	30.7%	78	14.8%	16	3.0%	23	4.4%
<i>Baricitinib</i>	51,437	49,358	96.0%	1,093	2.1%	808	1.6%	144	0.3%	34	0.1%
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.	.	.
<i>Cannabidiol</i>	20,980	7,655	36.5%	4,833	23.0%	5,020	23.9%	2,596	12.4%	876	4.2%
<i>Plazomicin</i>	249	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
<i>Binimetinib</i>	2,872	1,622	56.5%	745	25.9%	435	15.1%	54	1.9%	16	0.6%
<i>Encorafenib</i>	3,371	1,910	56.7%	850	25.2%	540	16.0%	53	1.6%	18	0.5%
<i>Tecovirimat</i>	27	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<i>Ivosidenib</i>	1,476	731	49.5%	433	29.3%	277	18.8%	*****	*****	*****	*****
<i>Tafenoquine</i>	197	153	77.7%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Elagolix sodium</i>	25,153	14,859	59.1%	6,190	24.6%	3,615	14.4%	411	1.6%	78	0.3%
<i>Fish oil triglycerides</i>	141	128	90.8%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Lusutrombopag</i>	390	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	4,522	1	1	1	1	3	1.0	0.1
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	175,440	1	30	60	178	1,898	168.3	267.7
<i>Tezacaftor and ivacaftor</i>	3,794	3	28	56	140	1,820	139.6	222.3
<i>Apalutamide</i>	11,580	1	30	60	150	1,752	123.7	176.7
<i>Ibalizumab-uiyk</i>	307	1	1	14	42	972	50.4	120.8
<i>Tildrakizumab</i>	7,837	1	1	1	1	1,146	10.2	41.7
<i>Burosumab-twza</i>	1,038	1	1	1	28	1,484	69.7	192.9
<i>Fostamatinib</i>	1,120	1	30	32	90	1,613	89.3	135.1
<i>Fosnetupitant and palonosetron</i>	24,863	1	1	1	1	226	1.5	5.9
<i>Lofexidine hydrochloride</i>	5,773	1	8	9	14	411	12.1	10.0
<i>Erenumab-aooe</i>	158,717	1	30	30	90	1,687	94.9	151.9
<i>Sodium zirconium cyclosilicate</i>	78,091	1	14	30	56	1,396	47.0	72.6
<i>Avatrombopag</i>	2,406	1	5	7	30	1,040	41.6	92.1
<i>Pegvaliase-pqpz</i>	528	3	28	35	86	1,503	124.9	250.1
<i>Baricitinib</i>	51,437	1	1	1	1	1,460	8.5	46.0
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	20,980	1	30	60	211	1,627	185.9	261.3
<i>Plazomicin</i>	249	1	1	3	5	554	5.8	35.0
<i>Binimetinib</i>	2,872	1	30	30	73	1,626	74.1	106.0
<i>Encorafenib</i>	3,371	1	30	30	76	1,626	73.5	104.9
<i>Tecovirimat</i>	27	9	14	14	14	112	18.6	19.1
<i>Ivosidenib</i>	1,476	1	30	33	90	1,050	78.4	101.7
<i>Tafenoquine</i>	197	1	1	14	30	528	30.1	57.6
<i>Elagolix sodium</i>	25,153	1	28	28	84	1,360	68.8	94.0
<i>Fish oil triglycerides</i>	141	1	1	1	7	643	13.1	56.4
<i>Lusutrombopag</i>	390	3	7	7	7	57	8.1	5.2

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>4,522</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	2,218	2,218	49.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,304	2,304	51.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>72,301</b>	<b>100.0%</b>	<b>41,877</b>	<b>100.0%</b>	<b>39,241</b>	<b>100.0%</b>	<b>12,929</b>	<b>100.0%</b>	<b>9,092</b>	<b>100.0%</b>
Female	45,683	19,928	27.6%	10,925	26.1%	9,690	24.7%	3,243	25.1%	1,897	20.9%
Male	129,757	52,373	72.4%	30,952	73.9%	29,551	75.3%	9,686	74.9%	7,195	79.1%
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>1,737</b>	<b>100.0%</b>	<b>851</b>	<b>100.0%</b>	<b>815</b>	<b>100.0%</b>	<b>271</b>	<b>100.0%</b>	<b>120</b>	<b>100.0%</b>
Female	1,889	888	51.1%	421	49.5%	392	48.1%	131	48.3%	57	47.5%
Male	1,905	849	48.9%	430	50.5%	423	51.9%	140	51.7%	63	52.5%
<b>Apalutamide</b>	<b>11,580</b>	<b>4,968</b>	<b>100.0%</b>	<b>2,912</b>	<b>100.0%</b>	<b>2,863</b>	<b>100.0%</b>	<b>627</b>	<b>100.0%</b>	<b>210</b>	<b>100.0%</b>
Female	****	0	0.0%	0	0.0%	****	****	0	0.0%	0	0.0%
Male	****	4,968	100.0%	2,912	100.0%	****	****	627	100.0%	210	100.0%
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>228</b>	<b>100.0%</b>	<b>42</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	72	56	24.6%	****	****	****	****	0	0.0%	0	0.0%
Male	235	172	75.4%	****	****	****	****	****	****	****	****
<b>Tildrakizumab</b>	<b>7,837</b>	<b>7,394</b>	<b>100.0%</b>	<b>250</b>	<b>100.0%</b>	<b>171</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	4,152	3,916	53.0%	135	54.0%	****	****	****	****	0	0.0%
Male	3,685	3,478	47.0%	115	46.0%	****	****	****	****	****	100.0%
<b>Burosumab-twza</b>	<b>1,038</b>	<b>799</b>	<b>100.0%</b>	<b>105</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>31</b>	<b>100.0%</b>
Female	673	504	63.1%	75	71.4%	53	72.6%	****	****	****	****
Male	365	295	36.9%	30	28.6%	20	27.4%	****	****	****	****
<b>Fostamatinib</b>	<b>1,120</b>	<b>558</b>	<b>100.0%</b>	<b>324</b>	<b>100.0%</b>	<b>194</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
Female	621	320	57.3%	175	54.0%	104	53.6%	****	****	****	****
Male	499	238	42.7%	149	46.0%	90	46.4%	****	****	****	****
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>24,726</b>	<b>100.0%</b>	<b>117</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	14,012	13,932	56.3%	****	****	****	****	0	NaN	0	NaN
Male	10,851	10,794	43.7%	****	****	****	****	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>5,680</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	2,998	2,952	52.0%	****	****	****	****	****	100.0%	0	NaN
Male	2,775	2,728	48.0%	****	****	****	****	0	0.0%	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>83,119</b>	<b>100.0%</b>	<b>40,102</b>	<b>100.0%</b>	<b>28,263</b>	<b>100.0%</b>	<b>5,024</b>	<b>100.0%</b>	<b>2,209</b>	<b>100.0%</b>
Female	135,234	70,639	85.0%	34,233	85.4%	24,184	85.6%	4,288	85.4%	1,890	85.6%
Male	23,483	12,480	15.0%	5,869	14.6%	4,079	14.4%	736	14.6%	319	14.4%
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>54,883</b>	<b>100.0%</b>	<b>16,719</b>	<b>100.0%</b>	<b>5,752</b>	<b>100.0%</b>	<b>613</b>	<b>100.0%</b>	<b>124</b>	<b>100.0%</b>
Female	33,612	24,035	43.8%	7,046	42.1%	2,263	39.3%	221	36.1%	47	37.9%
Male	44,479	30,848	56.2%	9,673	57.9%	3,489	60.7%	392	63.9%	77	62.1%
<b>Avatrombopag</b>	<b>2,406</b>	<b>1,896</b>	<b>100.0%</b>	<b>288</b>	<b>100.0%</b>	<b>180</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	1,174	912	48.1%	146	50.7%	92	51.1%	*****	*****	*****	*****
Male	1,232	984	51.9%	142	49.3%	88	48.9%	*****	*****	*****	*****
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>249</b>	<b>100.0%</b>	<b>162</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>
Female	276	123	49.4%	93	57.4%	43	55.1%	*****	*****	*****	*****
Male	252	126	50.6%	69	42.6%	35	44.9%	*****	*****	*****	*****
<b>Baricitinib</b>	<b>51,437</b>	<b>49,358</b>	<b>100.0%</b>	<b>1,093</b>	<b>100.0%</b>	<b>808</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>
Female	24,881	23,181	47.0%	889	81.3%	668	82.7%	*****	*****	*****	*****
Male	26,556	26,177	53.0%	204	18.7%	140	17.3%	*****	*****	*****	*****
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>7,655</b>	<b>100.0%</b>	<b>4,833</b>	<b>100.0%</b>	<b>5,020</b>	<b>100.0%</b>	<b>2,596</b>	<b>100.0%</b>	<b>876</b>	<b>100.0%</b>
Female	9,510	3,429	44.8%	2,188	45.3%	2,299	45.8%	1,190	45.8%	404	46.1%
Male	11,470	4,226	55.2%	2,645	54.7%	2,721	54.2%	1,406	54.2%	472	53.9%
<b>Plazomicin</b>	<b>249</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	164	*****	*****	0	NaN	0	NaN	0	0.0%	0	NaN
Male	85	*****	*****	0	NaN	0	NaN	*****	100.0%	0	NaN
<b>Binimetinib</b>	<b>2,872</b>	<b>1,622</b>	<b>100.0%</b>	<b>745</b>	<b>100.0%</b>	<b>435</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>
Female	1,259	718	44.3%	333	44.7%	177	40.7%	*****	*****	*****	*****
Male	1,613	904	55.7%	412	55.3%	258	59.3%	*****	*****	*****	*****
<b>Encorafenib</b>	<b>3,371</b>	<b>1,910</b>	<b>100.0%</b>	<b>850</b>	<b>100.0%</b>	<b>540</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>
Female	1,556	906	47.4%	392	46.1%	229	42.4%	*****	*****	*****	*****
Male	1,815	1,004	52.6%	458	53.9%	311	57.6%	*****	*****	*****	*****
<b>Tecovirimat</b>	<b>27</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	****	****	****	0	NaN	0	0.0%	0	NaN	0	NaN
Male	****	****	****	0	NaN	****	100.0%	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>1,476</b>	<b>731</b>	<b>100.0%</b>	<b>433</b>	<b>100.0%</b>	<b>277</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>
Female	750	387	52.9%	214	49.4%	133	48.0%	****	****	****	****
Male	726	344	47.1%	219	50.6%	144	52.0%	****	****	****	****
<b>Tafenoquine</b>	<b>197</b>	<b>153</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	124	95	62.1%	****	****	****	****	****	100.0%	0	NaN
Male	73	58	37.9%	****	****	****	****	0	0.0%	0	NaN
<b>Elagolix sodium</b>	<b>25,153</b>	<b>14,859</b>	<b>100.0%</b>	<b>6,190</b>	<b>100.0%</b>	<b>3,615</b>	<b>100.0%</b>	<b>411</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>
Female	25,123	****	****	****	****	****	****	****	****	****	****
Male	30	****	****	****	****	****	****	****	****	0	0.0%
<b>Fish oil triglycerides</b>	<b>141</b>	<b>128</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	81	****	****	****	****	0	0.0%	****	100.0%	0	NaN
Male	60	****	****	****	****	****	100.0%	0	0.0%	0	NaN
<b>Lusutrombopag</b>	<b>390</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	175	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	215	****	****	****	****	0	NaN	0	NaN	0	NaN

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.1</b>
Female	2,218	1	1	1	1	2	1.0	0.0
Male	2,304	1	1	1	1	3	1.0	0.1
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>178</b>	<b>1,898</b>	<b>168.3</b>	<b>267.7</b>
Female	45,683	1	30	60	150	1,836	151.6	240.1
Male	129,757	1	30	60	180	1,898	174.2	276.5
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>3</b>	<b>28</b>	<b>56</b>	<b>140</b>	<b>1,820</b>	<b>139.6</b>	<b>222.3</b>
Female	1,889	3	28	56	140	1,724	136.0	220.5
Male	1,905	3	28	56	140	1,820	143.2	224.0
<b>Apalutamide</b>	<b>11,580</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,752</b>	<b>123.7</b>	<b>176.7</b>
Female	*****	120	120	120	120	120	120.0	NaN
Male	*****	1	30	60	150	1,752	123.7	176.7
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>42</b>	<b>972</b>	<b>50.4</b>	<b>120.8</b>
Female	72	1	1	1	28	336	32.1	65.5
Male	235	1	1	14	42	972	56.1	132.8
<b>Tildrakizumab</b>	<b>7,837</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,146</b>	<b>10.2</b>	<b>41.7</b>
Female	4,152	1	1	1	1	700	10.1	41.1
Male	3,685	1	1	1	1	1,146	10.3	42.4
<b>Burosumab-twza</b>	<b>1,038</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1,484</b>	<b>69.7</b>	<b>192.9</b>
Female	673	1	1	1	36	1,484	75.0	202.7
Male	365	1	1	1	28	1,367	60.0	173.2
<b>Fostamatinib</b>	<b>1,120</b>	<b>1</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>1,613</b>	<b>89.3</b>	<b>135.1</b>
Female	621	1	30	30	90	1,470	86.5	129.9
Male	499	2	30	48	90	1,613	92.6	141.3
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>226</b>	<b>1.5</b>	<b>5.9</b>
Female	14,012	1	1	1	1	226	1.6	6.2
Male	10,851	1	1	1	1	147	1.5	5.6
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>411</b>	<b>12.1</b>	<b>10.0</b>
Female	2,998	1	8	9	14	411	12.1	10.2
Male	2,775	1	8	9	14	240	12.0	9.8
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,687</b>	<b>94.9</b>	<b>151.9</b>
Female	135,234	1	30	30	90	1,687	95.1	152.3
Male	23,483	1	30	30	90	1,608	93.7	149.5
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>56</b>	<b>1,396</b>	<b>47.0</b>	<b>72.6</b>
Female	33,612	1	11	30	50	1,336	44.5	68.8
Male	44,479	1	15	30	60	1,396	49.0	75.4
<b>Avatrombopag</b>	<b>2,406</b>	<b>1</b>	<b>5</b>	<b>7</b>	<b>30</b>	<b>1,040</b>	<b>41.6</b>	<b>92.1</b>
Female	1,174	1	5	15	30	1,040	45.5	102.1
Male	1,232	1	5	5	30	896	37.9	81.4
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>3</b>	<b>28</b>	<b>35</b>	<b>86</b>	<b>1,503</b>	<b>124.9</b>	<b>250.1</b>
Female	276	4	28	35	87	1,487	116.4	232.1
Male	252	3	28	33	86	1,503	134.3	268.6
<b>Baricitinib</b>	<b>51,437</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,460</b>	<b>8.5</b>	<b>46.0</b>
Female	24,881	1	1	1	1	1,460	13.6	58.9
Male	26,556	1	1	1	1	1,350	3.7	28.2
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>211</b>	<b>1,627</b>	<b>185.9</b>	<b>261.3</b>
Female	9,510	1	30	60	221	1,611	188.3	263.1
Male	11,470	1	30	60	210	1,627	184.0	259.7
<b>Plazomicin</b>	<b>249</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>554</b>	<b>5.8</b>	<b>35.0</b>
Female	164	1	1	3	5	20	3.6	2.8
Male	85	1	1	3	5	554	10.1	59.8
<b>Binimetinib</b>	<b>2,872</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>73</b>	<b>1,626</b>	<b>74.1</b>	<b>106.0</b>
Female	1,259	2	30	30	60	997	70.7	92.7
Male	1,613	1	30	30	83	1,626	76.8	115.4
<b>Ecorafenib</b>	<b>3,371</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>76</b>	<b>1,626</b>	<b>73.5</b>	<b>104.9</b>
Female	1,556	2	30	30	60	997	68.2	88.2
Male	1,815	1	30	30	90	1,626	78.1	117.1
<b>Tecovirimat</b>	<b>27</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>18.6</b>	<b>19.1</b>
Female	*****	14	14	14	14	14	14.0	NaN
Male	*****	9	14	14	14	112	18.7	19.5
<b>Ivosidenib</b>	<b>1,476</b>	<b>1</b>	<b>30</b>	<b>33</b>	<b>90</b>	<b>1,050</b>	<b>78.4</b>	<b>101.7</b>
Female	750	1	30	30	90	842	74.4	91.6
Male	726	4	30	44	90	1,050	82.6	111.1
<b>Tafenoquine</b>	<b>197</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>528</b>	<b>30.1</b>	<b>57.6</b>
Female	124	1	1	15	30	528	30.7	59.4
Male	73	1	1	7	28	330	29.1	54.9
<b>Elagolix sodium</b>	<b>25,153</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>1,360</b>	<b>68.8</b>	<b>94.0</b>
Female	25,123	1	28	28	84	1,360	68.8	94.0
Male	30	4	28	28	56	476	57.4	86.6
<b>Fish oil triglycerides</b>	<b>141</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>7</b>	<b>643</b>	<b>13.1</b>	<b>56.4</b>
Female	81	1	1	1	6	643	15.3	72.4
Male	60	1	1	1	7	118	10.2	21.1
<b>Lusutrombopag</b>	<b>390</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>57</b>	<b>8.1</b>	<b>5.2</b>
Female	175	7	7	7	7	57	8.1	5.3
Male	215	3	7	7	7	56	8.2	5.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>4,522</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,121	1,121	24.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,294	3,294	72.8%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>72,301</b>	<b>100.0%</b>	<b>41,877</b>	<b>100.0%</b>	<b>39,241</b>	<b>100.0%</b>	<b>12,929</b>	<b>100.0%</b>	<b>9,092</b>	<b>100.0%</b>
0-17 years	966	374	0.5%	224	0.5%	250	0.6%	95	0.7%	23	0.3%
18-24 years	8,703	4,034	5.6%	2,221	5.3%	1,844	4.7%	459	3.6%	145	1.6%
25-40 years	52,127	24,134	33.4%	13,150	31.4%	10,712	27.3%	2,809	21.7%	1,322	14.5%
41-64 years	94,953	36,979	51.1%	22,167	52.9%	21,925	55.9%	7,967	61.6%	5,915	65.1%
≥ 65 years	18,691	6,780	9.4%	4,115	9.8%	4,510	11.5%	1,599	12.4%	1,687	18.6%
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>1,737</b>	<b>100.0%</b>	<b>851</b>	<b>100.0%</b>	<b>815</b>	<b>100.0%</b>	<b>271</b>	<b>100.0%</b>	<b>120</b>	<b>100.0%</b>
0-17 years	1,360	590	34.0%	298	35.0%	322	39.5%	113	41.7%	37	30.8%
18-24 years	787	389	22.4%	187	22.0%	146	17.9%	42	15.5%	23	19.2%
25-40 years	1,229	586	33.7%	276	32.4%	260	31.9%	76	28.0%	31	25.8%
41-64 years	365	155	8.9%	*****	*****	71	8.7%	*****	*****	*****	*****
≥ 65 years	53	17	1.0%	*****	*****	16	2.0%	*****	*****	*****	*****
<b>Apalutamide</b>	<b>11,580</b>	<b>4,968</b>	<b>100.0%</b>	<b>2,912</b>	<b>100.0%</b>	<b>2,863</b>	<b>100.0%</b>	<b>627</b>	<b>100.0%</b>	<b>210</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	280	9.6%	280	9.8%	69	11.0%	*****	*****
≥ 65 years	10,415	4,453	89.6%	2,632	90.4%	2,583	90.2%	558	89.0%	*****	*****
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>228</b>	<b>100.0%</b>	<b>42</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	214	158	*****	30	71.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	39	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<b>Tildrakizumab</b>	<b>7,837</b>	<b>7,394</b>	<b>100.0%</b>	<b>250</b>	<b>100.0%</b>	<b>171</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	343	268	3.6%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,038	844	11.4%	122	48.8%	*****	*****	*****	*****	0	0.0%
≥ 65 years	6,395	6,238	84.4%	75	30.0%	*****	*****	*****	*****	*****	*****
<b>Burosumab-twza</b>	<b>1,038</b>	<b>799</b>	<b>100.0%</b>	<b>105</b>	<b>100.0%</b>	<b>73</b>	<b>100.0%</b>	<b>30</b>	<b>100.0%</b>	<b>31</b>	<b>100.0%</b>
0-17 years	582	436	54.6%	69	65.7%	52	71.2%	12	40.0%	13	41.9%
18-24 years	75	59	7.4%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	137	113	14.1%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	161	123	15.4%	14	13.3%	*****	*****	*****	*****	*****	*****
≥ 65 years	83	68	8.5%	*****	*****	*****	*****	*****	*****	*****	*****
<b>Fostamatinib</b>	<b>1,120</b>	<b>558</b>	<b>100.0%</b>	<b>324</b>	<b>100.0%</b>	<b>194</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	129	74	13.3%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	374	183	32.8%	104	32.1%	69	35.6%	*****	*****	*****	*****
≥ 65 years	579	280	50.2%	181	55.9%	97	50.0%	*****	*****	*****	*****
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>24,726</b>	<b>100.0%</b>	<b>117</b>	<b>100.0%</b>	<b>20</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	659	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	5,418	5,401	21.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	18,709	18,591	75.2%	*****	86.3%	*****	*****	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>5,680</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	2,011	1,975	34.8%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	2,821	2,771	48.8%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	637	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>83,119</b>	<b>100.0%</b>	<b>40,102</b>	<b>100.0%</b>	<b>28,263</b>	<b>100.0%</b>	<b>5,024</b>	<b>100.0%</b>	<b>2,209</b>	<b>100.0%</b>
0-17 years	900	451	0.5%	239	0.6%	167	0.6%	29	0.6%	14	0.6%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	8,287	4,470	5.4%	2,106	5.3%	1,402	5.0%	247	4.9%	62	2.8%
25-40 years	40,874	21,488	25.9%	10,322	25.7%	7,414	26.2%	1,211	24.1%	439	19.9%
41-64 years	81,933	42,550	51.2%	20,520	51.2%	14,775	52.3%	2,783	55.4%	1,305	59.1%
≥ 65 years	26,723	14,160	17.0%	6,915	17.2%	4,505	15.9%	754	15.0%	389	17.6%
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>54,883</b>	<b>100.0%</b>	<b>16,719</b>	<b>100.0%</b>	<b>5,752</b>	<b>100.0%</b>	<b>613</b>	<b>100.0%</b>	<b>124</b>	<b>100.0%</b>
0-17 years	25	11	0.0%	****	0.0%	****	****	****	****	0	0.0%
18-24 years	284	199	0.4%	****	0.4%	****	****	****	****	0	0.0%
25-40 years	3,800	2,712	4.9%	815	4.9%	233	4.1%	****	****	****	****
41-64 years	23,205	15,941	29.0%	5,150	30.8%	1,851	32.2%	****	****	****	****
≥ 65 years	50,777	36,020	65.6%	10,686	63.9%	3,639	63.3%	356	58.1%	76	61.3%
<b>Avatrombopag</b>	<b>2,406</b>	<b>1,896</b>	<b>100.0%</b>	<b>288</b>	<b>100.0%</b>	<b>180</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
0-17 years	****	****	****	0	0.0%	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	13	4.5%	****	****	****	****	0	0.0%
25-40 years	180	136	7.2%	24	8.3%	****	****	****	****	0	0.0%
41-64 years	1,059	876	46.2%	98	34.0%	68	37.8%	****	****	****	****
≥ 65 years	1,121	857	45.2%	153	53.1%	89	49.4%	****	****	****	****
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>249</b>	<b>100.0%</b>	<b>162</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>	<b>23</b>	<b>100.0%</b>
0-17 years	****	16	****	****	****	****	****	****	****	****	****
18-24 years	139	73	29.3%	****	****	****	****	****	****	****	****
25-40 years	230	114	45.8%	64	39.5%	****	****	****	****	12	52.2%
41-64 years	120	46	18.5%	50	30.9%	****	****	****	****	****	****
≥ 65 years	****	0	****	****	****	****	****	0	0.0%	0	0.0%
<b>Baricitinib</b>	<b>51,437</b>	<b>49,358</b>	<b>100.0%</b>	<b>1,093</b>	<b>100.0%</b>	<b>808</b>	<b>100.0%</b>	<b>144</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>
0-17 years	81	46	0.1%	****	****	15	1.9%	****	****	****	****
18-24 years	257	205	0.4%	31	2.8%	****	****	****	****	0	0.0%
25-40 years	2,083	1,843	3.7%	145	13.3%	****	****	****	****	0	0.0%
41-64 years	13,732	12,535	25.4%	615	56.3%	477	59.0%	84	****	21	****
≥ 65 years	35,284	34,729	70.4%	289	26.4%	208	25.7%	****	****	****	****
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>7,655</b>	<b>100.0%</b>	<b>4,833</b>	<b>100.0%</b>	<b>5,020</b>	<b>100.0%</b>	<b>2,596</b>	<b>100.0%</b>	<b>876</b>	<b>100.0%</b>
0-17 years	11,082	4,003	52.3%	2,506	51.9%	2,698	53.7%	1,592	61.3%	283	32.3%
18-24 years	3,471	1,346	17.6%	842	17.4%	809	16.1%	364	14.0%	110	12.6%
25-40 years	4,318	1,532	20.0%	1,014	21.0%	1,001	19.9%	474	18.3%	297	33.9%
41-64 years	1,950	699	9.1%	432	8.9%	480	9.6%	****	****	****	****
≥ 65 years	159	75	1.0%	39	0.8%	32	0.6%	****	****	****	****
<b>Plazomicin</b>	<b>249</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	0.0%	0	NaN
25-40 years	****	****	****	0	NaN	0	NaN	****	100.0%	0	NaN
41-64 years	****	****	****	0	NaN	0	NaN	0	0.0%	0	NaN
≥ 65 years	189	189	****	0	NaN	0	NaN	0	0.0%	0	NaN
<b>Binimetinib</b>	<b>2,872</b>	<b>1,622</b>	<b>100.0%</b>	<b>745</b>	<b>100.0%</b>	<b>435</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>
0-17 years	23	****	****	****	****	****	****	****	****	0	0.0%
18-24 years	32	****	****	****	****	****	****	0	0.0%	****	****
25-40 years	224	132	8.1%	****	****	33	7.6%	****	****	****	****
41-64 years	943	502	30.9%	261	35.0%	157	36.1%	****	****	****	****
≥ 65 years	1,650	962	59.3%	419	56.2%	230	52.9%	****	****	****	****
<b>Encorafenib</b>	<b>3,371</b>	<b>1,910</b>	<b>100.0%</b>	<b>850</b>	<b>100.0%</b>	<b>540</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>
0-17 years	****	****	****	0	0.0%	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	****	****	****	****
25-40 years	244	140	7.3%	****	****	****	****	****	****	****	****
41-64 years	1,109	578	30.3%	300	35.3%	207	38.3%	****	****	****	****
≥ 65 years	1,991	1,178	61.7%	486	57.2%	286	53.0%	****	****	****	****
<b>Tecovirimat</b>	<b>27</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN
18-24 years	****	****	****	0	NaN	****	100.0%	0	NaN	0	NaN
25-40 years	****	****	****	0	NaN	0	0.0%	0	NaN	0	NaN
41-64 years	****	****	****	0	NaN	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Number of Patients by First Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<b>Ivosidenib</b>	<b>1,476</b>	<b>731</b>	<b>100.0%</b>	<b>433</b>	<b>100.0%</b>	*****	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>	*****	<b>100.0%</b>
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	19	6.9%	*****	*****	*****	*****
41-64 years	313	150	20.5%	96	22.2%	54	19.5%	*****	*****	*****	*****
≥ 65 years	1,075	536	73.3%	316	73.0%	204	73.6%	*****	*****	*****	*****
<b>Tafenoquine</b>	<b>197</b>	<b>153</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	53	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	101	76	*****	*****	*****	*****	*****	*****	100.0%	0	NaN
≥ 65 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<b>Elagolix sodium</b>	<b>25,153</b>	<b>14,859</b>	<b>100.0%</b>	<b>6,190</b>	<b>100.0%</b>	<b>3,615</b>	<b>100.0%</b>	<b>411</b>	<b>100.0%</b>	<b>78</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	76	1.2%	*****	*****	*****	*****	*****	*****
18-24 years	4,359	2,618	17.6%	1,052	17.0%	602	16.7%	70	17.0%	17	21.8%
25-40 years	15,403	9,150	61.6%	3,789	61.2%	2,174	60.1%	245	59.6%	45	57.7%
41-64 years	5,053	2,892	19.5%	1,273	20.6%	788	21.8%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
<b>Fish oil triglycerides</b>	<b>141</b>	<b>128</b>	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	110	98	76.6%	*****	100.0%	*****	100.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	*****	100.0%	0	NaN
25-40 years	12	12	9.4%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
<b>Lusutrombopag</b>	<b>390</b>	*****	<b>100.0%</b>	*****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	282	*****	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	86	86	*****	0	0.0%	0	NaN	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>4,522</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.1</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	94	1	1	1	1	3	1.0	0.2
41-64 years	1,121	1	1	1	1	3	1.0	0.1
≥ 65 years	3,294	1	1	1	1	1	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>175,440</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>178</b>	<b>1,898</b>	<b>168.3</b>	<b>267.7</b>
0-17 years	966	3	30	60	180	1,447	152.4	200.9
18-24 years	8,703	1	30	60	120	1,770	115.0	168.7
25-40 years	52,127	1	30	60	120	1,898	124.6	198.4
41-64 years	94,953	1	30	60	180	1,849	186.1	286.6
≥ 65 years	18,691	1	30	80	240	1,862	226.0	344.5
<b>Tezacaftor and ivacaftor</b>	<b>3,794</b>	<b>3</b>	<b>28</b>	<b>56</b>	<b>140</b>	<b>1,820</b>	<b>139.6</b>	<b>222.3</b>
0-17 years	1,360	3	28	56	140	1,820	143.8	214.5
18-24 years	787	7	28	39	112	1,724	122.0	210.8
25-40 years	1,229	4	28	56	112	1,652	126.5	201.9
41-64 years	365	3	28	56	196	1,770	196.8	307.5
≥ 65 years	53	28	28	84	208	1,064	203.0	263.9
<b>Apalutamide</b>	<b>11,580</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>150</b>	<b>1,752</b>	<b>123.7</b>	<b>176.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	NaN
41-64 years	*****	1	30	60	130	1,262	122.2	170.5
≥ 65 years	10,415	1	30	60	150	1,752	123.8	177.4
<b>Ibalizumab-uiyk</b>	<b>307</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>42</b>	<b>972</b>	<b>50.4</b>	<b>120.8</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	154	336	82.3	138.5
25-40 years	47	1	1	14	42	316	30.0	54.1
41-64 years	214	1	1	14	42	972	52.8	132.0
≥ 65 years	*****	1	1	14	28	446	58.5	113.6
<b>Tildrakizumab</b>	<b>7,837</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,146</b>	<b>10.2</b>	<b>41.7</b>
0-17 years	*****	1	1	1	28	28	10.0	15.6
18-24 years	*****	1	1	28	38	700	52.3	110.4
25-40 years	343	1	1	1	28	532	35.2	67.0
41-64 years	1,038	1	1	1	28	618	30.3	67.6
≥ 65 years	6,395	1	1	1	1	1,146	5.2	30.1
<b>Burosumab-twza</b>	<b>1,038</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1,484</b>	<b>69.7</b>	<b>192.9</b>
0-17 years	582	1	1	14	35	1,376	61.9	158.5
18-24 years	75	1	1	1	28	987	74.4	181.7
25-40 years	137	1	1	1	28	1,435	71.6	225.2
41-64 years	161	1	1	1	28	1,484	78.0	215.2
≥ 65 years	83	1	1	1	28	1,334	101.4	294.5
<b>Fostamatinib</b>	<b>1,120</b>	<b>1</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>1,613</b>	<b>89.3</b>	<b>135.1</b>
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	5	30	30	90	690	82.5	117.5
25-40 years	129	1	30	30	90	720	80.8	108.3

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	374	2	30	43	90	1,470	97.0	153.6
≥ 65 years	579	5	30	44	90	1,613	86.7	128.8
<b>Fosnetupitant and palonosetron</b>	<b>24,863</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>226</b>	<b>1.5</b>	<b>5.9</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	659	1	1	1	1	86	1.4	4.4
41-64 years	5,418	1	1	1	1	168	1.4	4.8
≥ 65 years	18,709	1	1	1	1	226	1.6	6.3
<b>Lofexidine hydrochloride</b>	<b>5,773</b>	<b>1</b>	<b>8</b>	<b>9</b>	<b>14</b>	<b>411</b>	<b>12.1</b>	<b>10.0</b>
0-17 years	*****	8	11	12	14	14	11.7	2.3
18-24 years	*****	2	8	9	12	32	10.7	4.8
25-40 years	2,011	1	8	9	14	411	12.1	11.7
41-64 years	2,821	1	8	9	14	240	12.1	8.4
≥ 65 years	637	1	8	9	14	224	12.4	12.4
<b>Erenumab-aooe</b>	<b>158,717</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,687</b>	<b>94.9</b>	<b>151.9</b>
0-17 years	900	1	30	30	90	1,228	97.1	148.8
18-24 years	8,287	1	30	30	90	1,474	84.8	125.7
25-40 years	40,874	1	30	30	90	1,619	90.2	139.9
41-64 years	81,933	1	30	30	90	1,687	98.4	159.1
≥ 65 years	26,723	1	30	30	90	1,630	94.1	153.9
<b>Sodium zirconium cyclosilicate</b>	<b>78,091</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>56</b>	<b>1,396</b>	<b>47.0</b>	<b>72.6</b>
0-17 years	25	9	30	60	129	390	90.5	90.6
18-24 years	284	1	22	30	54	480	44.0	50.9
25-40 years	3,800	1	28	30	48	998	47.5	71.4
41-64 years	23,205	1	22	30	60	1,375	50.4	76.8
≥ 65 years	50,777	1	11	30	55	1,396	45.5	70.8
<b>Avatrombopag</b>	<b>2,406</b>	<b>1</b>	<b>5</b>	<b>7</b>	<b>30</b>	<b>1,040</b>	<b>41.6</b>	<b>92.1</b>
0-17 years	*****	30	30	30	75	120	52.5	45.0
18-24 years	*****	5	30	30	60	641	68.3	112.9
25-40 years	180	3	5	30	30	595	47.2	77.4
41-64 years	1,059	1	5	5	30	1,038	35.0	88.5
≥ 65 years	1,121	1	5	23	30	1,040	46.0	96.5
<b>Pegvaliase-pqpz</b>	<b>528</b>	<b>3</b>	<b>28</b>	<b>35</b>	<b>86</b>	<b>1,503</b>	<b>124.9</b>	<b>250.1</b>
0-17 years	*****	7	28	35	135	1,214	184.2	325.3
18-24 years	139	3	28	30	69	1,487	104.4	208.4
25-40 years	230	7	28	33	90	1,488	137.6	267.9
41-64 years	120	8	30	35	74	1,503	105.1	232.3
≥ 65 years	*****	70	70	185	300	300	185.0	162.6
<b>Baricitinib</b>	<b>51,437</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,460</b>	<b>8.5</b>	<b>46.0</b>
0-17 years	81	1	20	30	105	832	105.2	174.7
18-24 years	257	1	1	15	30	420	29.7	46.0
25-40 years	2,083	1	1	1	2	494	17.7	46.2
41-64 years	13,732	1	1	1	1	1,447	17.2	67.7
≥ 65 years	35,284	1	1	1	1	1,460	4.1	31.8
<b>Moxidectin</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>20,980</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>211</b>	<b>1,627</b>	<b>185.9</b>	<b>261.3</b>
0-17 years	11,082	1	30	60	228	1,611	179.3	233.7
18-24 years	3,471	1	30	60	180	1,627	164.9	240.2
25-40 years	4,318	1	30	60	238	1,526	207.3	304.3
41-64 years	1,950	1	30	60	231	1,495	219.0	330.7
≥ 65 years	159	7	30	34	120	1,399	123.7	205.5
<b>Plazomicin</b>	<b>249</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>554</b>	<b>5.8</b>	<b>35.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	7	554	94.2	225.3
41-64 years	*****	1	1	4	7	13	3.8	2.8
≥ 65 years	189	1	1	3	5	20	3.6	2.9
<b>Binimetinib</b>	<b>2,872</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>73</b>	<b>1,626</b>	<b>74.1</b>	<b>106.0</b>
0-17 years	23	11	28	60	213	640	142.4	167.8
18-24 years	32	10	30	38	107	771	105.2	149.7
25-40 years	224	2	30	30	60	960	70.2	98.2
41-64 years	943	1	30	30	85	1,599	76.8	108.6
≥ 65 years	1,650	1	30	30	60	1,626	71.6	103.2
<b>Encorafenib</b>	<b>3,371</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>76</b>	<b>1,626</b>	<b>73.5</b>	<b>104.9</b>
0-17 years	*****	12	21	75	120	120	70.5	57.6
18-24 years	*****	28	30	30	120	771	123.5	179.0
25-40 years	244	2	30	30	71	960	72.4	99.0
41-64 years	1,109	1	30	30	90	1,599	79.0	115.1
≥ 65 years	1,991	2	30	30	60	1,626	70.1	98.2
<b>Tecovirimat</b>	<b>27</b>	<b>9</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>112</b>	<b>18.6</b>	<b>19.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	9	12	14	63	112	37.3	49.9
25-40 years	*****	14	14	14	14	30	15.7	4.9
41-64 years	*****	14	14	14	14	14	14.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>1,476</b>	<b>1</b>	<b>30</b>	<b>33</b>	<b>90</b>	<b>1,050</b>	<b>78.4</b>	<b>101.7</b>
0-17 years	*****	35	35	61	86	86	60.5	36.1
18-24 years	*****	9	15	28	90	90	43.2	37.0
25-40 years	*****	15	30	30	120	961	91.2	130.9
41-64 years	313	4	30	43	90	750	81.3	103.4
≥ 65 years	1,075	1	30	31	90	1,050	76.9	99.0
<b>Tafenoquine</b>	<b>197</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>528</b>	<b>30.1</b>	<b>57.6</b>
0-17 years	*****	1	1	11	28	282	44.6	87.7
18-24 years	*****	1	3	26	70	180	42.8	53.5
25-40 years	53	1	1	7	28	90	17.2	22.4
41-64 years	101	1	1	14	30	528	34.9	69.7
≥ 65 years	21	1	1	9	54	112	25.6	33.5
<b>Elagolix sodium</b>	<b>25,153</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>84</b>	<b>1,360</b>	<b>68.8</b>	<b>94.0</b>
0-17 years	*****	2	28	28	84	784	74.9	106.9



**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	4,359	1	28	28	84	1,258	69.2	96.6
25-40 years	15,403	1	28	28	79	1,360	67.6	91.8
41-64 years	5,053	1	28	28	84	1,265	71.6	96.6
≥ 65 years	*****	28	28	280	729	729	345.7	355.1
<b>Fish oil triglycerides</b>	<b>141</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>7</b>	<b>643</b>	<b>13.1</b>	<b>56.4</b>
0-17 years	110	1	1	1	7	118	10.4	20.2
18-24 years	*****	1	1	1	2	643	108.2	262.0
25-40 years	12	1	1	1	1	14	2.1	3.8
41-64 years	*****	1	1	1	4	14	3.4	4.8
≥ 65 years	*****	1	1	1	1	6	2.0	2.2
<b>Lusutrombopag</b>	<b>390</b>	<b>3</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>57</b>	<b>8.1</b>	<b>5.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	7	7	7	7	7	7.0	0.0
25-40 years	*****	7	7	7	7	21	7.7	3.2
41-64 years	282	3	7	7	7	57	8.4	6.0
≥ 65 years	86	7	7	7	7	14	7.5	1.7

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<i>Lutetium Lu 177 dotatate</i>	9,399	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	524,155	54.0%	138,082	26.3%	82,536	15.7%	14,901	2.8%	5,726	1.1%	
<i>Tezacaftor and ivacaftor</i>	10,850	59.8%	2,764	25.5%	1,468	13.5%	120	1.1%	14	0.1%	
<i>Apalutamide</i>	24,785	52.4%	6,721	27.1%	4,346	17.5%	583	2.4%	137	0.6%	
<i>Ibalizumab-uiyk</i>	3,490	89.9%	151	4.3%	163	4.7%	25	0.7%	12	0.3%	
<i>Tildrakizumab</i>	29,005	95.8%	855	2.9%	321	1.1%	*****	0.1%	*****	0.0%	
<i>Burosumab-twza</i>	11,722	93.1%	444	3.8%	285	2.4%	54	0.5%	24	0.2%	
<i>Fostamatinib</i>	1,830	54.9%	513	28.0%	273	14.9%	*****	*****	*****	*****	
<i>Fosnetupitant and palonosetron</i>	107,487	99.8%	186	0.2%	42	0.0%	0	0.0%	0	0.0%	
<i>Lofexidine hydrochloride</i>	1,462	95.6%	50	3.4%	*****	*****	*****	*****	0	0.0%	
<i>Erenumab-aooe</i>	418,448	55.0%	114,168	27.3%	63,734	15.2%	8,245	2.0%	2,340	0.6%	
<i>Sodium zirconium cyclosilicate</i>	97,175	65.8%	24,742	25.5%	7,812	8.0%	647	0.7%	80	0.1%	
<i>Avatrombopag</i>	2,536	70.3%	480	18.9%	243	9.6%	*****	*****	*****	*****	
<i>Pegvaliase-pqz</i>	2,392	66.5%	523	21.9%	231	9.7%	32	1.3%	15	0.6%	
<i>Baricitinib</i>	8,409	60.2%	2,072	24.6%	1,130	13.4%	122	1.5%	26	0.3%	
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.	.	
<i>Cannabidiol</i>	40,593	50.7%	10,670	26.3%	7,035	17.3%	1,809	4.5%	513	1.3%	
<i>Plazomicin</i>	425	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
<i>Binimetinib</i>	5,407	61.4%	1,393	25.8%	610	11.3%	*****	*****	*****	*****	
<i>Encorafenib</i>	5,948	59.3%	1,598	26.9%	732	12.3%	*****	*****	*****	*****	
<i>Tecovirimat</i>	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
<i>Ivosidenib</i>	1,879	48.9%	578	30.8%	343	18.3%	*****	*****	*****	*****	
<i>Tafenoquine</i>	169	85.8%	*****	*****	*****	*****	*****	*****	0	0.0%	
<i>Elagolix sodium</i>	35,676	63.7%	8,802	24.7%	3,875	10.9%	240	0.7%	40	0.1%	
<i>Fish oil triglycerides</i>	2,702	97.9%	41	1.5%	*****	*****	*****	*****	0	0.0%	
<i>Lusutrombopag</i>	138	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	9,399	1	1	1	1	2	1.0	0.0
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	524,155	1	30	30	90	1,770	88.8	141.2
<i>Tezacaftor and ivacaftor</i>	10,850	1	28	28	56	1,368	62.6	78.4
<i>Apalutamide</i>	24,785	1	30	30	90	1,644	83.3	113.7
<i>Ibalizumab-uiyk</i>	3,490	1	1	1	1	1,655	21.6	88.8
<i>Tildrakizumab</i>	29,005	1	1	1	1	952	6.4	32.4
<i>Burosumab-twza</i>	11,722	1	1	1	1	1,350	14.1	66.7
<i>Fostamatinib</i>	1,830	1	30	30	90	1,504	75.0	106.3
<i>Fosnetupitant and palonosetron</i>	107,487	1	1	1	1	270	1.2	3.9
<i>Lofexidine hydrochloride</i>	1,462	1	8	10	15	644	14.9	25.2
<i>Erenumab-aooe</i>	418,448	1	30	30	84	1,688	76.8	110.3
<i>Sodium zirconium cyclosilicate</i>	97,175	1	28	30	60	1,415	50.4	64.6
<i>Avatrombopag</i>	2,536	1	14	30	58	1,115	49.6	78.8
<i>Pegvaliase-pqpz</i>	2,392	1	30	30	60	1,403	62.3	104.5
<i>Baricitinib</i>	8,409	1	30	30	60	1,476	65.2	94.0
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	40,593	1	30	30	90	1,512	99.3	158.5
<i>Plazomicin</i>	425	1	1	1	1	10	1.6	1.6
<i>Binimetinib</i>	5,407	1	30	30	60	1,332	63.4	82.4
<i>Encorafenib</i>	5,948	1	30	30	60	1,332	64.7	82.3
<i>Tecovirimat</i>	*****	14	14	14	14	14	14.0	0.0
<i>Ivosidenib</i>	1,879	1	30	38	90	1,139	78.2	98.2
<i>Tafenoquine</i>	169	1	1	2	27	531	19.2	47.7
<i>Elagolix sodium</i>	35,676	1	28	28	56	1,189	55.8	66.9
<i>Fish oil triglycerides</i>	2,702	1	1	1	1	716	3.6	22.4
<i>Lusutrombopag</i>	138	6	7	7	7	37	8.9	5.1

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>9,399</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	4,650	4,650	49.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	4,749	4,749	50.5%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>282,910</b>	<b>100.0%</b>	<b>138,082</b>	<b>100.0%</b>	<b>82,536</b>	<b>100.0%</b>	<b>14,901</b>	<b>100.0%</b>	<b>5,726</b>	<b>100.0%</b>
Female	138,694	77,015	27.2%	36,081	26.1%	20,784	25.2%	3,631	24.4%	1,183	20.7%
Male	385,461	205,895	72.8%	102,001	73.9%	61,752	74.8%	11,270	75.6%	4,543	79.3%
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>6,484</b>	<b>100.0%</b>	<b>2,764</b>	<b>100.0%</b>	<b>1,468</b>	<b>100.0%</b>	<b>120</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>
Female	5,462	3,323	51.2%	1,359	49.2%	712	48.5%	*****	*****	*****	*****
Male	5,388	3,161	48.8%	1,405	50.8%	756	51.5%	*****	*****	*****	*****
<b>Apalutamide</b>	<b>24,785</b>	<b>12,998</b>	<b>100.0%</b>	<b>6,721</b>	<b>100.0%</b>	<b>4,346</b>	<b>100.0%</b>	<b>583</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male	24,785	12,998	100.0%	6,721	100.0%	4,346	100.0%	583	100.0%	137	100.0%
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>3,139</b>	<b>100.0%</b>	<b>151</b>	<b>100.0%</b>	<b>163</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
Female	1,003	933	29.7%	32	21.2%	*****	*****	*****	*****	0	0.0%
Male	2,487	2,206	70.3%	119	78.8%	*****	*****	*****	*****	12	100.0%
<b>Tildrakizumab</b>	<b>29,005</b>	<b>27,793</b>	<b>100.0%</b>	<b>855</b>	<b>100.0%</b>	<b>321</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	14,793	14,155	50.9%	449	52.5%	174	54.2%	*****	*****	*****	*****
Male	14,212	13,638	49.1%	406	47.5%	147	45.8%	*****	*****	*****	*****
<b>Burosumab-twza</b>	<b>11,722</b>	<b>10,915</b>	<b>100.0%</b>	<b>444</b>	<b>100.0%</b>	<b>285</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	<b>24</b>	<b>100.0%</b>
Female	7,102	6,573	60.2%	280	63.1%	200	70.2%	*****	*****	*****	*****
Male	4,620	4,342	39.8%	164	36.9%	85	29.8%	*****	*****	*****	*****
<b>Fostamatinib</b>	<b>1,830</b>	<b>1,005</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>	<b>273</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
Female	1,154	632	62.9%	329	64.1%	168	61.5%	*****	*****	*****	*****
Male	676	373	37.1%	184	35.9%	105	38.5%	*****	*****	*****	*****
<b>Fosnetupitant and</b>	<b>107,487</b>	<b>107,259</b>	<b>100.0%</b>	<b>186</b>	<b>100.0%</b>	<b>42</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	60,020	59,894	55.8%	106	57.0%	20	47.6%	0	NaN	0	NaN
Male	47,467	47,365	44.2%	80	43.0%	22	52.4%	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1,397</b>	<b>100.0%</b>	<b>50</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	718	694	49.7%	*****	*****	*****	*****	*****	100.0%	0	NaN

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	744	703	50.3%	****	****	****	****	0	0.0%	0	NaN
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>229,961</b>	<b>100.0%</b>	<b>114,168</b>	<b>100.0%</b>	<b>63,734</b>	<b>100.0%</b>	<b>8,245</b>	<b>100.0%</b>	<b>2,340</b>	<b>100.0%</b>
Female	358,468	197,071	85.7%	97,945	85.8%	54,460	85.4%	7,016	85.1%	1,976	84.4%
Male	59,980	32,890	14.3%	16,223	14.2%	9,274	14.6%	1,229	14.9%	364	15.6%
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>63,894</b>	<b>100.0%</b>	<b>24,742</b>	<b>100.0%</b>	<b>7,812</b>	<b>100.0%</b>	<b>647</b>	<b>100.0%</b>	<b>80</b>	<b>100.0%</b>
Female	40,129	26,899	42.1%	9,882	39.9%	3,072	39.3%	244	37.7%	32	40.0%
Male	57,046	36,995	57.9%	14,860	60.1%	4,740	60.7%	403	62.3%	48	60.0%
<b>Avatrombopag</b>	<b>2,536</b>	<b>1,782</b>	<b>100.0%</b>	<b>480</b>	<b>100.0%</b>	<b>243</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	1,347	960	53.9%	252	52.5%	121	49.8%	****	****	****	****
Male	1,189	822	46.1%	228	47.5%	122	50.2%	****	****	****	****
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1,591</b>	<b>100.0%</b>	<b>523</b>	<b>100.0%</b>	<b>231</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	<b>15</b>	<b>100.0%</b>
Female	1,108	714	44.9%	253	48.4%	120	51.9%	****	****	****	****
Male	1,284	877	55.1%	270	51.6%	111	48.1%	****	****	****	****
<b>Baricitinib</b>	<b>8,409</b>	<b>5,059</b>	<b>100.0%</b>	<b>2,072</b>	<b>100.0%</b>	<b>1,130</b>	<b>100.0%</b>	<b>122</b>	<b>100.0%</b>	<b>26</b>	<b>100.0%</b>
Female	6,517	3,738	73.9%	1,736	83.8%	921	81.5%	****	****	****	****
Male	1,892	1,321	26.1%	336	16.2%	209	18.5%	****	****	****	****
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
Female	.	.	.	.	.	.	.	.	.	.	.
Male	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>20,566</b>	<b>100.0%</b>	<b>10,670</b>	<b>100.0%</b>	<b>7,035</b>	<b>100.0%</b>	<b>1,809</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>
Female	18,046	9,256	45.0%	4,720	44.2%	3,059	43.5%	783	43.3%	228	44.4%
Male	22,547	11,310	55.0%	5,950	55.8%	3,976	56.5%	1,026	56.7%	285	55.6%
<b>Plazomicin</b>	<b>425</b>	<b>425</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	321	321	75.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	104	104	24.5%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Binimetinib</b>	<b>5,407</b>	<b>3,320</b>	<b>100.0%</b>	<b>1,393</b>	<b>100.0%</b>	<b>610</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	2,569	1,612	48.6%	637	45.7%	276	45.2%	****	****	****	****
Male	2,838	1,708	51.4%	756	54.3%	334	54.8%	****	****	****	****
<b>Encorafenib</b>	<b>5,948</b>	<b>3,525</b>	<b>100.0%</b>	<b>1,598</b>	<b>100.0%</b>	<b>732</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
Female	2,880	1,727	49.0%	746	46.7%	358	48.9%	****	****	****	****
Male	3,068	1,798	51.0%	852	53.3%	374	51.1%	****	****	****	****

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Tecovirimat</b>	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
<b>Ivosidenib</b>	1,879	919	100.0%	578	100.0%	343	100.0%	*****	100.0%	*****	100.0%
Female	1,036	533	58.0%	297	51.4%	179	52.2%	*****	*****	*****	*****
Male	843	386	42.0%	281	48.6%	164	47.8%	*****	*****	*****	*****
<b>Tafenoquine</b>	169	145	100.0%	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	112	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Male	57	*****	*****	*****	*****	*****	*****	*****	100.0%	0	NaN
<b>Elagolix sodium</b>	35,676	22,719	100.0%	8,802	100.0%	3,875	100.0%	240	100.0%	40	100.0%
Female	35,625	22,682	99.8%	*****	*****	*****	*****	240	100.0%	40	100.0%
Male	51	37	0.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
<b>Fish oil triglycerides</b>	2,702	2,644	100.0%	41	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,534	1,499	56.7%	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,168	1,145	43.3%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Lusutrombopag</b>	138	*****	100.0%	*****	100.0%	0	NaN	0	NaN	0	NaN
Female	87	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	51	*****	*****	*****	100.0%	0	NaN	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>1.0</b>	<b>0.0</b>
Female	4,650	1	1	1	1	2	1.0	0.0
Male	4,749	1	1	1	1	1	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,770</b>	<b>88.8</b>	<b>141.2</b>
Female	138,694	1	30	30	90	1,703	83.4	129.1
Male	385,461	1	30	30	90	1,770	90.7	145.3
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,368</b>	<b>62.6</b>	<b>78.4</b>
Female	5,462	1	28	28	56	1,368	61.1	76.0
Male	5,388	1	28	28	56	1,148	64.2	80.7
<b>Apalutamide</b>	<b>24,785</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,644</b>	<b>83.3</b>	<b>113.7</b>
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	24,785	1	30	30	90	1,644	83.3	113.7
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,655</b>	<b>21.6</b>	<b>88.8</b>
Female	1,003	1	1	1	1	602	13.0	52.3
Male	2,487	1	1	1	1	1,655	25.1	99.6
<b>Tildrakizumab</b>	<b>29,005</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>952</b>	<b>6.4</b>	<b>32.4</b>
Female	14,793	1	1	1	1	924	6.5	30.5
Male	14,212	1	1	1	1	952	6.4	34.3
<b>Burosumab-twza</b>	<b>11,722</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,350</b>	<b>14.1</b>	<b>66.7</b>
Female	7,102	1	1	1	1	1,350	15.6	70.4
Male	4,620	1	1	1	1	1,350	11.8	60.4
<b>Fostamatinib</b>	<b>1,830</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,504</b>	<b>75.0</b>	<b>106.3</b>
Female	1,154	1	30	30	90	930	74.0	98.9
Male	676	2	30	30	78	1,504	76.6	118.0
<b>Fosnetupitant and palonosetron</b>	<b>107,487</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>270</b>	<b>1.2</b>	<b>3.9</b>
Female	60,020	1	1	1	1	226	1.2	3.7
Male	47,467	1	1	1	1	270	1.2	4.3
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1</b>	<b>8</b>	<b>10</b>	<b>15</b>	<b>644</b>	<b>14.9</b>	<b>25.2</b>
Female	718	1	8	9	14	644	14.3	29.4
Male	744	1	8	12	16	348	15.4	20.4
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>84</b>	<b>1,688</b>	<b>76.8</b>	<b>110.3</b>
Female	358,468	1	30	30	84	1,591	76.6	109.8
Male	59,980	1	30	30	86	1,688	78.1	113.3
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>60</b>	<b>1,415</b>	<b>50.4</b>	<b>64.6</b>
Female	40,129	1	26	30	60	1,349	48.5	62.9
Male	57,046	1	28	30	60	1,415	51.7	65.7
<b>Avatrombopag</b>	<b>2,536</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>58</b>	<b>1,115</b>	<b>49.6</b>	<b>78.8</b>
Female	1,347	1	13	30	47	1,115	47.6	77.0
Male	1,189	1	15	30	60	960	51.9	80.8
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,403</b>	<b>62.3</b>	<b>104.5</b>
Female	1,108	1	30	30	60	1,091	62.4	96.7
Male	1,284	1	30	30	60	1,403	62.2	110.9
<b>Baricitinib</b>	<b>8,409</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,476</b>	<b>65.2</b>	<b>94.0</b>
Female	6,517	1	30	30	90	1,476	69.7	95.8
Male	1,892	1	1	30	60	1,056	49.8	85.8

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Moxidectin</b>	<b>0</b>	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,512</b>	<b>99.3</b>	<b>158.5</b>
Female	18,046	1	30	30	90	1,512	98.3	157.6
Male	22,547	1	30	30	90	1,486	100.1	159.2
<b>Plazomicin</b>	<b>425</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>1.6</b>	<b>1.6</b>
Female	321	1	1	1	1	10	1.6	1.6
Male	104	1	1	1	1	9	1.7	1.8
<b>Binimetinib</b>	<b>5,407</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,332</b>	<b>63.4</b>	<b>82.4</b>
Female	2,569	1	30	30	60	1,332	63.7	85.9
Male	2,838	1	30	30	60	1,020	63.3	79.2
<b>Encorafenib</b>	<b>5,948</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,332</b>	<b>64.7</b>	<b>82.3</b>
Female	2,880	1	30	30	60	1,332	66.1	88.6
Male	3,068	1	30	30	60	1,020	63.3	76.0
<b>Tecovirimat</b>	<b>*****</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14.0</b>	<b>0.0</b>
Female	*****	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	14	14	14	14	14	14.0	0.0
<b>Ivosidenib</b>	<b>1,879</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>1,139</b>	<b>78.2</b>	<b>98.2</b>
Female	1,036	1	30	30	90	991	77.3	98.8
Male	843	1	30	58	90	1,139	79.4	97.6
<b>Tafenoquine</b>	<b>169</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>27</b>	<b>531</b>	<b>19.2</b>	<b>47.7</b>
Female	112	1	1	2	24	140	15.0	26.3
Male	57	1	1	7	28	531	27.5	73.1
<b>Elagolix sodium</b>	<b>35,676</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,189</b>	<b>55.8</b>	<b>66.9</b>
Female	35,625	1	28	28	56	1,189	55.8	66.9
Male	51	11	28	28	56	174	46.7	39.8
<b>Fish oil triglycerides</b>	<b>2,702</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>716</b>	<b>3.6</b>	<b>22.4</b>
Female	1,534	1	1	1	1	610	3.5	19.6
Male	1,168	1	1	1	1	716	3.8	25.5
<b>Lusutrombopag</b>	<b>138</b>	<b>6</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>37</b>	<b>8.9</b>	<b>5.1</b>
Female	87	6	7	7	7	28	9.4	4.9
Male	51	7	7	7	7	37	8.2	5.3

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>9,399</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	162	162	1.7%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	2,171	2,171	23.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	7,052	7,052	75.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>282,910</b>	<b>100.0%</b>	<b>138,082</b>	<b>100.0%</b>	<b>82,536</b>	<b>100.0%</b>	<b>14,901</b>	<b>100.0%</b>	<b>5,726</b>	<b>100.0%</b>
0-17 years	2,122	1,236	0.4%	527	0.4%	309	0.4%	*****	*****	*****	*****
18-24 years	22,685	13,891	4.9%	5,762	4.2%	2,651	3.2%	*****	*****	*****	*****
25-40 years	147,541	86,852	30.7%	37,698	27.3%	19,558	23.7%	2,719	18.2%	714	12.5%
41-64 years	291,458	152,341	53.8%	77,545	56.2%	48,486	58.7%	9,422	63.2%	3,664	64.0%
≥ 65 years	60,349	28,590	10.1%	16,550	12.0%	11,532	14.0%	2,391	16.0%	1,286	22.5%
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>6,484</b>	<b>100.0%</b>	<b>2,764</b>	<b>100.0%</b>	<b>1,468</b>	<b>100.0%</b>	<b>120</b>	<b>100.0%</b>	<b>14</b>	<b>100.0%</b>
0-17 years	3,486	2,014	31.1%	922	33.4%	512	34.9%	*****	*****	*****	*****
18-24 years	2,116	1,347	20.8%	513	18.6%	239	16.3%	*****	*****	*****	*****
25-40 years	3,983	2,469	38.1%	1,006	36.4%	458	31.2%	*****	*****	*****	*****
41-64 years	1,144	610	9.4%	293	10.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	121	44	0.7%	30	1.1%	*****	*****	*****	*****	0	0.0%
<b>Apalutamide</b>	<b>24,785</b>	<b>12,998</b>	<b>100.0%</b>	<b>6,721</b>	<b>100.0%</b>	<b>4,346</b>	<b>100.0%</b>	<b>583</b>	<b>100.0%</b>	<b>137</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	*****	*****	*****	*****	57	9.8%	15	10.9%
≥ 65 years	22,322	11,654	89.7%	6,032	89.7%	3,988	91.8%	526	90.2%	122	89.1%
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>3,139</b>	<b>100.0%</b>	<b>151</b>	<b>100.0%</b>	<b>163</b>	<b>100.0%</b>	<b>25</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	91	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	465	*****	*****	22	14.6%	*****	*****	*****	*****	0	0.0%
41-64 years	2,441	2,182	69.5%	117	77.5%	113	69.3%	*****	*****	*****	*****

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	493	454	14.5%	****	****	24	14.7%	****	****	****	****
<b>Tildrakizumab</b>	<b>29,005</b>	<b>27,793</b>	<b>100.0%</b>	<b>855</b>	<b>100.0%</b>	<b>321</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
0-17 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
25-40 years	790	587	2.1%	149	17.4%	****	****	****	****	0	0.0%
41-64 years	2,553	2,007	7.2%	397	46.4%	133	41.4%	****	****	****	****
≥ 65 years	25,523	25,094	90.3%	285	33.3%	126	39.3%	****	****	****	****
<b>Burosumab-twza</b>	<b>11,722</b>	<b>10,915</b>	<b>100.0%</b>	<b>444</b>	<b>100.0%</b>	<b>285</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	<b>24</b>	<b>100.0%</b>
0-17 years	6,448	5,854	53.6%	327	73.6%	217	76.1%	****	****	****	****
18-24 years	524	501	4.6%	****	****	****	****	****	****	****	****
25-40 years	1,583	1,517	13.9%	36	8.1%	****	****	****	****	****	****
41-64 years	2,008	1,923	17.6%	46	10.4%	27	9.5%	****	****	****	****
≥ 65 years	1,159	1,120	10.3%	****	****	****	****	****	****	****	****
<b>Fostamatinib</b>	<b>1,830</b>	<b>1,005</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>	<b>273</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>
0-17 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
25-40 years	259	168	16.7%	58	11.3%	****	****	****	****	****	****
41-64 years	676	380	37.8%	183	35.7%	100	36.6%	****	****	****	****
≥ 65 years	818	408	40.6%	252	49.1%	135	49.5%	****	****	****	****
<b>Fosnetupitant and</b>	<b>107,487</b>	<b>107,259</b>	<b>100.0%</b>	<b>186</b>	<b>100.0%</b>	<b>42</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	2,266	2,264	2.1%	****	****	****	****	0	NaN	0	NaN
41-64 years	22,020	21,985	20.5%	****	****	****	****	0	NaN	0	NaN
≥ 65 years	82,887	82,696	77.1%	****	****	****	****	0	NaN	0	NaN
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1,397</b>	<b>100.0%</b>	<b>50</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>****</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	****	****	****	****	****	0	0.0%	0	0.0%	0	NaN
18-24 years	****	****	****	****	****	0	0.0%	0	0.0%	0	NaN
25-40 years	518	501	35.9%	****	****	****	****	0	0.0%	0	NaN
41-64 years	684	651	46.6%	****	****	****	****	****	100.0%	0	NaN
≥ 65 years	187	174	12.5%	****	****	****	****	0	0.0%	0	NaN

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>229,961</b>	<b>100.0%</b>	<b>114,168</b>	<b>100.0%</b>	<b>63,734</b>	<b>100.0%</b>	<b>8,245</b>	<b>100.0%</b>	<b>2,340</b>	<b>100.0%</b>
0-17 years	1,993	1,130	0.5%	514	0.5%	299	0.5%	*****	*****	*****	*****
18-24 years	19,896	11,696	5.1%	5,316	4.7%	2,558	4.0%	*****	*****	*****	*****
25-40 years	102,247	58,046	25.2%	27,687	24.3%	14,389	22.6%	1,688	20.5%	437	18.7%
41-64 years	224,081	122,909	53.4%	60,649	53.1%	34,478	54.1%	4,697	57.0%	1,348	57.6%
≥ 65 years	70,231	36,180	15.7%	20,002	17.5%	12,010	18.8%	1,542	18.7%	497	21.2%
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>63,894</b>	<b>100.0%</b>	<b>24,742</b>	<b>100.0%</b>	<b>7,812</b>	<b>100.0%</b>	<b>647</b>	<b>100.0%</b>	<b>80</b>	<b>100.0%</b>
0-17 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	256	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	4,227	2,806	4.4%	1,062	4.3%	*****	*****	*****	*****	0	0.0%
41-64 years	29,298	19,269	30.2%	7,509	30.3%	2,301	29.5%	197	30.4%	22	27.5%
≥ 65 years	63,373	41,631	65.2%	16,103	65.1%	5,158	66.0%	423	65.4%	58	72.5%
<b>Avatrombopag</b>	<b>2,536</b>	<b>1,782</b>	<b>100.0%</b>	<b>480</b>	<b>100.0%</b>	<b>243</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	122	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	202	139	7.8%	40	8.3%	*****	*****	*****	*****	0	0.0%
41-64 years	1,015	758	42.5%	162	33.8%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,186	784	44.0%	256	53.3%	129	*****	*****	*****	*****	*****
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1,591</b>	<b>100.0%</b>	<b>523</b>	<b>100.0%</b>	<b>231</b>	<b>100.0%</b>	<b>32</b>	<b>100.0%</b>	<b>15</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	22	4.2%	*****	*****	*****	*****	0	0.0%
18-24 years	645	448	28.2%	140	26.8%	*****	*****	*****	*****	*****	*****
25-40 years	966	662	41.6%	198	37.9%	88	38.1%	*****	*****	*****	*****
41-64 years	654	400	25.1%	163	31.2%	77	33.3%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
<b>Baricitinib</b>	<b>8,409</b>	<b>5,059</b>	<b>100.0%</b>	<b>2,072</b>	<b>100.0%</b>	<b>1,130</b>	<b>100.0%</b>	<b>122</b>	<b>100.0%</b>	<b>26</b>	<b>100.0%</b>
0-17 years	86	49	1.0%	19	0.9%	*****	*****	*****	*****	*****	*****
18-24 years	199	134	2.6%	50	2.4%	15	1.3%	0	0.0%	0	0.0%
25-40 years	852	535	10.6%	222	10.7%	*****	*****	*****	*****	*****	*****
41-64 years	4,533	2,703	53.4%	1,111	53.6%	641	56.7%	66	54.1%	12	46.2%
≥ 65 years	2,739	1,638	32.4%	670	32.3%	374	33.1%	*****	*****	*****	*****

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Moxidectin</b>	.	.	.	.	.	.	.	.	.	.	.
0-17 years	.	.	.	.	.	.	.	.	.	.	.
18-24 years	.	.	.	.	.	.	.	.	.	.	.
25-40 years	.	.	.	.	.	.	.	.	.	.	.
41-64 years	.	.	.	.	.	.	.	.	.	.	.
≥ 65 years	.	.	.	.	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>20,566</b>	<b>100.0%</b>	<b>10,670</b>	<b>100.0%</b>	<b>7,035</b>	<b>100.0%</b>	<b>1,809</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>
0-17 years	18,531	9,298	45.2%	4,861	45.6%	3,289	46.8%	967	53.5%	116	22.6%
18-24 years	6,645	3,432	16.7%	1,663	15.6%	1,212	17.2%	*****	*****	*****	*****
25-40 years	9,748	5,072	24.7%	2,542	23.8%	1,598	22.7%	352	19.5%	184	35.9%
41-64 years	5,340	2,589	12.6%	1,523	14.3%	883	12.6%	202	11.2%	143	27.9%
≥ 65 years	329	175	0.9%	81	0.8%	53	0.8%	*****	*****	*****	*****
<b>Plazomicin</b>	<b>425</b>	<b>425</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	27	27	6.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	22	22	5.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	376	376	88.5%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Binimetinib</b>	<b>5,407</b>	<b>3,320</b>	<b>100.0%</b>	<b>1,393</b>	<b>100.0%</b>	<b>610</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	41	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	471	291	8.8%	126	9.0%	*****	*****	*****	*****	0	0.0%
41-64 years	1,864	1,194	36.0%	447	32.1%	197	32.3%	*****	*****	*****	*****
≥ 65 years	3,013	1,801	54.2%	803	57.6%	361	59.2%	*****	*****	*****	*****
<b>Encorafenib</b>	<b>5,948</b>	<b>3,525</b>	<b>100.0%</b>	<b>1,598</b>	<b>100.0%</b>	<b>732</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	487	284	8.1%	136	8.5%	*****	*****	*****	*****	0	0.0%
41-64 years	1,951	1,188	33.7%	512	32.0%	218	29.8%	*****	*****	*****	*****
≥ 65 years	3,471	2,032	57.6%	937	58.6%	452	61.7%	*****	*****	*****	*****

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Tecovirimat</b>	****	****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Ivosidenib</b>	<b>1,879</b>	<b>919</b>	<b>100.0%</b>	<b>578</b>	<b>100.0%</b>	<b>343</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>
0-17 years	****	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	0	0.0%	****	****
25-40 years	96	45	4.9%	****	****	****	****	****	****	0	0.0%
41-64 years	357	189	20.6%	100	17.3%	****	****	****	****	****	****
≥ 65 years	1,399	669	72.8%	440	76.1%	262	76.4%	****	****	****	****
<b>Tafenoquine</b>	<b>169</b>	<b>145</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	****	****	****	****	****	0	0.0%	0	0.0%	0	NaN
18-24 years	****	****	****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	56	****	****	****	****	****	****	0	0.0%	0	NaN
41-64 years	85	72	****	****	****	****	****	****	100.0%	0	NaN
≥ 65 years	11	****	****	****	****	0	0.0%	0	0.0%	0	NaN
<b>Elagolix sodium</b>	<b>35,676</b>	<b>22,719</b>	<b>100.0%</b>	<b>8,802</b>	<b>100.0%</b>	<b>3,875</b>	<b>100.0%</b>	<b>240</b>	<b>100.0%</b>	<b>40</b>	<b>100.0%</b>
0-17 years	****	****	****	****	****	****	****	****	****	****	****
18-24 years	6,464	4,210	18.5%	1,568	17.8%	631	16.3%	****	****	****	****
25-40 years	21,170	13,548	59.6%	5,169	58.7%	2,305	59.5%	126	****	22	****
41-64 years	7,362	4,536	20.0%	1,895	21.5%	866	22.3%	****	****	****	****
≥ 65 years	****	****	****	****	****	****	****	****	****	0	0.0%
<b>Fish oil triglycerides</b>	<b>2,702</b>	<b>2,644</b>	<b>100.0%</b>	<b>41</b>	<b>100.0%</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	2,418	2,362	89.3%	40	97.6%	****	****	****	100.0%	0	NaN
18-24 years	181	****	****	****	****	0	0.0%	0	0.0%	0	NaN
25-40 years	39	39	1.5%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	45	45	1.7%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	19	****	****	0	0.0%	****	****	0	0.0%	0	NaN
<b>Lusutrombopag</b>	<b>138</b>	****	<b>100.0%</b>	****	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	111	110	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	162	1	1	1	1	1	1.0	0.0
41-64 years	2,171	1	1	1	1	2	1.0	0.0
≥ 65 years	7,052	1	1	1	1	2	1.0	0.0
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,770</b>	<b>88.8</b>	<b>141.2</b>
0-17 years	2,122	1	30	30	61	1,440	73.0	101.0
18-24 years	22,685	1	30	30	60	1,644	65.2	88.5
25-40 years	147,541	1	30	30	60	1,758	72.5	106.9
41-64 years	291,458	1	30	30	90	1,770	94.2	149.3
≥ 65 years	60,349	1	30	60	97	1,719	111.7	180.9
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,368</b>	<b>62.6</b>	<b>78.4</b>
0-17 years	3,486	1	28	28	58	1,064	64.1	77.2
18-24 years	2,116	1	28	28	56	962	56.1	70.7
25-40 years	3,983	1	28	28	56	1,368	59.3	75.3
41-64 years	1,144	4	28	28	84	812	76.2	95.8
≥ 65 years	121	28	28	56	168	532	114.0	113.6
<b>Apalutamide</b>	<b>24,785</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,644</b>	<b>83.3</b>	<b>113.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	24	30	60	60	120	59.1	31.1
41-64 years	*****	1	30	30	82	1,149	78.4	113.1
≥ 65 years	22,322	1	30	30	90	1,644	83.9	113.8
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,655</b>	<b>21.6</b>	<b>88.8</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	91	1	1	1	1	406	8.2	44.2
25-40 years	465	1	1	1	1	420	17.9	53.5
41-64 years	2,441	1	1	1	1	1,655	23.2	96.9
≥ 65 years	493	1	1	1	1	1,056	19.7	78.6
<b>Tildrakizumab</b>	<b>29,005</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>952</b>	<b>6.4</b>	<b>32.4</b>
0-17 years	*****	30	57	84	94	252	93.9	69.3
18-24 years	*****	1	1	1	30	252	25.2	47.6
25-40 years	790	1	1	1	31	534	30.0	58.4
41-64 years	2,553	1	1	1	30	952	28.3	65.3
≥ 65 years	25,523	1	1	1	1	924	3.4	23.8
<b>Burosumab-twza</b>	<b>11,722</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1,350</b>	<b>14.1</b>	<b>66.7</b>
0-17 years	6,448	1	1	1	1	1,350	17.6	66.4
18-24 years	524	1	1	1	1	1,315	12.2	87.6
25-40 years	1,583	1	1	1	1	1,168	9.6	63.2
41-64 years	2,008	1	1	1	1	1,350	11.1	72.5
≥ 65 years	1,159	1	1	1	1	950	7.0	47.6
<b>Fostatinib</b>	<b>1,830</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,504</b>	<b>75.0</b>	<b>106.3</b>
0-17 years	*****	30	30	81	128	189	89.8	61.3
18-24 years	*****	5	30	30	60	360	49.3	50.0

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	259	1	30	30	60	861	59.7	79.6
41-64 years	676	1	30	30	68	1,504	73.9	114.8
≥ 65 years	818	1	30	32	90	894	82.8	109.5
<b>Fosnetupitant and palonosetron</b>	<b>107,487</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>270</b>	<b>1.2</b>	<b>3.9</b>
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	2,266	1	1	1	1	105	1.1	2.7
41-64 years	22,020	1	1	1	1	147	1.2	2.9
≥ 65 years	82,887	1	1	1	1	270	1.3	4.2
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1</b>	<b>8</b>	<b>10</b>	<b>15</b>	<b>644</b>	<b>14.9</b>	<b>25.2</b>
0-17 years	*****	14	14	14	70	70	32.7	32.3
18-24 years	*****	1	7	9	14	48	10.8	6.9
25-40 years	518	1	8	12	14	226	13.6	14.5
41-64 years	684	1	8	9	15	644	15.2	30.2
≥ 65 years	187	2	9	12	18	348	18.7	31.6
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>84</b>	<b>1,688</b>	<b>76.8</b>	<b>110.3</b>
0-17 years	1,993	1	28	30	84	1,167	73.3	97.2
18-24 years	19,896	1	28	30	60	1,366	66.0	89.1
25-40 years	102,247	1	30	30	77	1,526	71.4	100.7
41-64 years	224,081	1	30	30	84	1,688	78.0	112.7
≥ 65 years	70,231	1	30	30	90	1,550	84.2	120.8
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>1</b>	<b>28</b>	<b>30</b>	<b>60</b>	<b>1,415</b>	<b>50.4</b>	<b>64.6</b>
0-17 years	21	13	30	30	30	116	42.5	28.9
18-24 years	256	1	28	30	58	374	46.0	46.0
25-40 years	4,227	1	28	30	60	714	49.5	60.0
41-64 years	29,298	1	28	30	60	1,415	50.3	64.9
≥ 65 years	63,373	1	28	30	60	1,349	50.5	64.8
<b>Avatrombopag</b>	<b>2,536</b>	<b>1</b>	<b>14</b>	<b>30</b>	<b>58</b>	<b>1,115</b>	<b>49.6</b>	<b>78.8</b>
0-17 years	11	16	27	30	56	172	47.6	44.0
18-24 years	122	5	30	30	30	367	44.2	48.8
25-40 years	202	2	30	30	60	600	52.8	70.6
41-64 years	1,015	2	5	30	31	1,115	43.0	75.0
≥ 65 years	1,186	1	23	30	60	1,077	55.3	85.4
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,403</b>	<b>62.3</b>	<b>104.5</b>
0-17 years	124	3	30	30	60	510	72.4	101.3
18-24 years	645	1	30	30	60	1,019	54.4	84.5
25-40 years	966	1	30	30	60	1,403	61.6	112.6
41-64 years	*****	1	30	30	60	1,091	69.3	110.3
≥ 65 years	*****	5	5	30	125	125	53.3	63.3
<b>Baricitinib</b>	<b>8,409</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,476</b>	<b>65.2</b>	<b>94.0</b>
0-17 years	86	6	30	30	84	840	86.8	136.4
18-24 years	199	1	30	30	60	270	46.6	42.7
25-40 years	852	1	30	30	60	1,476	57.6	88.3
41-64 years	4,533	1	30	30	60	1,140	67.2	91.3
≥ 65 years	2,739	1	7	30	90	1,077	65.1	100.7



**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment								
Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Moxidectin</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>1,512</b>	<b>99.3</b>	<b>158.5</b>
0-17 years	18,531	1	30	30	90	1,512	97.9	143.2
18-24 years	6,645	1	30	30	90	1,465	95.4	146.0
25-40 years	9,748	1	30	30	90	1,486	99.6	171.7
41-64 years	5,340	1	30	32	90	1,448	108.6	194.3
≥ 65 years	329	2	30	30	90	1,307	98.4	156.5
<b>Plazomicin</b>	<b>425</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>1.6</b>	<b>1.6</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	27	1	1	1	1	5	1.1	0.8
41-64 years	22	1	1	2	6	7	3.3	2.6
≥ 65 years	376	1	1	1	1	10	1.5	1.5
<b>Binimetinib</b>	<b>5,407</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,332</b>	<b>63.4</b>	<b>82.4</b>
0-17 years	18	15	30	30	48	273	58.9	69.2
18-24 years	41	12	30	30	70	559	75.3	106.4
25-40 years	471	1	30	30	60	690	61.0	78.5
41-64 years	1,864	1	30	30	60	1,332	61.5	84.4
≥ 65 years	3,013	1	30	30	60	1,020	64.9	81.5
<b>Encorafenib</b>	<b>5,948</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>1,332</b>	<b>64.7</b>	<b>82.3</b>
0-17 years	*****	14	30	30	48	90	42.4	29.2
18-24 years	*****	22	30	30	70	557	70.3	95.5
25-40 years	487	1	30	30	60	727	63.4	79.8
41-64 years	1,951	1	30	30	60	1,332	63.9	84.2
≥ 65 years	3,471	1	30	30	60	1,110	65.3	81.6
<b>Tecovirimat</b>	<b>*****</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14</b>	<b>14.0</b>	<b>0.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	14	14	14	14	14	14.0	NaN
41-64 years	*****	14	14	14	14	14	14.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>1,879</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>1,139</b>	<b>78.2</b>	<b>98.2</b>
0-17 years	*****	28	28	41	54	54	41.0	18.4
18-24 years	*****	2	30	30	60	750	76.4	145.9
25-40 years	96	3	30	39	90	508	75.5	85.7
41-64 years	357	4	30	30	90	1,087	75.7	98.7
≥ 65 years	1,399	1	30	45	90	1,139	79.1	98.0
<b>Tafenoquine</b>	<b>169</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>27</b>	<b>531</b>	<b>19.2</b>	<b>47.7</b>
0-17 years	*****	1	1	1	7	60	10.7	19.3
18-24 years	*****	1	1	1	1	30	5.8	11.8
25-40 years	56	1	1	1	6	154	14.8	30.9

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	85	1	1	7	28	531	24.9	61.3
≥ 65 years	11	1	3	3	24	56	13.5	17.3
<b>Elagolix sodium</b>	<b>35,676</b>	<b>1</b>	<b>28</b>	<b>28</b>	<b>56</b>	<b>1,189</b>	<b>55.8</b>	<b>66.9</b>
0-17 years	*****	1	28	28	56	1,094	62.0	102.1
18-24 years	6,464	1	28	28	56	868	53.9	64.2
25-40 years	21,170	1	28	28	56	1,189	55.1	65.3
41-64 years	7,362	1	28	28	56	952	58.6	69.7
≥ 65 years	*****	28	56	112	112	420	145.6	157.6
<b>Fish oil triglycerides</b>	<b>2,702</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>716</b>	<b>3.6</b>	<b>22.4</b>
0-17 years	2,418	1	1	1	1	716	3.9	23.5
18-24 years	181	1	1	1	1	64	1.5	4.7
25-40 years	39	1	1	1	1	1	1.0	0.0
41-64 years	45	1	1	1	1	2	1.0	0.1
≥ 65 years	19	1	1	1	7	96	7.6	21.6
<b>Lusutrombopag</b>	<b>138</b>	<b>6</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>37</b>	<b>8.9</b>	<b>5.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	7	7	7	7	30	10.3	8.7
41-64 years	111	6	7	7	7	37	9.1	5.1
≥ 65 years	*****	7	7	7	7	14	7.7	2.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	9,399	2	55	55	62	1,510	70.1	84.7
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	524,155	1	3	7	20	1,804	24.5	63.8
<i>Tezacaftor and ivacaftor</i>	10,850	1	3	7	18	1,163	19.7	48.2
<i>Apalutamide</i>	24,785	1	3	6	17	1,643	19.1	52.8
<i>Ibalizumab-uiyk</i>	3,490	1	13	13	13	830	15.2	28.4
<i>Tildrakizumab</i>	29,005	1	82	83	90	1,057	80.4	47.6
<i>Burosumab-twza</i>	11,722	1	14	27	28	1,083	26.1	28.7
<i>Fostamatinib</i>	1,830	1	3	6	16	836	19.4	54.1
<i>Fosnetupitant and palonosetron</i>	107,487	1	13	18	20	1,161	20.5	36.9
<i>Lofexidine hydrochloride</i>	1,462	1	10	27	88	1,504	81.5	144.8
<i>Erenumab-aooe</i>	418,448	1	3	7	20	1,603	24.4	64.3
<i>Sodium zirconium cyclosilicate</i>	97,175	1	5	15	45	1,220	45.2	86.2
<i>Avatrombopag</i>	2,536	1	4	13	39	1,394	50.4	118.7
<i>Pegvaliase-pqpz</i>	2,392	1	4	8	19	1,024	18.8	45.5
<i>Baricitinib</i>	8,409	1	3	7	18	1,203	20.3	52.4
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	40,593	1	3	7	18	1,477	21.2	52.5
<i>Plazomicin</i>	425	1	3	6	11	838	28.1	82.7
<i>Binimetinib</i>	5,407	1	3	8	23	1,036	24.2	59.3
<i>Encorafenib</i>	5,948	1	3	8	21	1,036	22.6	56.1
<i>Tecovirimat</i>	2	15	15	36	56	56	35.5	29.0
<i>Ivosidenib</i>	1,879	1	3	6	15	765	19.6	51.5
<i>Tafenoquine</i>	169	1	12	32	69	798	64.0	115.9
<i>Elagolix sodium</i>	35,676	1	3	7	20	1,280	24.7	66.3
<i>Fish oil triglycerides</i>	2,702	1	3	6	6	448	7.0	16.6
<i>Lusutrombopag</i>	138	1	16	52	129	1,186	119.7	195.1

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>2</b>	<b>55</b>	<b>55</b>	<b>62</b>	<b>1,510</b>	<b>70.1</b>	<b>84.7</b>
Female	4,650	4	55	55	61	1,510	71.6	94.3
Male	4,749	2	55	55	62	1,229	68.6	74.1
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,804</b>	<b>24.5</b>	<b>63.8</b>
Female	138,694	1	3	8	21	1,557	24.8	62.2
Male	385,461	1	3	7	20	1,804	24.4	64.3
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,163</b>	<b>19.7</b>	<b>48.2</b>
Female	5,462	1	3	7	18	1,163	21.0	54.9
Male	5,388	1	3	7	16	1,009	18.5	40.2
<b>Apalutamide</b>	<b>24,785</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>1,643</b>	<b>19.1</b>	<b>52.8</b>
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	24,785	1	3	6	17	1,643	19.1	52.8
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>1</b>	<b>13</b>	<b>13</b>	<b>13</b>	<b>830</b>	<b>15.2</b>	<b>28.4</b>
Female	1,003	1	13	13	13	830	17.1	39.8
Male	2,487	1	12	13	13	738	14.4	22.2
<b>Tildrakizumab</b>	<b>29,005</b>	<b>1</b>	<b>82</b>	<b>83</b>	<b>90</b>	<b>1,057</b>	<b>80.4</b>	<b>47.6</b>
Female	14,793	1	80	83	90	1,057	79.5	48.5
Male	14,212	1	83	83	90	972	81.4	46.7
<b>Burosumab-twza</b>	<b>11,722</b>	<b>1</b>	<b>14</b>	<b>27</b>	<b>28</b>	<b>1,083</b>	<b>26.1</b>	<b>28.7</b>
Female	7,102	1	15	27	29	1,083	26.4	29.7
Male	4,620	1	13	27	28	775	25.5	27.1
<b>Fostamatinib</b>	<b>1,830</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>836</b>	<b>19.4</b>	<b>54.1</b>
Female	1,154	1	3	6	15	836	18.2	53.0
Male	676	1	3	6	17	608	21.4	55.9
<b>Fosnetupitant and palonosetron</b>	<b>107,487</b>	<b>1</b>	<b>13</b>	<b>18</b>	<b>20</b>	<b>1,161</b>	<b>20.5</b>	<b>36.9</b>
Female	60,020	1	13	20	20	1,161	21.2	38.8
Male	47,467	1	13	13	20	1,043	19.7	34.4
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1</b>	<b>10</b>	<b>27</b>	<b>88</b>	<b>1,504</b>	<b>81.5</b>	<b>144.8</b>
Female	718	1	11	29	94	1,504	83.5	152.1
Male	744	1	10	25	84	1,207	79.7	137.5
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,603</b>	<b>24.4</b>	<b>64.3</b>
Female	358,468	1	3	7	20	1,603	24.5	64.8
Male	59,980	1	3	7	20	1,531	23.6	61.0
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>1</b>	<b>5</b>	<b>15</b>	<b>45</b>	<b>1,220</b>	<b>45.2</b>	<b>86.2</b>
Female	40,129	1	5	16	45	1,220	46.0	87.6
Male	57,046	1	5	15	44	1,213	44.7	85.1
<b>Avatrombopag</b>	<b>2,536</b>	<b>1</b>	<b>4</b>	<b>13</b>	<b>39</b>	<b>1,394</b>	<b>50.4</b>	<b>118.7</b>
Female	1,347	1	5	15	45	1,394	53.7	124.2
Male	1,189	1	4	11	37	1,359	46.7	112.1
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>19</b>	<b>1,024</b>	<b>18.8</b>	<b>45.5</b>
Female	1,108	1	4	8	18	763	17.8	40.1
Male	1,284	1	4	9	20	1,024	19.6	49.8
<b>Baricitinib</b>	<b>8,409</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,203</b>	<b>20.3</b>	<b>52.4</b>
Female	6,517	1	3	7	19	1,203	21.4	54.3
Male	1,892	1	3	6	15	850	16.7	44.9
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,477</b>	<b>21.2</b>	<b>52.5</b>
Female	18,046	1	3	7	18	1,127	20.9	51.0
Male	22,547	1	3	6	18	1,477	21.4	53.7
<b>Plazomicin</b>	<b>425</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>11</b>	<b>838</b>	<b>28.1</b>	<b>82.7</b>
Female	321	1	3	6	13	498	25.4	65.9
Male	104	1	2	6	7	838	36.4	120.6
<b>Binimetinib</b>	<b>5,407</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>23</b>	<b>1,036</b>	<b>24.2</b>	<b>59.3</b>
Female	2,569	1	3	9	25	1,036	25.4	59.6
Male	2,838	1	3	8	21	944	23.2	59.0
<b>Encorafenib</b>	<b>5,948</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>21</b>	<b>1,036</b>	<b>22.6</b>	<b>56.1</b>
Female	2,880	1	3	8	22	1,036	23.3	57.2
Male	3,068	1	3	7	20	944	22.0	55.0
<b>Tecovirimat</b>	<b>2</b>	<b>15</b>	<b>15</b>	<b>36</b>	<b>56</b>	<b>56</b>	<b>35.5</b>	<b>29.0</b>
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2	15	15	36	56	56	35.5	29.0
<b>Ivosidenib</b>	<b>1,879</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>15</b>	<b>765</b>	<b>19.6</b>	<b>51.5</b>
Female	1,036	1	2	6	16	765	20.3	54.6
Male	843	1	3	6	15	524	18.9	47.4
<b>Tafenoquine</b>	<b>169</b>	<b>1</b>	<b>12</b>	<b>32</b>	<b>69</b>	<b>798</b>	<b>64.0</b>	<b>115.9</b>
Female	112	1	14	32	61	314	48.6	53.3
Male	57	1	9	27	79	798	94.3	182.3
<b>Elagolix sodium</b>	<b>35,676</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,280</b>	<b>24.7</b>	<b>66.3</b>
Female	35,625	1	3	7	20	1,280	24.7	66.3
Male	51	1	3	7	16	569	26.4	83.9
<b>Fish oil triglycerides</b>	<b>2,702</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>6</b>	<b>448</b>	<b>7.0</b>	<b>16.6</b>
Female	1,534	1	3	6	6	281	6.7	13.1
Male	1,168	1	3	6	6	448	7.4	20.3
<b>Lusutrombopag</b>	<b>138</b>	<b>1</b>	<b>16</b>	<b>52</b>	<b>129</b>	<b>1,186</b>	<b>119.7</b>	<b>195.1</b>
Female	87	1	10	30	92	1,186	108.7	212.2
Male	51	1	34	77	182	770	138.6	161.9

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>9,399</b>	<b>2</b>	<b>55</b>	<b>55</b>	<b>62</b>	<b>1,510</b>	<b>70.1</b>	<b>84.7</b>
0-17 years	1	55	55	55	55	55	55.0	NaN
18-24 years	13	54	55	55	55	153	68.2	29.6
25-40 years	162	50	55	55	62	244	62.7	21.5
41-64 years	2,171	4	55	55	61	1,229	72.1	94.8
≥ 65 years	7,052	2	55	55	62	1,510	69.7	82.4
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>524,155</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,804</b>	<b>24.5</b>	<b>63.8</b>
0-17 years	2,122	1	3	8	21	736	22.7	50.2
18-24 years	22,685	1	4	10	26	1,431	30.8	68.4
25-40 years	147,541	1	4	9	25	1,718	29.0	68.6
41-64 years	291,458	1	3	7	19	1,804	23.1	62.4
≥ 65 years	60,349	1	2	5	14	1,500	17.9	55.3
<b>Tezacaftor and ivacaftor</b>	<b>10,850</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,163</b>	<b>19.7</b>	<b>48.2</b>
0-17 years	3,486	1	3	6	16	495	16.8	32.1
18-24 years	2,116	1	3	8	21	439	21.5	40.1
25-40 years	3,983	1	3	7	17	1,163	21.4	58.9
41-64 years	1,144	1	3	6	14	1,126	18.1	52.8
≥ 65 years	121	1	2	6	15	763	32.5	95.9
<b>Apalutamide</b>	<b>24,785</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>1,643</b>	<b>19.1</b>	<b>52.8</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	7	1	1	4	27	42	12.6	16.0
41-64 years	2,456	1	3	6	15	752	17.2	42.3
≥ 65 years	22,322	1	2	6	18	1,643	19.3	53.9
<b>Ibalizumab-uiyk</b>	<b>3,490</b>	<b>1</b>	<b>13</b>	<b>13</b>	<b>13</b>	<b>830</b>	<b>15.2</b>	<b>28.4</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	91	3	13	13	14	111	18.4	17.6
25-40 years	465	1	13	13	13	830	17.3	47.1
41-64 years	2,441	1	13	13	13	738	15.0	26.1
≥ 65 years	493	1	13	13	13	263	13.2	13.7
<b>Tildrakizumab</b>	<b>29,005</b>	<b>1</b>	<b>82</b>	<b>83</b>	<b>90</b>	<b>1,057</b>	<b>80.4</b>	<b>47.6</b>
0-17 years	8	2	7	29	93	206	58.1	71.8
18-24 years	131	2	55	83	92	645	82.7	66.2
25-40 years	790	1	30	83	92	887	80.8	79.6
41-64 years	2,553	1	31	83	91	860	77.4	69.1
≥ 65 years	25,523	1	83	83	90	1,057	80.7	43.4
<b>Burosumab-twza</b>	<b>11,722</b>	<b>1</b>	<b>14</b>	<b>27</b>	<b>28</b>	<b>1,083</b>	<b>26.1</b>	<b>28.7</b>
0-17 years	6,448	1	13	24	28	775	23.2	25.7
18-24 years	524	1	26	27	32	388	32.6	32.5
25-40 years	1,583	1	26	27	30	1,083	31.2	40.9
41-64 years	2,008	1	26	27	29	1,057	28.4	28.8
≥ 65 years	1,159	1	27	27	28	433	28.4	18.6
<b>Fostamatinib</b>	<b>1,830</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>16</b>	<b>836</b>	<b>19.4</b>	<b>54.1</b>
0-17 years	6	1	2	3	42	69	20.0	28.8
18-24 years	71	1	4	7	21	449	24.9	57.4
25-40 years	259	1	4	9	23	482	23.5	47.4

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	676	1	3	6	14	608	19.0	52.2
≥ 65 years	818	1	3	6	15	836	17.8	57.4
<b>Fosnetupitant and palonosetron</b>	<b>107,487</b>	<b>1</b>	<b>13</b>	<b>18</b>	<b>20</b>	<b>1,161</b>	<b>20.5</b>	<b>36.9</b>
0-17 years	1	2	2	2	2	2	2.0	NaN
18-24 years	313	2	13	13	20	83	16.9	10.3
25-40 years	2,266	1	13	13	20	685	18.7	28.2
41-64 years	22,020	1	13	13	20	1,062	19.4	32.7
≥ 65 years	82,887	1	13	19	20	1,161	20.9	38.2
<b>Lofexidine hydrochloride</b>	<b>1,462</b>	<b>1</b>	<b>10</b>	<b>27</b>	<b>88</b>	<b>1,504</b>	<b>81.5</b>	<b>144.8</b>
0-17 years	3	35	35	58	114	114	69.0	40.6
18-24 years	70	1	13	50	191	849	116.2	148.5
25-40 years	518	1	10	26	82	1,207	75.9	132.8
41-64 years	684	1	11	28	94	1,504	84.2	151.9
≥ 65 years	187	1	10	20	68	1,070	74.6	148.9
<b>Erenumab-aooe</b>	<b>418,448</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,603</b>	<b>24.4</b>	<b>64.3</b>
0-17 years	1,993	1	3	7	18	836	22.1	57.1
18-24 years	19,896	1	3	7	20	1,134	23.4	58.9
25-40 years	102,247	1	3	7	20	1,603	24.1	62.7
41-64 years	224,081	1	3	7	21	1,557	24.8	65.0
≥ 65 years	70,231	1	3	6	19	1,420	23.8	65.9
<b>Sodium zirconium cyclosilicate</b>	<b>97,175</b>	<b>1</b>	<b>5</b>	<b>15</b>	<b>45</b>	<b>1,220</b>	<b>45.2</b>	<b>86.2</b>
0-17 years	21	1	5	19	57	258	46.9	70.8
18-24 years	256	1	5	18	66	601	57.9	90.2
25-40 years	4,227	1	6	19	61	1,166	57.6	102.6
41-64 years	29,298	1	5	16	47	1,150	48.7	92.5
≥ 65 years	63,373	1	5	15	43	1,220	42.7	81.6
<b>Avatrombopag</b>	<b>2,536</b>	<b>1</b>	<b>4</b>	<b>13</b>	<b>39</b>	<b>1,394</b>	<b>50.4</b>	<b>118.7</b>
0-17 years	11	1	2	8	47	256	38.1	74.9
18-24 years	122	1	5	13	31	309	26.7	43.3
25-40 years	202	1	5	16	46	542	41.5	73.6
41-64 years	1,015	1	5	13	44	1,394	54.6	122.8
≥ 65 years	1,186	1	4	12	38	1,285	51.0	126.4
<b>Pegvaliase-pqpz</b>	<b>2,392</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>19</b>	<b>1,024</b>	<b>18.8</b>	<b>45.5</b>
0-17 years	124	1	4	8	18	161	16.0	22.9
18-24 years	645	1	4	8	20	1,024	24.0	67.5
25-40 years	966	1	4	9	20	651	18.7	38.1
41-64 years	654	1	3	7	17	447	14.3	28.6
≥ 65 years	3	2	2	4	22	22	9.3	11.0
<b>Baricitinib</b>	<b>8,409</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,203</b>	<b>20.3</b>	<b>52.4</b>
0-17 years	86	1	3	6	15	368	20.9	50.5
18-24 years	199	1	4	8	20	314	18.8	38.6
25-40 years	852	1	3	8	19	1,203	22.1	64.0
41-64 years	4,533	1	3	7	18	853	18.9	45.6
≥ 65 years	2,739	1	3	7	17	948	22.3	59.3
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>40,593</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>1,477</b>	<b>21.2</b>	<b>52.5</b>
0-17 years	18,531	1	3	7	19	1,477	23.6	55.1
18-24 years	6,645	1	3	6	18	1,127	22.6	59.7
25-40 years	9,748	1	3	6	16	1,019	18.8	48.0
41-64 years	5,340	1	2	6	14	834	15.9	40.9
≥ 65 years	329	1	3	7	16	210	14.7	25.2
<b>Plazomicin</b>	<b>425</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>11</b>	<b>838</b>	<b>28.1</b>	<b>82.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	27	5	6	6	6	214	14.2	40.0
41-64 years	22	1	1	2	10	838	73.0	193.6
≥ 65 years	376	1	3	6	13	729	26.5	73.4
<b>Binimetinib</b>	<b>5,407</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>23</b>	<b>1,036</b>	<b>24.2</b>	<b>59.3</b>
0-17 years	18	2	9	25	63	130	40.3	39.5
18-24 years	41	1	3	8	33	531	34.5	86.0
25-40 years	471	1	4	8	23	712	25.2	62.8
41-64 years	1,864	1	3	7	20	929	22.4	56.1
≥ 65 years	3,013	1	3	9	25	1,036	25.0	60.2
<b>Encorafenib</b>	<b>5,948</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>21</b>	<b>1,036</b>	<b>22.6</b>	<b>56.1</b>
0-17 years	5	4	8	9	37	62	24.0	25.0
18-24 years	34	1	2	7	35	531	40.7	99.3
25-40 years	487	1	3	8	20	712	24.5	62.2
41-64 years	1,951	1	3	7	20	724	21.6	51.6
≥ 65 years	3,471	1	3	8	22	1,036	22.8	57.0
<b>Tecovirimat</b>	<b>2</b>	<b>15</b>	<b>15</b>	<b>36</b>	<b>56</b>	<b>56</b>	<b>35.5</b>	<b>29.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	15	15	15	15	15	15.0	NaN
41-64 years	1	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>1,879</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>15</b>	<b>765</b>	<b>19.6</b>	<b>51.5</b>
0-17 years	2	2	2	5	7	7	4.5	3.5
18-24 years	25	1	2	5	19	39	10.6	11.7
25-40 years	96	1	2	6	14	101	12.6	19.0
41-64 years	357	1	3	6	17	524	17.9	40.8
≥ 65 years	1,399	1	3	6	15	765	20.7	55.7
<b>Tafenoquine</b>	<b>169</b>	<b>1</b>	<b>12</b>	<b>32</b>	<b>69</b>	<b>798</b>	<b>64.0</b>	<b>115.9</b>
0-17 years	11	22	37	48	123	273	85.4	75.9
18-24 years	6	10	27	54	80	352	96.2	128.5
25-40 years	56	1	12	31	56	727	59.8	108.2
41-64 years	85	1	9	29	60	798	63.4	130.3
≥ 65 years	11	8	12	32	86	197	52.2	56.5
<b>Elagolix sodium</b>	<b>35,676</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>20</b>	<b>1,280</b>	<b>24.7</b>	<b>66.3</b>
0-17 years	675	1	3	7	20	498	21.4	47.2



**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	6,464	1	3	8	22	1,061	25.6	62.5
25-40 years	21,170	1	3	7	20	1,280	24.6	68.6
41-64 years	7,362	1	3	7	20	1,071	24.3	64.4
≥ 65 years	5	1	3	8	9	186	41.4	80.9
<b>Fish oil triglycerides</b>	<b>2,702</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>6</b>	<b>448</b>	<b>7.0</b>	<b>16.6</b>
0-17 years	2,418	1	3	6	6	448	6.8	16.9
18-24 years	181	1	6	6	6	62	7.4	7.6
25-40 years	39	1	6	6	6	154	13.2	25.6
41-64 years	45	1	6	6	6	35	7.0	5.6
≥ 65 years	19	2	4	6	6	139	12.4	30.7
<b>Lusutrombopag</b>	<b>138</b>	<b>1</b>	<b>16</b>	<b>52</b>	<b>129</b>	<b>1,186</b>	<b>119.7</b>	<b>195.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	7	3	9	77	116	241	78.4	83.2
41-64 years	111	1	15	52	123	1,186	117.5	199.1
≥ 65 years	20	1	30	49	203	870	146.4	203.4

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lutetium Lu 177 dotatate</i>	3,776	4	55	55	61	819	62.4	27.8
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	117,539	1	3	8	23	1,804	32.8	88.3
<i>Tezacaftor and ivacaftor</i>	2,673	1	3	7	21	813	25.5	56.9
<i>Apalutamide</i>	6,927	1	2	6	17	1,643	22.0	69.9
<i>Ibalizumab-uiyk</i>	255	1	5	12	13	350	14.6	27.9
<i>Tildrakizumab</i>	6,814	1	27	28	73	972	49.2	53.0
<i>Burosumab-twza</i>	870	1	10	26	29	1,057	28.3	49.6
<i>Fostamatinib</i>	556	1	3	7	19	836	26.1	74.6
<i>Fosnetupitant and palonosetron</i>	21,243	1	13	20	20	1,161	19.5	25.0
<i>Lofexidine hydrochloride</i>	795	1	11	35	111	1,504	94.0	153.8
<i>Erenumab-aooe</i>	104,400	1	3	8	25	1,603	30.7	79.8
<i>Sodium zirconium cyclosilicate</i>	33,346	1	6	20	63	1,220	62.2	112.6
<i>Avatrombopag</i>	856	1	5	18	65	1,394	76.8	161.0
<i>Pegvaliase-pqpz</i>	392	1	4	8	18	651	20.2	47.1
<i>Baricitinib</i>	3,162	1	3	7	17	850	20.4	51.1
<i>Moxidectin</i>	0	.	.	.	.	.	.	.
<i>Cannabidiol</i>	11,768	1	3	7	22	1,477	30.0	73.8
<i>Plazomicin</i>	94	1	1	5	22	729	54.9	120.9
<i>Binimetinib</i>	1,587	1	3	9	24	1,036	28.5	75.2
<i>Encorafenib</i>	1,841	1	3	9	23	1,036	26.8	74.3
<i>Tecovirimat</i>	2	15	15	36	56	56	35.5	29.0
<i>Ivosidenib</i>	733	1	3	6	17	765	22.1	60.5
<i>Tafenoquine</i>	67	1	9	32	69	703	55.3	98.0
<i>Elagolix sodium</i>	12,357	1	3	7	22	1,280	28.4	77.4
<i>Fish oil triglycerides</i>	109	1	3	6	8	281	14.1	34.1
<i>Lusutrombopag</i>	73	1	27	72	162	1,186	148.7	232.4

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>3,776</b>	<b>4</b>	<b>55</b>	<b>55</b>	<b>61</b>	<b>819</b>	<b>62.4</b>	<b>27.8</b>
Female	1,874	4	55	55	61	363	62.1	20.6
Male	1,902	13	55	55	61	819	62.6	33.4
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>117,539</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>23</b>	<b>1,804</b>	<b>32.8</b>	<b>88.3</b>
Female	30,886	1	3	8	24	1,557	32.9	86.2
Male	86,653	1	3	7	23	1,804	32.8	89.0
<b>Tezacaftor and ivacaftor</b>	<b>2,673</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>21</b>	<b>813</b>	<b>25.5</b>	<b>56.9</b>
Female	1,348	1	3	7	21	813	26.6	61.4
Male	1,325	1	3	7	20	564	24.3	52.0
<b>Apalutamide</b>	<b>6,927</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>17</b>	<b>1,643</b>	<b>22.0</b>	<b>69.9</b>
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	6,927	1	2	6	17	1,643	22.0	69.9
<b>Ibalizumab-uiyk</b>	<b>255</b>	<b>1</b>	<b>5</b>	<b>12</b>	<b>13</b>	<b>350</b>	<b>14.6</b>	<b>27.9</b>
Female	63	1	5	13	13	111	15.6	20.2
Male	192	1	4	12	13	350	14.3	30.0
<b>Tildrakizumab</b>	<b>6,814</b>	<b>1</b>	<b>27</b>	<b>28</b>	<b>73</b>	<b>972</b>	<b>49.2</b>	<b>53.0</b>
Female	3,611	1	27	28	62	887	47.7	48.1
Male	3,203	1	27	28	82	972	50.8	58.0
<b>Burosumab-twza</b>	<b>870</b>	<b>1</b>	<b>10</b>	<b>26</b>	<b>29</b>	<b>1,057</b>	<b>28.3</b>	<b>49.6</b>
Female	562	1	9	26	29	1,057	28.1	54.6
Male	308	1	13	26	29	388	28.7	39.0
<b>Fostamatinib</b>	<b>556</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>836</b>	<b>26.1</b>	<b>74.6</b>
Female	328	1	3	8	22	836	30.0	87.2
Male	228	1	3	6	17	506	20.6	50.8
<b>Fosnetupitant and palonosetron</b>	<b>21,243</b>	<b>1</b>	<b>13</b>	<b>20</b>	<b>20</b>	<b>1,161</b>	<b>19.5</b>	<b>25.0</b>
Female	12,112	1	13	20	20	1,161	20.2	27.9
Male	9,131	1	13	20	20	670	18.7	20.6
<b>Lofexidine hydrochloride</b>	<b>795</b>	<b>1</b>	<b>11</b>	<b>35</b>	<b>111</b>	<b>1,504</b>	<b>94.0</b>	<b>153.8</b>
Female	405	1	12	37	106	1,504	93.4	162.8
Male	390	1	11	33	113	1,039	94.6	144.1
<b>Erenumab-aooe</b>	<b>104,400</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>25</b>	<b>1,603</b>	<b>30.7</b>	<b>79.8</b>
Female	89,346	1	3	8	25	1,603	30.7	80.0
Male	15,054	1	3	8	25	1,364	30.6	78.8
<b>Sodium zirconium cyclosilicate</b>	<b>33,346</b>	<b>1</b>	<b>6</b>	<b>20</b>	<b>63</b>	<b>1,220</b>	<b>62.2</b>	<b>112.6</b>
Female	13,818	1	6	21	64	1,220	63.6	115.2
Male	19,528	1	6	20	62	1,213	61.2	110.8
<b>Avatrombopag</b>	<b>856</b>	<b>1</b>	<b>5</b>	<b>18</b>	<b>65</b>	<b>1,394</b>	<b>76.8</b>	<b>161.0</b>
Female	453	1	5	19	65	1,394	79.7	166.0
Male	403	1	5	17	63	1,359	73.6	155.3
<b>Pegvaliase-pqpz</b>	<b>392</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>18</b>	<b>651</b>	<b>20.2</b>	<b>47.1</b>
Female	200	1	4	9	20	374	24.2	45.5

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Sex**

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	192	1	3	7	17	651	16.0	48.4
<b>Baricitinib</b>	<b>3,162</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>850</b>	<b>20.4</b>	<b>51.1</b>
Female	2,180	1	3	8	20	843	22.5	52.6
Male	982	1	3	6	12	850	15.8	47.2
<b>Moxidectin</b>	<b>0</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>11,768</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>22</b>	<b>1,477</b>	<b>30.0</b>	<b>73.8</b>
Female	5,205	1	3	7	22	1,127	29.4	70.6
Male	6,563	1	3	7	22	1,477	30.5	76.2
<b>Plazomicin</b>	<b>94</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>22</b>	<b>729</b>	<b>54.9</b>	<b>120.9</b>
Female	66	1	1	5	40	498	52.3	101.0
Male	28	1	2	3	9	729	60.9	160.3
<b>Binimetinib</b>	<b>1,587</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>24</b>	<b>1,036</b>	<b>28.5</b>	<b>75.2</b>
Female	707	1	4	10	26	1,036	33.1	88.5
Male	880	1	3	8	24	944	24.7	62.3
<b>Encorafenib</b>	<b>1,841</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>23</b>	<b>1,036</b>	<b>26.8</b>	<b>74.3</b>
Female	861	1	4	10	25	1,036	30.2	82.9
Male	980	1	3	8	21	944	23.7	65.8
<b>Tecovirimat</b>	<b>2</b>	<b>15</b>	<b>15</b>	<b>36</b>	<b>56</b>	<b>56</b>	<b>35.5</b>	<b>29.0</b>
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	2	15	15	36	56	56	35.5	29.0
<b>Ivosidenib</b>	<b>733</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>765</b>	<b>22.1</b>	<b>60.5</b>
Female	373	1	3	6	17	765	23.7	69.9
Male	360	1	3	6	17	524	20.4	48.9
<b>Tafenoquine</b>	<b>67</b>	<b>1</b>	<b>9</b>	<b>32</b>	<b>69</b>	<b>703</b>	<b>55.3</b>	<b>98.0</b>
Female	46	1	9	32	59	135	39.7	36.0
Male	21	1	7	28	86	703	89.6	164.3
<b>Elagolix sodium</b>	<b>12,357</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>22</b>	<b>1,280</b>	<b>28.4</b>	<b>77.4</b>
Female	12,341	1	3	7	22	1,280	28.4	77.5
Male	16	1	1	3	7	57	8.4	14.4
<b>Fish oil triglycerides</b>	<b>109</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>8</b>	<b>281</b>	<b>14.1</b>	<b>34.1</b>
Female	57	1	3	6	8	281	16.9	41.4
Male	52	1	3	6	8	157	11.1	23.6
<b>Lusutrombopag</b>	<b>73</b>	<b>1</b>	<b>27</b>	<b>72</b>	<b>162</b>	<b>1,186</b>	<b>148.7</b>	<b>232.4</b>
Female	36	5	24	62	110	1,186	157.8	281.8
Male	37	1	34	77	167	770	139.8	175.1

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Lutetium Lu 177 dotatate</b>	<b>3,776</b>	<b>4</b>	<b>55</b>	<b>55</b>	<b>61</b>	<b>819</b>	<b>62.4</b>	<b>27.8</b>
0-17 years	1	55	55	55	55	55	55.0	NaN
18-24 years	5	55	55	55	55	153	74.6	43.8
25-40 years	68	50	55	55	59	190	61.6	19.7
41-64 years	898	4	55	55	62	819	63.3	36.9
≥ 65 years	2,804	13	55	55	61	664	62.1	24.3
<b>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</b>	<b>117,539</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>23</b>	<b>1,804</b>	<b>32.8</b>	<b>88.3</b>
0-17 years	563	1	3	7	21	736	27.1	64.6
18-24 years	5,674	1	3	10	32	1,431	40.5	90.2
25-40 years	35,120	1	3	10	29	1,718	38.6	92.6
41-64 years	63,591	1	3	7	21	1,804	30.7	86.7
≥ 65 years	12,591	1	2	5	16	1,500	24.3	82.5
<b>Tezacaftor and ivacaftor</b>	<b>2,673</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>21</b>	<b>813</b>	<b>25.5</b>	<b>56.9</b>
0-17 years	932	1	3	7	21	495	22.4	46.6
18-24 years	544	1	4	9	29	439	29.2	53.7
25-40 years	914	1	3	7	18	813	26.9	67.1
41-64 years	249	1	3	6	14	403	20.4	47.1
≥ 65 years	34	1	6	10	31	584	47.6	106.6
<b>Apalutamide</b>	<b>6,927</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>17</b>	<b>1,643</b>	<b>22.0</b>	<b>69.9</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	4	4	4	4	4	4.0	NaN
41-64 years	703	1	2	5	15	752	18.3	46.1
≥ 65 years	6,223	1	2	6	17	1,643	22.4	72.1
<b>Ibalizumab-uiyk</b>	<b>255</b>	<b>1</b>	<b>5</b>	<b>12</b>	<b>13</b>	<b>350</b>	<b>14.6</b>	<b>27.9</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	5	7	12	13	13	111	31.2	44.7
25-40 years	38	1	5	13	14	43	12.7	9.8
41-64 years	181	1	5	13	14	350	15.8	31.8
≥ 65 years	31	1	4	7	11	21	7.3	5.0
<b>Tildrakizumab</b>	<b>6,814</b>	<b>1</b>	<b>27</b>	<b>28</b>	<b>73</b>	<b>972</b>	<b>49.2</b>	<b>53.0</b>
0-17 years	1	12	12	12	12	12	12.0	NaN
18-24 years	42	2	27	57	83	645	72.0	101.3
25-40 years	263	1	26	38	84	887	68.2	100.9
41-64 years	779	1	27	34	86	751	59.6	66.5
≥ 65 years	5,729	1	27	27	48	972	46.7	46.5
<b>Burosumab-twza</b>	<b>870</b>	<b>1</b>	<b>10</b>	<b>26</b>	<b>29</b>	<b>1,057</b>	<b>28.3</b>	<b>49.6</b>
0-17 years	494	1	7	20	28	464	24.5	36.6
18-24 years	57	1	24	27	31	388	37.6	57.6
25-40 years	115	1	25	27	32	333	32.7	35.7
41-64 years	136	1	20	27	30	1,057	34.2	90.2
≥ 65 years	68	1	27	27	29	180	29.2	22.1
<b>Fostamatinib</b>	<b>556</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>19</b>	<b>836</b>	<b>26.1</b>	<b>74.6</b>
0-17 years	2	2	2	36	69	69	35.5	47.4
18-24 years	13	1	5	38	55	449	69.8	120.9
25-40 years	79	1	5	11	26	482	36.3	73.5
41-64 years	199	1	3	7	19	379	19.6	39.3

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	263	1	3	6	17	836	25.8	90.4
<b>Fosnetupitant and palonosetron</b>	<b>21,243</b>	<b>1</b>	<b>13</b>	<b>20</b>	<b>20</b>	<b>1,161</b>	<b>19.5</b>	<b>25.0</b>
0-17 years	1	2	2	2	2	2	2.0	NaN
18-24 years	65	2	13	16	20	64	19.0	11.1
25-40 years	553	1	13	17	20	265	18.1	16.7
41-64 years	4,641	1	13	20	20	646	19.2	24.5
≥ 65 years	15,983	1	13	20	20	1,161	19.7	25.5
<b>Lofexidine hydrochloride</b>	<b>795</b>	<b>1</b>	<b>11</b>	<b>35</b>	<b>111</b>	<b>1,504</b>	<b>94.0</b>	<b>153.8</b>
0-17 years	1	58	58	58	58	58	58.0	NaN
18-24 years	49	2	18	55	191	849	123.0	159.0
25-40 years	292	1	10	30	108	1,039	84.4	133.2
41-64 years	369	1	13	37	112	1,504	100.3	171.9
≥ 65 years	84	1	10	26	100	594	83.1	131.6
<b>Erenumab-aooe</b>	<b>104,400</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>25</b>	<b>1,603</b>	<b>30.7</b>	<b>79.8</b>
0-17 years	591	1	3	7	20	643	25.0	60.3
18-24 years	5,349	1	3	8	23	1,134	26.7	65.2
25-40 years	26,669	1	3	8	24	1,603	29.1	75.5
41-64 years	54,643	1	3	8	26	1,557	31.5	82.1
≥ 65 years	17,148	1	3	8	25	1,265	32.0	83.5
<b>Sodium zirconium cyclosilicate</b>	<b>33,346</b>	<b>1</b>	<b>6</b>	<b>20</b>	<b>63</b>	<b>1,220</b>	<b>62.2</b>	<b>112.6</b>
0-17 years	11	1	8	22	57	160	35.6	46.9
18-24 years	105	1	9	29	104	601	75.8	107.2
25-40 years	1,564	1	7	25	85	884	77.6	128.3
41-64 years	10,439	1	6	21	68	1,150	66.5	119.4
≥ 65 years	21,227	1	5	19	60	1,220	58.9	107.8
<b>Avatrombopag</b>	<b>856</b>	<b>1</b>	<b>5</b>	<b>18</b>	<b>65</b>	<b>1,394</b>	<b>76.8</b>	<b>161.0</b>
0-17 years	3	1	1	2	4	4	2.3	1.5
18-24 years	28	1	5	19	41	309	39.1	66.6
25-40 years	81	1	6	20	50	542	51.4	93.4
41-64 years	346	1	5	22	78	1,394	84.2	165.6
≥ 65 years	398	1	5	15	57	1,191	78.8	172.1
<b>Pegvaliase-pqpz</b>	<b>392</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>18</b>	<b>651</b>	<b>20.2</b>	<b>47.1</b>
0-17 years	27	1	4	8	20	73	15.3	17.7
18-24 years	106	1	4	8	20	374	22.7	46.8
25-40 years	165	1	4	9	17	651	22.6	59.1
41-64 years	92	1	4	8	17	200	14.6	23.5
≥ 65 years	2	2	2	12	22	22	12.0	14.1
<b>Baricitinib</b>	<b>3,162</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>17</b>	<b>850</b>	<b>20.4</b>	<b>51.1</b>
0-17 years	34	1	2	7	12	368	28.5	72.3
18-24 years	79	1	4	8	19	314	18.8	40.2
25-40 years	330	1	3	7	19	843	22.6	60.9
41-64 years	1,527	1	3	7	19	850	20.2	51.3
≥ 65 years	1,192	1	3	7	15	654	19.9	47.6
<b>Moxidectin</b>	<b>0</b>	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	0	.	.	.	.	.	.	.
<b>Cannabidiol</b>	<b>11,768</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>22</b>	<b>1,477</b>	<b>30.0</b>	<b>73.8</b>
0-17 years	6,035	1	3	8	24	1,477	33.1	75.3
18-24 years	2,008	1	3	7	22	1,127	33.0	86.2
25-40 years	2,468	1	3	7	18	1,019	23.7	62.8
41-64 years	1,175	1	3	7	18	834	23.4	64.4
≥ 65 years	82	1	3	8	20	185	19.9	33.0
<b>Plazomicin</b>	<b>94</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>22</b>	<b>729</b>	<b>54.9</b>	<b>120.9</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	20	20	117	214	214	117.0	137.2
41-64 years	14	1	1	3	10	183	27.0	58.8
≥ 65 years	78	1	1	5	35	729	58.3	128.7
<b>Binimetinib</b>	<b>1,587</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>24</b>	<b>1,036</b>	<b>28.5</b>	<b>75.2</b>
0-17 years	9	2	4	17	21	68	21.8	23.1
18-24 years	18	1	2	4	33	531	42.6	123.3
25-40 years	150	1	3	8	21	712	30.7	89.8
41-64 years	533	1	3	9	23	699	24.8	59.2
≥ 65 years	877	1	4	10	25	1,036	30.0	80.2
<b>Encorafenib</b>	<b>1,841</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>23</b>	<b>1,036</b>	<b>26.8</b>	<b>74.3</b>
0-17 years	3	4	4	37	62	62	34.3	29.1
18-24 years	14	1	2	5	46	531	67.0	150.2
25-40 years	158	1	3	8	18	712	30.3	88.4
41-64 years	593	1	3	8	22	699	22.6	54.7
≥ 65 years	1,073	1	3	9	24	1,036	28.0	79.8
<b>Tecovirimat</b>	<b>2</b>	<b>15</b>	<b>15</b>	<b>36</b>	<b>56</b>	<b>56</b>	<b>35.5</b>	<b>29.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	15	15	15	15	15	15.0	NaN
41-64 years	1	56	56	56	56	56	56.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Ivosidenib</b>	<b>733</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>17</b>	<b>765</b>	<b>22.1</b>	<b>60.5</b>
0-17 years	1	7	7	7	7	7	7.0	NaN
18-24 years	4	1	2	2	4	6	2.8	2.2
25-40 years	46	1	1	4	14	100	13.7	20.4
41-64 years	144	1	3	8	20	208	19.3	32.5
≥ 65 years	538	1	3	6	17	765	23.7	68.3
<b>Tafenoquine</b>	<b>67</b>	<b>1</b>	<b>9</b>	<b>32</b>	<b>69</b>	<b>703</b>	<b>55.3</b>	<b>98.0</b>
0-17 years	4	22	24	43	91	123	57.5	46.7
18-24 years	2	10	10	44	77	77	43.5	47.4
25-40 years	20	1	7	24	36	135	29.8	32.4
41-64 years	35	1	9	32	69	703	66.8	128.4
≥ 65 years	6	8	9	79	86	197	76.3	69.2
<b>Elagolix sodium</b>	<b>12,357</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>22</b>	<b>1,280</b>	<b>28.4</b>	<b>77.4</b>
0-17 years	202	1	3	7	21	397	22.3	51.9
18-24 years	2,238	1	3	8	23	853	29.6	74.1
25-40 years	7,452	1	3	7	21	1,280	28.4	80.4
41-64 years	2,463	1	3	7	22	903	28.0	72.9

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023, by Age Group**

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	2	1	1	5	8	8	4.5	4.9
<b>Fish oil triglycerides</b>	<b>109</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>8</b>	<b>281</b>	<b>14.1</b>	<b>34.1</b>
0-17 years	93	1	3	6	7	281	14.4	36.3
18-24 years	5	1	4	6	7	13	6.2	4.4
25-40 years	4	1	6	26	49	56	27.0	25.8
41-64 years	4	1	2	6	22	35	11.8	15.8
≥ 65 years	3	3	3	5	6	6	4.7	1.5
<b>Lusutrombopag</b>	<b>73</b>	<b>1</b>	<b>27</b>	<b>72</b>	<b>162</b>	<b>1,186</b>	<b>148.7</b>	<b>232.4</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	3	3	22	81	81	35.3	40.7
41-64 years	53	5	26	78	151	1,186	153.4	244.2
≥ 65 years	17	1	30	58	184	870	153.9	215.8

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023<sup>1</sup>**

	Censoring Reason												
	End of Exposure Episode <sup>2</sup>		Occurrence of User-Defined Censoring Criteria <sup>3</sup>		Evidence of Death <sup>4</sup>		Disenrollment <sup>5</sup>		End of Data <sup>6</sup>		End of Study Period <sup>7</sup>		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Lutetium Lu 177 dotatate</i>	13,921	13,921	100.0%	0	0.0%	0	0.0%	*****	0.0%	*****	0.0%	*****	0.0%
<i>Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate</i>	699,595	697,253	99.7%	0	0.0%	2,486	0.4%	128,050	18.3%	82,842	11.8%	82,842	11.8%
<i>Tezacaftor and ivacaftor</i>	14,644	14,622	99.8%	0	0.0%	25	0.2%	948	6.5%	394	2.7%	394	2.7%
<i>Apalutamide</i>	36,365	35,957	98.9%	0	0.0%	438	1.2%	4,177	11.5%	3,299	9.1%	3,299	9.1%
<i>Ibalizumab-uiyk</i>	3,797	3,784	99.7%	0	0.0%	13	0.3%	72	1.9%	44	1.2%	44	1.2%
<i>Tildrakizumab</i>	36,842	36,828	100.0%	0	0.0%	15	0.0%	403	1.1%	247	0.7%	247	0.7%
<i>Burosumab-twza</i>	12,760	*****	100.0%	0	0.0%	*****	0.0%	402	3.2%	325	2.5%	325	2.5%
<i>Fostamatinib</i>	2,950	2,879	97.6%	0	0.0%	79	2.7%	298	10.1%	197	6.7%	197	6.7%
<i>Fosnetupitant and palonosetron</i>	132,350	132,331	100.0%	0	0.0%	25	0.0%	221	0.2%	165	0.1%	165	0.1%
<i>Lofexidine hydrochloride</i>	7,235	7,235	100.0%	0	0.0%	0	0.0%	132	1.8%	70	1.0%	70	1.0%
<i>Erenumab-aooe</i>	577,165	576,557	99.9%	0	0.0%	650	0.1%	65,143	11.3%	38,303	6.6%	38,303	6.6%
<i>Sodium zirconium cyclosilicate</i>	175,266	172,695	98.5%	0	0.0%	2,795	1.6%	15,736	9.0%	12,129	6.9%	12,129	6.9%
<i>Avatrombopag</i>	4,942	4,872	98.6%	0	0.0%	82	1.7%	478	9.7%	357	7.2%	357	7.2%
<i>Pegvaliase-pqpz</i>	2,920	2,920	100.0%	0	0.0%	0	0.0%	348	11.9%	200	6.8%	200	6.8%
<i>Baricitinib</i>	59,846	59,813	99.9%	0	0.0%	60	0.1%	1,555	2.6%	1,011	1.7%	1,011	1.7%
<i>Moxidectin</i>	0	.	.	.	.	.	.	.	.	.	.	.	.
<i>Cannabidiol</i>	61,573	61,362	99.7%	0	0.0%	225	0.4%	12,930	21.0%	10,589	17.2%	10,589	17.2%
<i>Plazomicin</i>	674	674	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	*****	*****
<i>Binimetinib</i>	8,279	8,027	97.0%	0	0.0%	286	3.5%	688	8.3%	439	5.3%	439	5.3%
<i>Encorafenib</i>	9,319	9,044	97.0%	0	0.0%	307	3.3%	835	9.0%	534	5.7%	534	5.7%

**Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023<sup>1</sup>**

	Censoring Reason												
	End of Exposure Episode <sup>2</sup>		Occurrence of User-Defined Censoring Criteria <sup>3</sup>		Evidence of Death <sup>4</sup>		Disenrollment <sup>5</sup>		End of Data <sup>6</sup>		End of Study Period <sup>7</sup>		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Tecovirimat</i>	29	29	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ivosidenib</i>	3,355	3,140	93.6%	0	0.0%	232	6.9%	406	12.1%	299	8.9%	299	8.9%
<i>Tafenoquine</i>	366	366	100.0%	0	0.0%	0	0.0%	24	6.6%	14	3.8%	14	3.8%
<i>Elagolix sodium</i>	60,829	*****	100.0%	0	0.0%	*****	0.0%	6,352	10.4%	3,472	5.7%	3,472	5.7%
<i>Fish oil triglycerides</i>	2,843	2,843	100.0%	0	0.0%	0	0.0%	27	0.9%	20	0.7%	20	0.7%
<i>Lusutrombopag</i>	528	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****	*****	*****

<sup>1</sup>An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

<sup>2</sup>Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

<sup>3</sup>Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

<sup>4</sup>Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

<sup>5</sup>Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

<sup>6</sup>Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

<sup>7</sup>Represents episodes censored due to user-specified study end date.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

\*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Lutetium Lu 177 dotatate		Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	4,814	223,831,806	226,265	223,610,355
Claim recorded during specified age range	4,814	0	226,265	0
Episode defining index claim recorded during the query period	4,814	0	226,265	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	4,522	292	175,440	50,825
Met inclusion and exclusion criteria	4,522	0	175,440	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	4,522	0	175,440	0
<b>Final cohort</b>				
Number of members	4,522	N/A	175,440	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Tezacaftor and ivacaftor		Apalutamide	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	4,398	223,832,222	12,718	223,823,902
Claim recorded during specified age range	4,398	0	12,718	0
Episode defining index claim recorded during the query period	4,398	0	12,718	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	3,794	604	11,580	1,138
Met inclusion and exclusion criteria	3,794	0	11,580	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	3,794	0	11,580	0
<b>Final cohort</b>				
Number of members	3,794	N/A	11,580	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Ibalizumab-uiyk		Tildrakizumab	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	343	223,836,277	8,200	223,828,420
Claim recorded during specified age range	343	0	8,200	0
Episode defining index claim recorded during the query period	343	0	8,200	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	307	36	7,837	363
Met inclusion and exclusion criteria	307	0	7,837	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	307	0	7,837	0
<b>Final cohort</b>				
Number of members	307	N/A	7,837	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Burosumab-twza		Fostamatinib	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	1,131	223,835,489	1,272	223,835,348
Claim recorded during specified age range	1,131	0	1,272	0
Episode defining index claim recorded during the query period	1,131	0	1,272	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	1,038	93	1,120	152
Met inclusion and exclusion criteria	1,038	0	1,120	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	1,038	0	1,120	0
<b>Final cohort</b>				
Number of members	1,038	N/A	1,120	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Fosnetupitant and palonosetron		Lofexidine hydrochloride	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	27,657	223,808,963	6,831	223,829,789
Claim recorded during specified age range	27,657	0	6,831	0
Episode defining index claim recorded during the query period	27,657	0	6,831	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	24,863	2,794	5,773	1,058
Met inclusion and exclusion criteria	24,863	0	5,773	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	24,863	0	5,773	0
<b>Final cohort</b>				
Number of members	24,863	N/A	5,773	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Erenumab-aooe		Sodium zirconium cyclosilicate	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	185,415	223,651,205	*****	*****
Claim recorded during specified age range	185,415	0	*****	*****
Episode defining index claim recorded during the query period	185,415	0	*****	*****
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	158,717	26,698	78,091	7,917
Met inclusion and exclusion criteria	158,717	0	78,091	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	158,717	0	78,091	0
<b>Final cohort</b>				
Number of members	158,717	N/A	78,091	N/A

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable



**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Avatrombopag		Pegvaliase-pqpz	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	2,666	223,833,954	656	223,835,964
Claim recorded during specified age range	2,666	0	656	0
Episode defining index claim recorded during the query period	2,666	0	656	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	2,406	260	528	128
Met inclusion and exclusion criteria	2,406	0	528	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	2,406	0	528	0
<b>Final cohort</b>				
Number of members	2,406	N/A	528	N/A

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Baricitinib		Moxidectin	
	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>				
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>				
Had any cohort-defining claim during the query period	56,068	223,780,552	0	223,836,620
Claim recorded during specified age range	56,068	0	0	0
Episode defining index claim recorded during the query period	56,068	0	0	0
<b>Members with required pre-index history</b>				
Had sufficient pre-index continuous enrollment	51,437	4,631	0	0
Met inclusion and exclusion criteria	51,437	0	0	0
<b>Members with required post-index follow-up</b>				
Had sufficient post-index continuous enrollment	51,437	0	0	0
<b>Final cohort</b>				
Number of members	51,437	N/A	0	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Cannabidiol		Plazomicin		Binimetinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	23,975	223,812,64 5	*****	*****	3,218	223,833,402
Claim recorded during specified age range	23,975	0	*****	0	3,218	0
Episode defining index claim recorded during the query period	23,975	0	*****	0	3,218	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	20,980	2,995	*****	*****	2,872	346
Met inclusion and exclusion criteria	20,980	0	*****	0	2,872	0
<b>Members with required post-index follow-up</b>						
Had sufficient post-index continuous enrollment	20,980	0	249	0	2,872	0
<b>Final cohort</b>						
Number of members	20,980	N/A	249	N/A	2,872	N/A

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Encorafenib		Tecovirimat		Ivosidenib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	3,790	223,832,830	*****	*****	1,649	223,834,971
Claim recorded during specified age range	3,790	0	*****	0	1,649	0
Episode defining index claim recorded during the query period	3,790	0	*****	0	1,649	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	3,371	419	*****	*****	1,476	173
Met inclusion and exclusion criteria	3,371	0	*****	0	1,476	0
<b>Members with required post-index follow-up</b>						
Had sufficient post-index continuous enrollment	3,371	0	27	0	1,476	0
<b>Final cohort</b>						
Number of members	3,371	N/A	27	N/A	1,476	N/A

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Tafenoquine		Elagolix sodium		Fish oil triglycerides	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>						
Enrolled at any point during the query period	303,804,471	N/A	303,804,471	N/A	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432	223,946,039	79,858,432	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461	223,919,578	26,461	223,919,578	26,461
Had requestable medical charts	223,919,578	0	223,919,578	0	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958	223,836,620	82,958	223,836,620	82,958
<b>Members with a valid index event</b>						
Had any cohort-defining claim during the query period	225	223,836,395	29,589	223,807,031	166	223,836,454
Claim recorded during specified age range	225	0	29,589	0	166	0
Episode defining index claim recorded during the query period	225	0	29,589	0	166	0
<b>Members with required pre-index history</b>						
Had sufficient pre-index continuous enrollment	197	28	25,153	4,436	141	25
Met inclusion and exclusion criteria	197	0	25,153	0	141	0
<b>Members with required post-index follow-up</b>						
Had sufficient post-index continuous enrollment	197	0	25,153	0	141	0
<b>Final cohort</b>						
Number of members	197	N/A	25,153	N/A	141	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

**Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

	Lusutrombopag	
	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>		
Enrolled at any point during the query period	303,804,471	N/A
Had required coverage type (medical and/or drug coverage)	223,946,039	79,858,432
Enrolled during specified age range	223,919,578	26,461
Had requestable medical charts	223,919,578	0
Met demographic requirements (sex, race, and Hispanic origin)	223,836,620	82,958
<b>Members with a valid index event</b>		
Had any cohort-defining claim during the query period	415	223,836,205
Claim recorded during specified age range	415	0
Episode defining index claim recorded during the query period	415	0
<b>Members with required pre-index history</b>		
Had sufficient pre-index continuous enrollment	390	25
Met inclusion and exclusion criteria	390	0
<b>Members with required post-index follow-up</b>		
Had sufficient post-index continuous enrollment	390	0
<b>Final cohort</b>		
Number of members	390	N/A

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable


**Figure 1a. Patient Entry into Study by Month for Lutetium Lu 177 dotatate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on January 26, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1b. Patient Entry into Study by Month for Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on February 7, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>




**Figure 1c. Patient Entry into Study by Month for Tezacaftor and ivacaftor in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on February 12, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1d. Patient Entry into Study by Month for Apalutamide in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on February 14, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


**Figure 1e. Patient Entry into Study by Month for Ibalizumab-uiyk in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on March 6, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

Figure 1f. Patient Entry into Study by Month for Tildrakizumab in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023



\*The FDA approval date for this drug was on March 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1g. Patient Entry into Study by Month for Burosumab-twza in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on April 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.


**Figure 1h. Patient Entry into Study by Month for Fostamatinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on April 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1i. Patient Entry into Study by Month for Fosnetupitant and palonosetron in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on April 19, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1j. Patient Entry into Study by Month for Lofexidine hydrochloride in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**


---

\*The FDA approval date for this drug was on May 16, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.




**Figure 1k. Patient Entry into Study by Month for Erenumab-aooe in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on May 17, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 11. Patient Entry into Study by Month for Sodium Zirconium Cyclosilicate in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on May 18, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1m. Patient Entry into Study by Month for Avatrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on May 21, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.


**Figure 1n. Patient Entry into Study by Month for Pegvaliase-pqpz in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on May 24, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>


\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1o. Patient Entry into Study by Month for Baricitinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**




\*The FDA approval date for this drug was on May 31, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1p. Patient Entry into Study by Month for Moxidectin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on June 13, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1q. Patient Entry into Study by Month for Cannabidiol in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**



\*The FDA approval date for this drug was on June 25, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1r. Patient Entry into Study by Month for Plazomicin in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on June 25, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.



**Figure 1s. Patient Entry into Study by Month for Binimetinib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on June 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1t. Patient Entry into Study by Month for Encorafenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on June 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1u. Patient Entry into Study by Month for Tecovirimat in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on July 13, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1v. Patient Entry into Study by Month for Ivosidenib in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on July 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.


**Figure 1w. Patient Entry into Study by Month for Tafenoquine in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on July 20, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

Figure 1x. Patient Entry into Study by Month for Elagolix sodium in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023



\*The FDA approval date for this drug was on July 23, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

**Figure 1y. Patient Entry into Study by Month for Fish oil triglycerides in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on July 27, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.

**Figure 1z. Patient Entry into Study by Month for Lusutrombopag in the Sentinel Distributed Database from January 1, 2018 to May 31, 2023**

---

\*The FDA approval date for this drug was on July 31, 2018, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>

\*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.



**Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (September 8, 2023)**

Masked DP ID	DP Start Date	DP End Date <sup>2</sup>
DP01	01/01/2004	11/30/2022
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	12/31/2022
DP04	01/01/2006	02/28/2023
DP05	01/01/2000	05/31/2023
DP06	01/01/2000	04/30/2023
DP07	01/01/2000	08/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	10/31/2022
DP10	01/01/2007	01/31/2023
DP11	01/01/2014	12/31/2020
DP12	01/01/2008	04/30/2023
DP13	01/01/2010	12/31/2022

<sup>1</sup>End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
	<b>lutetium Lu 177 dotatate</b>
lutetium Lu 177 dotatate	Lutathera
	<b>bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate</b>
bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate	Biktarvy
	<b>tezacaftor ivacaftor</b>
tezacaftor/ivacaftor	Symdeko
	<b>apalutamide</b>
apalutamide	Erleada
	<b>ibalizumab-uiyk</b>
ibalizumab-uiyk	Trogarzo
	<b>tildrakizumab</b>
tildrakizumab-asmn	Ilumya
	<b>burosumab-twza</b>
fostamatinib disodium	Tavalisse
	<b>fostamatinib</b>
burosumab-twza	Crysvita
	<b>fosnetupitant palonosetron</b>
fosnetupitant chloride HCl/palonosetron HCl	Akynzeo
	<b>lofexidine hydrochloride</b>
lofexidine HCl	Lucemyra
	<b>erenumab-aooe</b>
erenumab-aooe	Aimovig
	<b>sodium zirconium cyclosilicate</b>
sodium zirconium cyclosilicate	Lokelma
	<b>avatrombopag</b>
avatrombopag maleate	Doptelet
	<b>pegvaliase-pqpz</b>
pegvaliase-pqpz	Palynziq
	<b>baricitinib</b>
baricitinib	Olumiant
	<b>moxidectin</b>
moxidectin	Moxidectin
	<b>cannabidiol</b>
cannabidiol (CBD)	Epidioloex
	<b>plazomicin</b>
plazomicin sulfate	Zemdri
	<b>binimetinib</b>
binimetinib	Mektovi
	<b>encorafenib</b>
encorafenib	Braftovi
	<b>tecovirimat</b>
tecovirimat	TPOXX
	<b>ivosidenib</b>
ivosidenib	Tibsovo
	<b>tafenoquine</b>
tafenoquine succinate	Krintafel
	<b>elagolix sodium</b>
elagolix sodium	Orilissa

**Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request**

Non-Proprietary Name	Proprietary Name
fatty acids combo. no.6/fish oil/glycerin/phospholipids, Omegaven egg	fish oil triglycerides
lusutrombopag	lusutrombopag Mulpleta

**Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposures in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
<b>lutetium Lu 177 dotatate</b>			
A9513	Lutetium Lu 177, dotatate, therapeutic, 1 mCi	Procedure	HCPCS
C9031	Lutetium Lu 177, dotatate, therapeutic, 1 mCi	Procedure	HCPCS
<b>ibalizumab-uiyk</b>			
J1746	ibalizumab-uiyk	Procedure	HCPCS
<b>tildrakizumab</b>			
J3245	tildrakizumab	Procedure	HCPCS
<b>fostamatinib</b>			
J0584	Injection, burosumab-twza, 1 mg	Procedure	HCPCS
<b>fosnetupitant palonosetron</b>			
C9033	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Procedure	HCPCS
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	Procedure	HCPCS
<b>baricitinib</b>			
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
<b>plazomicin</b>			
C9039	Injection, plazomicin, 5 mg	Procedure	HCPCS
J0291	Injection, plazomicin, 5 mg	Procedure	HCPCS
XW033G4	Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4	Procedure	ICD-10-PCS
XW043G4	Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4	Procedure	ICD-10-PCS
<b>fish oil triglycerides</b>			
B4187	Omegaven, 10 g lipids	Procedure	HCPCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
<b>Acquired Hypothyroidism</b>			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
<b>Alcohol Abuse</b>			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
<b>Alzheimers</b>			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnesic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnesic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
<b>Acute Myocardial Infarction</b>			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
<b>Anemia</b>			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
<b>Asthma</b>			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
<b>Atrial Fibrillation</b>			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
<b>Benign Prostatic Hyperplasia</b>			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
<b>Breast Cancer</b>			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
<b>Cardiac Arrest</b>			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
<b>Chronic Kidney Disease</b>			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
<b>Colorectal Cancer</b>			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
<b>Chronic Obstructive Pulmonary Disease</b>			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
<b>Coronary Angioplasty Bypass</b>			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
<b>Depression</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
<b>Diabetes</b>			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
<b>Drug Abuse</b>			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
<b>Endometrial Cancer</b>			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
<b>Glaucoma</b>			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
<b>Heart Failure</b>			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
<b>Hyperlipidemia</b>			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
<b>Hypertension</b>			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
<b>Ischemic Heart Disease</b>			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
<b>Lung Cancer</b>			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
<b>Obesity</b>			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
<b>Osteoporosis</b>			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
<b>Overweight</b>			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
<b>Prostate</b>			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
<b>Rheumatoid Arthritis</b>			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
<b>Smoking</b>			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
<b>Transient Ischemic Attack</b>			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

**Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request**

Non-Proprietary Name	Proprietary Name
<b>Obesity</b>	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
<b>Smoking</b>	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool version 12.1.2 to investigate utilization and uptake of New Molecular Entities (NMEs) approved in year 2018 in the Sentinel Distributed Database (Sentinel Distributed Database).

**Query period:** 01/01/2018 - Most recent available data  
**Coverage requirement:** Medical and Drug Coverage  
**Pre-index enrollment requirement:** 183 days  
**Post-index requirement:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 0-17, 18-24, 25-40, 41-64, 65+ years  
**Stratifications:** Age group, Sex  
 Calendar Month (for Figures only)  
**Restrictions:** Male and Female  
**Distribution of index-defining codes:** No  
**Envelope macro:** Reclassify encounters during inpatient stay as inpatient  
**Freeze data:** No

**Exposure**

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	lutetium Lu 177 dotatate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	bictegravir sodium/ emtricitabine /tenofovir alafenamide fumarate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
3	tezacaftor; ivacaftor	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	apalutamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	ibalizumab-uiyk	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	tildrakizumab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	burosumab-twza	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

<b>Appendix F. Specifications Defining Parameters for this Request</b>										
<b>Scenario</b>	<b>Index Exposure/ Event</b>	<b>Cohort definition</b>	<b>Incident exposure washout period</b>	<b>Exclude evidence of days supply if exposure washout includes dispensing</b>	<b>Treatment episode gap</b>	<b>Treatment episode extension</b>	<b>Care setting</b>	<b>Principal diagnosis position</b>	<b>Create Baseline Table?</b>	<b>Censor treatment episode at evidence of:</b>
8	fostamatinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	fosnetupitant and palonosetron	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	lofexidine hydrochloride	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	erenumab-aooe	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	sodium zirconium cyclosilicate	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
13	avatrombopag	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	pegvaliase-pqpz	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	baricitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	moxidectin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	cannabidiol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
18	plazomicin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	binimetinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	encorafenib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	tecovirimat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	ivosidenib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

**Appendix F. Specifications Defining Parameters for this Request**

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
23	tafenoquine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	elagolix sodium	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	fish oil triglycerides	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	lusutrombopag	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug Codes (NDC) are checked against First Data Bank's FDB MedKnowledge®.

N/A: Not Applicable



**Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request**

Characteristics	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Acute Myocardial Infarction	1	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	3	IPP, IPS or	-183	-1	N/A	1	N/A
	4	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	5	3 or 4	-183	-1	N/A	N/A	N/A
Diabetes	6	IP*, IS* or	-183	-1	N/A	1	N/A
	7	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	8	6 or 7	-183	-1	N/A	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	N/A	1	N/A
Hyperlipidemia	10	IP*, IS* or	-183	-1	N/A	1	N/A
	11	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	12	10 or 11	-183	-1	N/A	N/A	N/A
Hypertension	13	IP*, IS* or	-183	-1	N/A	1	N/A
	14	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	15	13 or 14	-183	-1	N/A	N/A	N/A
Depression	16	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	N/A	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	N/A	1	N/A
	20	AV*, ED*, OA*	-183	-1	N/A	2	N/A
	21	19 or 20	-183	-1	N/A	N/A	N/A
Breast Cancer	22	IP*, IS* or	-183	-1	N/A	1	N/A
	23	AV*, ED* OA*	-183	-1	N/A	2	N/A
	24	22 or 23	-183	-1	N/A	N/A	N/A
Colorectal Cancer	25	IP*, IS* or	-183	-1	N/A	1	N/A
	26	AV*, ED* OA*	-183	-1	N/A	2	N/A
	27	25 or 26	-183	-1	N/A	N/A	N/A
Prostate Cancer	28	IP*, IS* or	-183	-1	N/A	1	N/A
	29	AV*, ED* OA*	-183	-1	N/A	2	N/A
	30	28 or 29	-183	-1	N/A	N/A	N/A
	31	IP*, IS* or	-183	-1	N/A	1	N/A

**Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request**

Characteristics	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Lung Cancer	32	AV*, ED* OA*	-183	-1	N/A	2	N/A
	33	31 or 32	-183	-1	N/A	N/A	N/A
Endometrial Cancer	34	IP*, IS* or	-183	-1	N/A	1	N/A
	35	AV*, ED* OA*	-183	-1	N/A	2	N/A
	36	34 or 35	-183	-1	N/A	N/A	N/A
Acquired Hypothyroidism	37	IP*, IS*, or	-183	-1	N/A	1	N/A
	38	AV*, ED* OA*	-183	-1	N/A	2	N/A
	39	37 or 38	-183	-1	N/A	N/A	N/A
Anemia	40	Any	-183	-1	N/A	1	N/A
Asthma	41	IP*, IS*, or	-183	-1	N/A	1	N/A
	42	AV*, ED* OA*	-183	-1	N/A	2	N/A
	43	41 or 42	-183	-1	N/A	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*, or	-183	-1	N/A	1	N/A
	45	AV*, ED* OA*	-183	-1	N/A	2	N/A
	46	44 or 45	-183	-1	N/A	N/A	N/A
Chronic Kidney Disease	47	IP*, IS*, or	-183	-1	N/A	1	N/A
	48	AV*, ED* OA*	-183	-1	N/A	2	N/A
	49	47 or 48	-183	-1	N/A	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*, or	-183	-1	N/A	1	N/A
	51	AV*, ED* OA*	-183	-1	N/A	2	N/A
	52	50 or 51	-183	-1	N/A	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	N/A	1	N/A
	54	IP*, IS*, or	-183	-1	N/A	1	N/A
Osteoporosis	55	AV*, ED* OA*	-183	-1	N/A	2	N/A
	56	54 or 55	-183	-1	N/A	N/A	N/A
	<i>Other</i>						
Obesity: diagnosed or identified by weight management procedures	57	Any	-183	-1	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	58	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	59	Any	-183	-1	N/A	1	N/A

## Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Characteristics	Covariate Number	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Smoking: diagnosed or identified by smoking cessation procedures	60	Any	-183	-1	N/A	1	N/A
Smoking: identified by smoking-related prescriptions	61	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	62	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	63	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	64	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	65	Any	-183	-1	N/A	1	N/A

### N/A: Not Applicable

\*The wildcard symbol (\*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

### <sup>1</sup>Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.


Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Appendix H. Design Diagram Used in this Request



<sup>1</sup> Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

<sup>2</sup> 26 scenarios defined on initiation of NMEs approved in 2019 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

<sup>3</sup> Baseline characteristics:

Window I: Age, Sex, Race, Hispanic Ethnicity, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

<sup>4</sup> Censoring: earliest of death, disenrollment, data partner data end date, query end date